#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery
#Text=Naltrexone is an opioid receptor antagonist used in the management of alcohol dependence.
1-1	0-7	Effects	_	
1-2	8-10	of	_	
1-3	11-21	naltrexone	_	
1-4	22-25	are	_	
1-5	26-36	influenced	_	
1-6	37-39	by	_	
1-7	40-49	childhood	_	
1-8	50-59	adversity	_	
1-9	60-66	during	_	
1-10	67-75	negative	_	
1-11	76-85	emotional	_	
1-12	86-96	processing	_	
1-13	97-99	in	_	
1-14	100-109	addiction	_	
1-15	110-118	recovery	_	
1-16	119-129	Naltrexone	_	
1-17	130-132	is	_	
1-18	133-135	an	_	
1-19	136-142	opioid	_	
1-20	143-151	receptor	_	
1-21	152-162	antagonist	_	
1-22	163-167	used	_	
1-23	168-170	in	_	
1-24	171-174	the	_	
1-25	175-185	management	_	
1-26	186-188	of	_	
1-27	189-196	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]	
1-28	197-207	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]	
1-29	207-208	.	_	

#Text=Although the endogenous opioid system has been implicated in emotion regulation, the effects of mu-opioid receptor blockade on brain systems underlying negative emotional processing are not clear in addiction.
2-1	209-217	Although	_	
2-2	218-221	the	_	
2-3	222-232	endogenous	_	
2-4	233-239	opioid	_	
2-5	240-246	system	_	
2-6	247-250	has	_	
2-7	251-255	been	_	
2-8	256-266	implicated	_	
2-9	267-269	in	_	
2-10	270-277	emotion	_	
2-11	278-288	regulation	_	
2-12	288-289	,	_	
2-13	290-293	the	_	
2-14	294-301	effects	_	
2-15	302-304	of	_	
2-16	305-314	mu-opioid	_	
2-17	315-323	receptor	_	
2-18	324-332	blockade	_	
2-19	333-335	on	_	
2-20	336-341	brain	_	
2-21	342-349	systems	_	
2-22	350-360	underlying	_	
2-23	361-369	negative	_	
2-24	370-379	emotional	_	
2-25	380-390	processing	_	
2-26	391-394	are	_	
2-27	395-398	not	_	
2-28	399-404	clear	_	
2-29	405-407	in	_	
2-30	408-417	addiction	_	
2-31	417-418	.	_	

#Text=Individuals meeting criteria for alcohol dependence alone (n=18, alcohol) and in combination with cocaine and/or opioid dependence (n=21, alcohol/drugs) and healthy individuals without a history of alcohol or drug dependence (n=21) were recruited.
3-1	419-430	Individuals	_	
3-2	431-438	meeting	_	
3-3	439-447	criteria	_	
3-4	448-451	for	_	
3-5	452-459	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]	
3-6	460-470	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]	
3-7	471-476	alone	_	
3-8	477-478	(	_	
3-9	478-479	n	_	
3-10	479-480	=	_	
3-11	480-482	18	_	
3-12	482-483	,	_	
3-13	484-491	alcohol	_	
3-14	491-492	)	_	
3-15	493-496	and	_	
3-16	497-499	in	_	
3-17	500-511	combination	_	
3-18	512-516	with	_	
3-19	517-524	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[3]	
3-20	525-528	and	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[3]	
3-21	528-529	/	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[3]	
3-22	529-531	or	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[3]	
3-23	532-538	opioid	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[3]	
3-24	539-549	dependence	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[3]	
3-25	550-551	(	_	
3-26	551-552	n	_	
3-27	552-553	=	_	
3-28	553-555	21	_	
3-29	555-556	,	_	
3-30	557-564	alcohol	_	
3-31	564-565	/	_	
3-32	565-570	drugs	_	
3-33	570-571	)	_	
3-34	572-575	and	_	
3-35	576-583	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-36	584-595	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-37	596-603	without	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-38	604-605	a	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-39	606-613	history	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-40	614-616	of	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-41	617-624	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-42	625-627	or	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-43	628-632	drug	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-44	633-643	dependence	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-45	644-645	(	_	
3-46	645-646	n	_	
3-47	646-647	=	_	
3-48	647-649	21	_	
3-49	649-650	)	_	
3-50	651-655	were	_	
3-51	656-665	recruited	_	
3-52	665-666	.	_	

#Text=Participants were alcohol and drug abstinent before entered into this double-blind, placebo-controlled, randomized, crossover study.
4-1	667-679	Participants	_	
4-2	680-684	were	_	
4-3	685-692	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]	
4-4	693-696	and	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]	
4-5	697-701	drug	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]	
4-6	702-711	abstinent	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]	
4-7	712-718	before	_	
4-8	719-726	entered	_	
4-9	727-731	into	_	
4-10	732-736	this	_	
4-11	737-749	double-blind	_	
4-12	749-750	,	_	
4-13	751-769	placebo-controlled	_	
4-14	769-770	,	_	
4-15	771-781	randomized	_	
4-16	781-782	,	_	
4-17	783-792	crossover	_	
4-18	793-798	study	_	
4-19	798-799	.	_	

#Text=Functional magnetic resonance imaging was used to investigate brain response while viewing aversive and neutral images relative to baseline on 50 mg of naltrexone and placebo.
5-1	800-810	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
5-2	811-819	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
5-3	820-829	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
5-4	830-837	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
5-5	838-841	was	_	
5-6	842-846	used	_	
5-7	847-849	to	_	
5-8	850-861	investigate	_	
5-9	862-867	brain	_	
5-10	868-876	response	_	
5-11	877-882	while	_	
5-12	883-890	viewing	_	
5-13	891-899	aversive	_	
5-14	900-903	and	_	
5-15	904-911	neutral	_	
5-16	912-918	images	_	
5-17	919-927	relative	_	
5-18	928-930	to	_	
5-19	931-939	baseline	_	
5-20	940-942	on	_	
5-21	943-945	50	_	
5-22	946-948	mg	_	
5-23	949-951	of	_	
5-24	952-962	naltrexone	_	
5-25	963-966	and	_	
5-26	967-974	placebo	_	
5-27	974-975	.	_	

#Text=We found that naltrexone modulated task-related activation in the medial prefrontal cortex and functional connectivity between the anterior cingulate cortex and the hippocampus as a function of childhood adversity (for aversive versus neutral images) in all groups.
6-1	976-978	We	_	
6-2	979-984	found	_	
6-3	985-989	that	_	
6-4	990-1000	naltrexone	_	
6-5	1001-1010	modulated	_	
6-6	1011-1023	task-related	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[7]	
6-7	1024-1034	activation	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[7]	
6-8	1035-1037	in	_	
6-9	1038-1041	the	_	
6-10	1042-1048	medial	_	
6-11	1049-1059	prefrontal	_	
6-12	1060-1066	cortex	_	
6-13	1067-1070	and	_	
6-14	1071-1081	functional	_	
6-15	1082-1094	connectivity	_	
6-16	1095-1102	between	_	
6-17	1103-1106	the	_	
6-18	1107-1115	anterior	_	
6-19	1116-1125	cingulate	_	
6-20	1126-1132	cortex	_	
6-21	1133-1136	and	_	
6-22	1137-1140	the	_	
6-23	1141-1152	hippocampus	_	
6-24	1153-1155	as	_	
6-25	1156-1157	a	_	
6-26	1158-1166	function	_	
6-27	1167-1169	of	_	
6-28	1170-1179	childhood	_	
6-29	1180-1189	adversity	_	
6-30	1190-1191	(	_	
6-31	1191-1194	for	_	
6-32	1195-1203	aversive	_	
6-33	1204-1210	versus	_	
6-34	1211-1218	neutral	_	
6-35	1219-1225	images	_	
6-36	1225-1226	)	_	
6-37	1227-1229	in	_	
6-38	1230-1233	all	_	
6-39	1234-1240	groups	_	
6-40	1240-1241	.	_	

#Text=Furthermore, there was a group-by-treatment-by-condition interaction in the right amygdala, which was mainly driven by a normalization of response for aversive relative to neutral images under naltrexone in the alcohol/drugs group.
7-1	1242-1253	Furthermore	_	
7-2	1253-1254	,	_	
7-3	1255-1260	there	_	
7-4	1261-1264	was	_	
7-5	1265-1266	a	_	
7-6	1267-1298	group-by-treatment-by-condition	_	
7-7	1299-1310	interaction	_	
7-8	1311-1313	in	_	
7-9	1314-1317	the	_	
7-10	1318-1323	right	_	
7-11	1324-1332	amygdala	_	
7-12	1332-1333	,	_	
7-13	1334-1339	which	_	
7-14	1340-1343	was	_	
7-15	1344-1350	mainly	_	
7-16	1351-1357	driven	_	
7-17	1358-1360	by	_	
7-18	1361-1362	a	_	
7-19	1363-1376	normalization	_	
7-20	1377-1379	of	_	
7-21	1380-1388	response	_	
7-22	1389-1392	for	_	
7-23	1393-1401	aversive	_	
7-24	1402-1410	relative	_	
7-25	1411-1413	to	_	
7-26	1414-1421	neutral	_	
7-27	1422-1428	images	_	
7-28	1429-1434	under	_	
7-29	1435-1445	naltrexone	_	
7-30	1446-1448	in	_	
7-31	1449-1452	the	_	
7-32	1453-1460	alcohol	_	
7-33	1460-1461	/	_	
7-34	1461-1466	drugs	_	
7-35	1467-1472	group	_	
7-36	1472-1473	.	_	

#Text=We conclude that early childhood adversity is one environmental factor that influences pharmacological response to naltrexone.
8-1	1474-1476	We	_	
8-2	1477-1485	conclude	_	
8-3	1486-1490	that	_	
8-4	1491-1496	early	_	
8-5	1497-1506	childhood	_	
8-6	1507-1516	adversity	_	
8-7	1517-1519	is	_	
8-8	1520-1523	one	_	
8-9	1524-1537	environmental	_	
8-10	1538-1544	factor	_	
8-11	1545-1549	that	_	
8-12	1550-1560	influences	_	
8-13	1561-1576	pharmacological	_	
8-14	1577-1585	response	_	
8-15	1586-1588	to	_	
8-16	1589-1599	naltrexone	_	
8-17	1599-1600	.	_	

#Text=Pharmacotherapy with naltrexone may also have some ameliorative effects on negative emotional processing in combined alcohol and drug dependence, possibly due to alterations in endogenous opioid transmission or the kappa-opioid receptor antagonist actions of naltrexone.
9-1	1601-1616	Pharmacotherapy	_	
9-2	1617-1621	with	_	
9-3	1622-1632	naltrexone	_	
9-4	1633-1636	may	_	
9-5	1637-1641	also	_	
9-6	1642-1646	have	_	
9-7	1647-1651	some	_	
9-8	1652-1664	ameliorative	_	
9-9	1665-1672	effects	_	
9-10	1673-1675	on	_	
9-11	1676-1684	negative	_	
9-12	1685-1694	emotional	_	
9-13	1695-1705	processing	_	
9-14	1706-1708	in	_	
9-15	1709-1717	combined	_	
9-16	1718-1725	alcohol	_	
9-17	1726-1729	and	_	
9-18	1730-1734	drug	_	
9-19	1735-1745	dependence	_	
9-20	1745-1746	,	_	
9-21	1747-1755	possibly	_	
9-22	1756-1759	due	_	
9-23	1760-1762	to	_	
9-24	1763-1774	alterations	_	
9-25	1775-1777	in	_	
9-26	1778-1788	endogenous	_	
9-27	1789-1795	opioid	_	
9-28	1796-1808	transmission	_	
9-29	1809-1811	or	_	
9-30	1812-1815	the	_	
9-31	1816-1828	kappa-opioid	_	
9-32	1829-1837	receptor	_	
9-33	1838-1848	antagonist	_	
9-34	1849-1856	actions	_	
9-35	1857-1859	of	_	
9-36	1860-1870	naltrexone	_	
9-37	1870-1871	.	_	

#Text=Introduction
#Text=Emotions have a critical role in the development, maintenance and successful treatment of addiction.
10-1	1872-1884	Introduction	_	
10-2	1885-1893	Emotions	_	
10-3	1894-1898	have	_	
10-4	1899-1900	a	_	
10-5	1901-1909	critical	_	
10-6	1910-1914	role	_	
10-7	1915-1917	in	_	
10-8	1918-1921	the	_	
10-9	1922-1933	development	_	
10-10	1933-1934	,	_	
10-11	1935-1946	maintenance	_	
10-12	1947-1950	and	_	
10-13	1951-1961	successful	_	
10-14	1962-1971	treatment	_	
10-15	1972-1974	of	_	
10-16	1975-1984	addiction	_	
10-17	1984-1985	.	_	

#Text=Suppression of negative affective states such as anxiety and withdrawal symptoms is one motivational pathway to support the consumption of alcohol.
11-1	1986-1997	Suppression	_	
11-2	1998-2000	of	_	
11-3	2001-2009	negative	_	
11-4	2010-2019	affective	_	
11-5	2020-2026	states	_	
11-6	2027-2031	such	_	
11-7	2032-2034	as	_	
11-8	2035-2042	anxiety	_	
11-9	2043-2046	and	_	
11-10	2047-2057	withdrawal	_	
11-11	2058-2066	symptoms	_	
11-12	2067-2069	is	_	
11-13	2070-2073	one	_	
11-14	2074-2086	motivational	_	
11-15	2087-2094	pathway	_	
11-16	2095-2097	to	_	
11-17	2098-2105	support	_	
11-18	2106-2109	the	_	
11-19	2110-2121	consumption	_	
11-20	2122-2124	of	_	
11-21	2125-2132	alcohol	_	
11-22	2132-2133	.	_	

#Text=As negatively reinforced drinking becomes more pronounced, negative affective states increase, thereby escalating alcohol intake and raising vulnerability to relapse after treatment.
12-1	2134-2136	As	_	
12-2	2137-2147	negatively	_	
12-3	2148-2158	reinforced	_	
12-4	2159-2167	drinking	_	
12-5	2168-2175	becomes	_	
12-6	2176-2180	more	_	
12-7	2181-2191	pronounced	_	
12-8	2191-2192	,	_	
12-9	2193-2201	negative	_	
12-10	2202-2211	affective	_	
12-11	2212-2218	states	_	
12-12	2219-2227	increase	_	
12-13	2227-2228	,	_	
12-14	2229-2236	thereby	_	
12-15	2237-2247	escalating	_	
12-16	2248-2255	alcohol	_	
12-17	2256-2262	intake	_	
12-18	2263-2266	and	_	
12-19	2267-2274	raising	_	
12-20	2275-2288	vulnerability	_	
12-21	2289-2291	to	_	
12-22	2292-2299	relapse	_	
12-23	2300-2305	after	_	
12-24	2306-2315	treatment	_	
12-25	2315-2316	.	_	

#Text=Negative reinforcement is driven by activation of stress-induced neurocircuitry in what is widely referred to as the ‘dark side' view of addiction.
13-1	2317-2325	Negative	_	
13-2	2326-2339	reinforcement	_	
13-3	2340-2342	is	_	
13-4	2343-2349	driven	_	
13-5	2350-2352	by	_	
13-6	2353-2363	activation	_	
13-7	2364-2366	of	_	
13-8	2367-2381	stress-induced	_	
13-9	2382-2396	neurocircuitry	_	
13-10	2397-2399	in	_	
13-11	2400-2404	what	_	
13-12	2405-2407	is	_	
13-13	2408-2414	widely	_	
13-14	2415-2423	referred	_	
13-15	2424-2426	to	_	
13-16	2427-2429	as	_	
13-17	2430-2433	the	_	
13-18	2434-2435	‘	_	
13-19	2435-2439	dark	_	
13-20	2440-2444	side	_	
13-21	2444-2445	'	_	
13-22	2446-2450	view	_	
13-23	2451-2453	of	_	
13-24	2454-2463	addiction	_	
13-25	2463-2464	.	_	

#Text=Negative emotion is thus a key affective process that could be targeted by treatment interventions for addiction.
14-1	2465-2473	Negative	_	
14-2	2474-2481	emotion	_	
14-3	2482-2484	is	_	
14-4	2485-2489	thus	_	
14-5	2490-2491	a	_	
14-6	2492-2495	key	_	
14-7	2496-2505	affective	_	
14-8	2506-2513	process	_	
14-9	2514-2518	that	_	
14-10	2519-2524	could	_	
14-11	2525-2527	be	_	
14-12	2528-2536	targeted	_	
14-13	2537-2539	by	_	
14-14	2540-2549	treatment	_	
14-15	2550-2563	interventions	_	
14-16	2564-2567	for	_	
14-17	2568-2577	addiction	_	
14-18	2577-2578	.	_	

#Text=Functional abnormalities during negative emotional processing have been found in limbic and cortical networks in substance dependence.
15-1	2579-2589	Functional	_	
15-2	2590-2603	abnormalities	_	
15-3	2604-2610	during	_	
15-4	2611-2619	negative	_	
15-5	2620-2629	emotional	_	
15-6	2630-2640	processing	_	
15-7	2641-2645	have	_	
15-8	2646-2650	been	_	
15-9	2651-2656	found	_	
15-10	2657-2659	in	_	
15-11	2660-2666	limbic	_	
15-12	2667-2670	and	_	
15-13	2671-2679	cortical	_	
15-14	2680-2688	networks	_	
15-15	2689-2691	in	_	
15-16	2692-2701	substance	_	
15-17	2702-2712	dependence	_	
15-18	2712-2713	.	_	

#Text=Threat-related reactivity of the amygdala, for example, is strongly associated with negatively reinforced problem drinking.
16-1	2714-2728	Threat-related	_	
16-2	2729-2739	reactivity	_	
16-3	2740-2742	of	_	
16-4	2743-2746	the	_	
16-5	2747-2755	amygdala	_	
16-6	2755-2756	,	_	
16-7	2757-2760	for	_	
16-8	2761-2768	example	_	
16-9	2768-2769	,	_	
16-10	2770-2772	is	_	
16-11	2773-2781	strongly	_	
16-12	2782-2792	associated	_	
16-13	2793-2797	with	_	
16-14	2798-2808	negatively	_	
16-15	2809-2819	reinforced	_	
16-16	2820-2827	problem	_	
16-17	2828-2836	drinking	_	
16-18	2836-2837	.	_	

#Text=Connectivity between the amygdala and the hippocampus is associated with maladaptive emotional processing, and alterations in hippocampal network activation and connectivity have been shown to predict relapse.
17-1	2838-2850	Connectivity	_	
17-2	2851-2858	between	_	
17-3	2859-2862	the	_	
17-4	2863-2871	amygdala	_	
17-5	2872-2875	and	_	
17-6	2876-2879	the	_	
17-7	2880-2891	hippocampus	_	
17-8	2892-2894	is	_	
17-9	2895-2905	associated	_	
17-10	2906-2910	with	_	
17-11	2911-2922	maladaptive	_	
17-12	2923-2932	emotional	_	
17-13	2933-2943	processing	_	
17-14	2943-2944	,	_	
17-15	2945-2948	and	_	
17-16	2949-2960	alterations	_	
17-17	2961-2963	in	_	
17-18	2964-2975	hippocampal	_	
17-19	2976-2983	network	_	
17-20	2984-2994	activation	_	
17-21	2995-2998	and	_	
17-22	2999-3011	connectivity	_	
17-23	3012-3016	have	_	
17-24	3017-3021	been	_	
17-25	3022-3027	shown	_	
17-26	3028-3030	to	_	
17-27	3031-3038	predict	_	
17-28	3039-3046	relapse	_	
17-29	3046-3047	.	_	

#Text=The prefrontal cortex has extensive connections with subcortical structures that regulate emotional processing, including the amygdala.
18-1	3048-3051	The	_	
18-2	3052-3062	prefrontal	_	
18-3	3063-3069	cortex	_	
18-4	3070-3073	has	_	
18-5	3074-3083	extensive	_	
18-6	3084-3095	connections	_	
18-7	3096-3100	with	_	
18-8	3101-3112	subcortical	_	
18-9	3113-3123	structures	_	
18-10	3124-3128	that	_	
18-11	3129-3137	regulate	_	
18-12	3138-3147	emotional	_	
18-13	3148-3158	processing	_	
18-14	3158-3159	,	_	
18-15	3160-3169	including	_	
18-16	3170-3173	the	_	
18-17	3174-3182	amygdala	_	
18-18	3182-3183	.	_	

#Text=Alcohol and drug exposure impairs emotion regulation in this region, with interconnected medial and cingulate networks showing enhanced reactivity to arousing stimuli and reduced capacity to suppress negative affect.
19-1	3184-3191	Alcohol	_	
19-2	3192-3195	and	_	
19-3	3196-3200	drug	_	
19-4	3201-3209	exposure	_	
19-5	3210-3217	impairs	_	
19-6	3218-3225	emotion	_	
19-7	3226-3236	regulation	_	
19-8	3237-3239	in	_	
19-9	3240-3244	this	_	
19-10	3245-3251	region	_	
19-11	3251-3252	,	_	
19-12	3253-3257	with	_	
19-13	3258-3272	interconnected	_	
19-14	3273-3279	medial	_	
19-15	3280-3283	and	_	
19-16	3284-3293	cingulate	_	
19-17	3294-3302	networks	_	
19-18	3303-3310	showing	_	
19-19	3311-3319	enhanced	_	
19-20	3320-3330	reactivity	_	
19-21	3331-3333	to	_	
19-22	3334-3342	arousing	_	
19-23	3343-3350	stimuli	_	
19-24	3351-3354	and	_	
19-25	3355-3362	reduced	_	
19-26	3363-3371	capacity	_	
19-27	3372-3374	to	_	
19-28	3375-3383	suppress	_	
19-29	3384-3392	negative	_	
19-30	3393-3399	affect	_	
19-31	3399-3400	.	_	

#Text=The medial prefrontal cortex (mPFC) and anterior cingulate cortex (ACC) also act to appraise and regulate negative emotions.
20-1	3401-3404	The	_	
20-2	3405-3411	medial	_	
20-3	3412-3422	prefrontal	_	
20-4	3423-3429	cortex	_	
20-5	3430-3431	(	_	
20-6	3431-3435	mPFC	_	
20-7	3435-3436	)	_	
20-8	3437-3440	and	_	
20-9	3441-3449	anterior	_	
20-10	3450-3459	cingulate	_	
20-11	3460-3466	cortex	_	
20-12	3467-3468	(	_	
20-13	3468-3471	ACC	_	
20-14	3471-3472	)	_	
20-15	3473-3477	also	_	
20-16	3478-3481	act	_	
20-17	3482-3484	to	_	
20-18	3485-3493	appraise	_	
20-19	3494-3497	and	_	
20-20	3498-3506	regulate	_	
20-21	3507-3515	negative	_	
20-22	3516-3524	emotions	_	
20-23	3524-3525	.	_	

#Text=These cortical areas over-activate in response to substance-related and naturally evocative stimuli and, together with limbic regions associated with impaired emotional processing in addiction, are candidate loci for pharmacological intervention.
21-1	3526-3531	These	_	
21-2	3532-3540	cortical	_	
21-3	3541-3546	areas	_	
21-4	3547-3560	over-activate	_	
21-5	3561-3563	in	_	
21-6	3564-3572	response	_	
21-7	3573-3575	to	_	
21-8	3576-3593	substance-related	_	
21-9	3594-3597	and	_	
21-10	3598-3607	naturally	_	
21-11	3608-3617	evocative	_	
21-12	3618-3625	stimuli	_	
21-13	3626-3629	and	_	
21-14	3629-3630	,	_	
21-15	3631-3639	together	_	
21-16	3640-3644	with	_	
21-17	3645-3651	limbic	_	
21-18	3652-3659	regions	_	
21-19	3660-3670	associated	_	
21-20	3671-3675	with	_	
21-21	3676-3684	impaired	_	
21-22	3685-3694	emotional	_	
21-23	3695-3705	processing	_	
21-24	3706-3708	in	_	
21-25	3709-3718	addiction	_	
21-26	3718-3719	,	_	
21-27	3720-3723	are	_	
21-28	3724-3733	candidate	_	
21-29	3734-3738	loci	_	
21-30	3739-3742	for	_	
21-31	3743-3758	pharmacological	_	
21-32	3759-3771	intervention	_	
21-33	3771-3772	.	_	

#Text=Naltrexone is one pharmacotherapy used in the management of alcohol dependence that works by modulating opioid control of dopaminergic cell firing in the ventral tegmental area, thus preventing an increase in dopaminergic activity.
22-1	3773-3783	Naltrexone	_	
22-2	3784-3786	is	_	
22-3	3787-3790	one	_	
22-4	3791-3806	pharmacotherapy	_	
22-5	3807-3811	used	_	
22-6	3812-3814	in	_	
22-7	3815-3818	the	_	
22-8	3819-3829	management	_	
22-9	3830-3832	of	_	
22-10	3833-3840	alcohol	_	
22-11	3841-3851	dependence	_	
22-12	3852-3856	that	_	
22-13	3857-3862	works	_	
22-14	3863-3865	by	_	
22-15	3866-3876	modulating	_	
22-16	3877-3883	opioid	_	
22-17	3884-3891	control	_	
22-18	3892-3894	of	_	
22-19	3895-3907	dopaminergic	_	
22-20	3908-3912	cell	_	
22-21	3913-3919	firing	_	
22-22	3920-3922	in	_	
22-23	3923-3926	the	_	
22-24	3927-3934	ventral	_	
22-25	3935-3944	tegmental	_	
22-26	3945-3949	area	_	
22-27	3949-3950	,	_	
22-28	3951-3955	thus	_	
22-29	3956-3966	preventing	_	
22-30	3967-3969	an	_	
22-31	3970-3978	increase	_	
22-32	3979-3981	in	_	
22-33	3982-3994	dopaminergic	_	
22-34	3995-4003	activity	_	
22-35	4003-4004	.	_	

#Text=The endogenous opioid system has been implicated in emotion regulation.
23-1	4005-4008	The	_	
23-2	4009-4019	endogenous	_	
23-3	4020-4026	opioid	_	
23-4	4027-4033	system	_	
23-5	4034-4037	has	_	
23-6	4038-4042	been	_	
23-7	4043-4053	implicated	_	
23-8	4054-4056	in	_	
23-9	4057-4064	emotion	_	
23-10	4065-4075	regulation	_	
23-11	4075-4076	.	_	

#Text=There is some evidence of naltrexone dampening responses to negative emotional stimuli in healthy adults, although this likely reflects stress-reducing effects of the potent kappa-opioid receptor (KOR) antagonist actions of naltrexone. mu-opioid receptor (MOR) antagonism is known to precipitate withdrawal symptoms in humans with current and previous opiate use.
24-1	4077-4082	There	_	
24-2	4083-4085	is	_	
24-3	4086-4090	some	_	
24-4	4091-4099	evidence	_	
24-5	4100-4102	of	_	
24-6	4103-4113	naltrexone	_	
24-7	4114-4123	dampening	_	
24-8	4124-4133	responses	_	
24-9	4134-4136	to	_	
24-10	4137-4145	negative	_	
24-11	4146-4155	emotional	_	
24-12	4156-4163	stimuli	_	
24-13	4164-4166	in	_	
24-14	4167-4174	healthy	_	
24-15	4175-4181	adults	_	
24-16	4181-4182	,	_	
24-17	4183-4191	although	_	
24-18	4192-4196	this	_	
24-19	4197-4203	likely	_	
24-20	4204-4212	reflects	_	
24-21	4213-4228	stress-reducing	_	
24-22	4229-4236	effects	_	
24-23	4237-4239	of	_	
24-24	4240-4243	the	_	
24-25	4244-4250	potent	_	
24-26	4251-4263	kappa-opioid	_	
24-27	4264-4272	receptor	_	
24-28	4273-4274	(	_	
24-29	4274-4277	KOR	_	
24-30	4277-4278	)	_	
24-31	4279-4289	antagonist	_	
24-32	4290-4297	actions	_	
24-33	4298-4300	of	_	
24-34	4301-4311	naltrexone	_	
24-35	4311-4312	.	_	
24-36	4313-4322	mu-opioid	_	
24-37	4323-4331	receptor	_	
24-38	4332-4333	(	_	
24-39	4333-4336	MOR	_	
24-40	4336-4337	)	_	
24-41	4338-4348	antagonism	_	
24-42	4349-4351	is	_	
24-43	4352-4357	known	_	
24-44	4358-4360	to	_	
24-45	4361-4372	precipitate	_	
24-46	4373-4383	withdrawal	_	
24-47	4384-4392	symptoms	_	
24-48	4393-4395	in	_	
24-49	4396-4402	humans	_	
24-50	4403-4407	with	_	
24-51	4408-4415	current	_	
24-52	4416-4419	and	_	
24-53	4420-4428	previous	_	
24-54	4429-4435	opiate	_	
24-55	4436-4439	use	_	
24-56	4439-4440	.	_	

#Text=MOR antagonism also precipitates aversive consequences of withdrawal from chronic opioid exposure in animals.
25-1	4441-4444	MOR	_	
25-2	4445-4455	antagonism	_	
25-3	4456-4460	also	_	
25-4	4461-4473	precipitates	_	
25-5	4474-4482	aversive	_	
25-6	4483-4495	consequences	_	
25-7	4496-4498	of	_	
25-8	4499-4509	withdrawal	_	
25-9	4510-4514	from	_	
25-10	4515-4522	chronic	_	
25-11	4523-4529	opioid	_	
25-12	4530-4538	exposure	_	
25-13	4539-4541	in	_	
25-14	4542-4549	animals	_	
25-15	4549-4550	.	_	

#Text=Naltrexone increases negative emotions in response to stress- and drug-related images in individuals with opioid dependence and increases anxiety in response to drug-related films in individuals with alcohol and cocaine dependence.
26-1	4551-4561	Naltrexone	_	
26-2	4562-4571	increases	_	
26-3	4572-4580	negative	_	
26-4	4581-4589	emotions	_	
26-5	4590-4592	in	_	
26-6	4593-4601	response	_	
26-7	4602-4604	to	_	
26-8	4605-4611	stress	_	
26-9	4611-4612	-	_	
26-10	4613-4616	and	_	
26-11	4617-4629	drug-related	_	
26-12	4630-4636	images	_	
26-13	4637-4639	in	_	
26-14	4640-4651	individuals	_	
26-15	4652-4656	with	_	
26-16	4657-4663	opioid	_	
26-17	4664-4674	dependence	_	
26-18	4675-4678	and	_	
26-19	4679-4688	increases	_	
26-20	4689-4696	anxiety	_	
26-21	4697-4699	in	_	
26-22	4700-4708	response	_	
26-23	4709-4711	to	_	
26-24	4712-4724	drug-related	_	
26-25	4725-4730	films	_	
26-26	4731-4733	in	_	
26-27	4734-4745	individuals	_	
26-28	4746-4750	with	_	
26-29	4751-4758	alcohol	_	
26-30	4759-4762	and	_	
26-31	4763-4770	cocaine	_	
26-32	4771-4781	dependence	_	
26-33	4781-4782	.	_	

#Text=However, the efficacy of naltrexone treatment has been shown to be associated with greater naltrexone-induced aversion (that is, the more negative the aversive stimulus, the greater the treatment response).
27-1	4783-4790	However	_	
27-2	4790-4791	,	_	
27-3	4792-4795	the	_	
27-4	4796-4804	efficacy	_	
27-5	4805-4807	of	_	
27-6	4808-4818	naltrexone	_	
27-7	4819-4828	treatment	_	
27-8	4829-4832	has	_	
27-9	4833-4837	been	_	
27-10	4838-4843	shown	_	
27-11	4844-4846	to	_	
27-12	4847-4849	be	_	
27-13	4850-4860	associated	_	
27-14	4861-4865	with	_	
27-15	4866-4873	greater	_	
27-16	4874-4892	naltrexone-induced	_	
27-17	4893-4901	aversion	_	
27-18	4902-4903	(	_	
27-19	4903-4907	that	_	
27-20	4908-4910	is	_	
27-21	4910-4911	,	_	
27-22	4912-4915	the	_	
27-23	4916-4920	more	_	
27-24	4921-4929	negative	_	
27-25	4930-4933	the	_	
27-26	4934-4942	aversive	_	
27-27	4943-4951	stimulus	_	
27-28	4951-4952	,	_	
27-29	4953-4956	the	_	
27-30	4957-4964	greater	_	
27-31	4965-4968	the	_	
27-32	4969-4978	treatment	_	
27-33	4979-4987	response	_	
27-34	4987-4988	)	_	
27-35	4988-4989	.	_	

#Text=This may be due, in part, by activation of the hypothalamic–pituitary–adrenal (HPA) axis associated with all substances of abuse potential.
28-1	4990-4994	This	_	
28-2	4995-4998	may	_	
28-3	4999-5001	be	_	
28-4	5002-5005	due	_	
28-5	5005-5006	,	_	
28-6	5007-5009	in	_	
28-7	5010-5014	part	_	
28-8	5014-5015	,	_	
28-9	5016-5018	by	_	
28-10	5019-5029	activation	_	
28-11	5030-5032	of	_	
28-12	5033-5036	the	_	
28-13	5037-5067	hypothalamic–pituitary–adrenal	_	
28-14	5068-5069	(	_	
28-15	5069-5072	HPA	_	
28-16	5072-5073	)	_	
28-17	5074-5078	axis	_	
28-18	5079-5089	associated	_	
28-19	5090-5094	with	_	
28-20	5095-5098	all	_	
28-21	5099-5109	substances	_	
28-22	5110-5112	of	_	
28-23	5113-5118	abuse	_	
28-24	5119-5128	potential	_	
28-25	5128-5129	.	_	

#Text=Specifically, naltrexone-induced adrenocorticotropic hormone and cortisol levels are thought to reduce craving in individuals with alcohol dependence.
29-1	5130-5142	Specifically	_	
29-2	5142-5143	,	_	
29-3	5144-5162	naltrexone-induced	_	
29-4	5163-5182	adrenocorticotropic	_	
29-5	5183-5190	hormone	_	
29-6	5191-5194	and	_	
29-7	5195-5203	cortisol	_	
29-8	5204-5210	levels	_	
29-9	5211-5214	are	_	
29-10	5215-5222	thought	_	
29-11	5223-5225	to	_	
29-12	5226-5232	reduce	_	
29-13	5233-5240	craving	_	
29-14	5241-5243	in	_	
29-15	5244-5255	individuals	_	
29-16	5256-5260	with	_	
29-17	5261-5268	alcohol	_	
29-18	5269-5279	dependence	_	
29-19	5279-5280	.	_	

#Text=Exposure to psychological trauma, another form of aversion, is also known to contribute to individual treatment responses to naltrexone.
30-1	5281-5289	Exposure	_	
30-2	5290-5292	to	_	
30-3	5293-5306	psychological	_	
30-4	5307-5313	trauma	_	
30-5	5313-5314	,	_	
30-6	5315-5322	another	_	
30-7	5323-5327	form	_	
30-8	5328-5330	of	_	
30-9	5331-5339	aversion	_	
30-10	5339-5340	,	_	
30-11	5341-5343	is	_	
30-12	5344-5348	also	_	
30-13	5349-5354	known	_	
30-14	5355-5357	to	_	
30-15	5358-5368	contribute	_	
30-16	5369-5371	to	_	
30-17	5372-5382	individual	_	
30-18	5383-5392	treatment	_	
30-19	5393-5402	responses	_	
30-20	5403-5405	to	_	
30-21	5406-5416	naltrexone	_	
30-22	5416-5417	.	_	

#Text=This is consistent with preclinical evidence showing that early environmental adversity is associated with better treatment effects of naltrexone, suggesting that adversity experienced in early stages of development upregulates endogenous opioid function.
31-1	5418-5422	This	_	
31-2	5423-5425	is	_	
31-3	5426-5436	consistent	_	
31-4	5437-5441	with	_	
31-5	5442-5453	preclinical	_	
31-6	5454-5462	evidence	_	
31-7	5463-5470	showing	_	
31-8	5471-5475	that	_	
31-9	5476-5481	early	_	
31-10	5482-5495	environmental	_	
31-11	5496-5505	adversity	_	
31-12	5506-5508	is	_	
31-13	5509-5519	associated	_	
31-14	5520-5524	with	_	
31-15	5525-5531	better	_	
31-16	5532-5541	treatment	_	
31-17	5542-5549	effects	_	
31-18	5550-5552	of	_	
31-19	5553-5563	naltrexone	_	
31-20	5563-5564	,	_	
31-21	5565-5575	suggesting	_	
31-22	5576-5580	that	_	
31-23	5581-5590	adversity	_	
31-24	5591-5602	experienced	_	
31-25	5603-5605	in	_	
31-26	5606-5611	early	_	
31-27	5612-5618	stages	_	
31-28	5619-5621	of	_	
31-29	5622-5633	development	_	
31-30	5634-5645	upregulates	_	
31-31	5646-5656	endogenous	_	
31-32	5657-5663	opioid	_	
31-33	5664-5672	function	_	
31-34	5672-5673	.	_	

#Text=Childhood adversity has long been known to be common in substance use disorders, with at least two-thirds of alcohol- or drug-dependent adults reporting a history of physical, sexual or emotional abuse.
32-1	5674-5683	Childhood	_	
32-2	5684-5693	adversity	_	
32-3	5694-5697	has	_	
32-4	5698-5702	long	_	
32-5	5703-5707	been	_	
32-6	5708-5713	known	_	
32-7	5714-5716	to	_	
32-8	5717-5719	be	_	
32-9	5720-5726	common	_	
32-10	5727-5729	in	_	
32-11	5730-5739	substance	_	
32-12	5740-5743	use	_	
32-13	5744-5753	disorders	_	
32-14	5753-5754	,	_	
32-15	5755-5759	with	_	
32-16	5760-5762	at	_	
32-17	5763-5768	least	_	
32-18	5769-5779	two-thirds	_	
32-19	5780-5782	of	_	
32-20	5783-5790	alcohol	_	
32-21	5790-5791	-	_	
32-22	5792-5794	or	_	
32-23	5795-5809	drug-dependent	_	
32-24	5810-5816	adults	_	
32-25	5817-5826	reporting	_	
32-26	5827-5828	a	_	
32-27	5829-5836	history	_	
32-28	5837-5839	of	_	
32-29	5840-5848	physical	_	
32-30	5848-5849	,	_	
32-31	5850-5856	sexual	_	
32-32	5857-5859	or	_	
32-33	5860-5869	emotional	_	
32-34	5870-5875	abuse	_	
32-35	5875-5876	.	_	

#Text=Childhood adversity leads to more illicit substance use and increases the risk of dependence in adulthood.
33-1	5877-5886	Childhood	_	
33-2	5887-5896	adversity	_	
33-3	5897-5902	leads	_	
33-4	5903-5905	to	_	
33-5	5906-5910	more	_	
33-6	5911-5918	illicit	_	
33-7	5919-5928	substance	_	
33-8	5929-5932	use	_	
33-9	5933-5936	and	_	
33-10	5937-5946	increases	_	
33-11	5947-5950	the	_	
33-12	5951-5955	risk	_	
33-13	5956-5958	of	_	
33-14	5959-5969	dependence	_	
33-15	5970-5972	in	_	
33-16	5973-5982	adulthood	_	
33-17	5982-5983	.	_	

#Text=Combined alcohol and drug dependence is particularly harmful, as individuals dependent on both consume more units of alcohol and have greater incidence and severity of psychiatric illness than individuals dependent on alcohol alone.
34-1	5984-5992	Combined	_	
34-2	5993-6000	alcohol	_	
34-3	6001-6004	and	_	
34-4	6005-6009	drug	_	
34-5	6010-6020	dependence	_	
34-6	6021-6023	is	_	
34-7	6024-6036	particularly	_	
34-8	6037-6044	harmful	_	
34-9	6044-6045	,	_	
34-10	6046-6048	as	_	
34-11	6049-6060	individuals	_	
34-12	6061-6070	dependent	_	
34-13	6071-6073	on	_	
34-14	6074-6078	both	_	
34-15	6079-6086	consume	_	
34-16	6087-6091	more	_	
34-17	6092-6097	units	_	
34-18	6098-6100	of	_	
34-19	6101-6108	alcohol	_	
34-20	6109-6112	and	_	
34-21	6113-6117	have	_	
34-22	6118-6125	greater	_	
34-23	6126-6135	incidence	_	
34-24	6136-6139	and	_	
34-25	6140-6148	severity	_	
34-26	6149-6151	of	_	
34-27	6152-6163	psychiatric	_	
34-28	6164-6171	illness	_	
34-29	6172-6176	than	_	
34-30	6177-6188	individuals	_	
34-31	6189-6198	dependent	_	
34-32	6199-6201	on	_	
34-33	6202-6209	alcohol	_	
34-34	6210-6215	alone	_	
34-35	6215-6216	.	_	

#Text=The heterogeneity of alcohol use disorders, including concurrent non-alcohol drug use, necessitates development of more tailored treatment approaches.
35-1	6217-6220	The	_	
35-2	6221-6234	heterogeneity	_	
35-3	6235-6237	of	_	
35-4	6238-6245	alcohol	_	
35-5	6246-6249	use	_	
35-6	6250-6259	disorders	_	
35-7	6259-6260	,	_	
35-8	6261-6270	including	_	
35-9	6271-6281	concurrent	_	
35-10	6282-6293	non-alcohol	_	
35-11	6294-6298	drug	_	
35-12	6299-6302	use	_	
35-13	6302-6303	,	_	
35-14	6304-6316	necessitates	_	
35-15	6317-6328	development	_	
35-16	6329-6331	of	_	
35-17	6332-6336	more	_	
35-18	6337-6345	tailored	_	
35-19	6346-6355	treatment	_	
35-20	6356-6366	approaches	_	
35-21	6366-6367	.	_	

#Text=However, patients are typically categorized according to their primary dependency or by the drug for which they seek treatment.
36-1	6368-6375	However	_	
36-2	6375-6376	,	_	
36-3	6377-6385	patients	_	
36-4	6386-6389	are	_	
36-5	6390-6399	typically	_	
36-6	6400-6411	categorized	_	
36-7	6412-6421	according	_	
36-8	6422-6424	to	_	
36-9	6425-6430	their	_	
36-10	6431-6438	primary	_	
36-11	6439-6449	dependency	_	
36-12	6450-6452	or	_	
36-13	6453-6455	by	_	
36-14	6456-6459	the	_	
36-15	6460-6464	drug	_	
36-16	6465-6468	for	_	
36-17	6469-6474	which	_	
36-18	6475-6479	they	_	
36-19	6480-6484	seek	_	
36-20	6485-6494	treatment	_	
36-21	6494-6495	.	_	

#Text=Personalized assessment and specialized treatments addressing the effects of combined alcohol and drug-taking behavior are often omitted, thus reducing the potential for more successful recovery.
37-1	6496-6508	Personalized	_	
37-2	6509-6519	assessment	_	
37-3	6520-6523	and	_	
37-4	6524-6535	specialized	_	
37-5	6536-6546	treatments	_	
37-6	6547-6557	addressing	_	
37-7	6558-6561	the	_	
37-8	6562-6569	effects	_	
37-9	6570-6572	of	_	
37-10	6573-6581	combined	_	
37-11	6582-6589	alcohol	_	
37-12	6590-6593	and	_	
37-13	6594-6605	drug-taking	_	
37-14	6606-6614	behavior	_	
37-15	6615-6618	are	_	
37-16	6619-6624	often	_	
37-17	6625-6632	omitted	_	
37-18	6632-6633	,	_	
37-19	6634-6638	thus	_	
37-20	6639-6647	reducing	_	
37-21	6648-6651	the	_	
37-22	6652-6661	potential	_	
37-23	6662-6665	for	_	
37-24	6666-6670	more	_	
37-25	6671-6681	successful	_	
37-26	6682-6690	recovery	_	
37-27	6690-6691	.	_	

#Text=We used functional magnetic resonance imaging (fMRI) to investigate brain response to aversive and neutral images.
38-1	6692-6694	We	_	
38-2	6695-6699	used	_	
38-3	6700-6710	functional	_	
38-4	6711-6719	magnetic	_	
38-5	6720-6729	resonance	_	
38-6	6730-6737	imaging	_	
38-7	6738-6739	(	_	
38-8	6739-6743	fMRI	_	
38-9	6743-6744	)	_	
38-10	6745-6747	to	_	
38-11	6748-6759	investigate	_	
38-12	6760-6765	brain	_	
38-13	6766-6774	response	_	
38-14	6775-6777	to	_	
38-15	6778-6786	aversive	_	
38-16	6787-6790	and	_	
38-17	6791-6798	neutral	_	
38-18	6799-6805	images	_	
38-19	6805-6806	.	_	

#Text=We sought to determine the effects of naltrexone at standard dose (50 mg) during negative emotional processing between groups dependent on alcohol alone, dependent on alcohol and drugs (both in abstinence) and healthy control volunteers.
39-1	6807-6809	We	_	
39-2	6810-6816	sought	_	
39-3	6817-6819	to	_	
39-4	6820-6829	determine	_	
39-5	6830-6833	the	_	
39-6	6834-6841	effects	_	
39-7	6842-6844	of	_	
39-8	6845-6855	naltrexone	_	
39-9	6856-6858	at	_	
39-10	6859-6867	standard	_	
39-11	6868-6872	dose	_	
39-12	6873-6874	(	_	
39-13	6874-6876	50	_	
39-14	6877-6879	mg	_	
39-15	6879-6880	)	_	
39-16	6881-6887	during	_	
39-17	6888-6896	negative	_	
39-18	6897-6906	emotional	_	
39-19	6907-6917	processing	_	
39-20	6918-6925	between	_	
39-21	6926-6932	groups	_	
39-22	6933-6942	dependent	_	
39-23	6943-6945	on	_	
39-24	6946-6953	alcohol	_	
39-25	6954-6959	alone	_	
39-26	6959-6960	,	_	
39-27	6961-6970	dependent	_	
39-28	6971-6973	on	_	
39-29	6974-6981	alcohol	_	
39-30	6982-6985	and	_	
39-31	6986-6991	drugs	_	
39-32	6992-6993	(	_	
39-33	6993-6997	both	_	
39-34	6998-7000	in	_	
39-35	7001-7011	abstinence	_	
39-36	7011-7012	)	_	
39-37	7013-7016	and	_	
39-38	7017-7024	healthy	_	
39-39	7025-7032	control	_	
39-40	7033-7043	volunteers	_	
39-41	7043-7044	.	_	

#Text=On the basis of previous research showing altered activation in limbic and cortical networks during negative emotional processing in substance-dependent individuals, including the processing of evocative and negative emotional images, we hypothesized that the dependent groups would show increased activation in the amygdala, the mPFC and the hippocampus in response to aversive images.
40-1	7045-7047	On	_	
40-2	7048-7051	the	_	
40-3	7052-7057	basis	_	
40-4	7058-7060	of	_	
40-5	7061-7069	previous	_	
40-6	7070-7078	research	_	
40-7	7079-7086	showing	_	
40-8	7087-7094	altered	_	
40-9	7095-7105	activation	_	
40-10	7106-7108	in	_	
40-11	7109-7115	limbic	_	
40-12	7116-7119	and	_	
40-13	7120-7128	cortical	_	
40-14	7129-7137	networks	_	
40-15	7138-7144	during	_	
40-16	7145-7153	negative	_	
40-17	7154-7163	emotional	_	
40-18	7164-7174	processing	_	
40-19	7175-7177	in	_	
40-20	7178-7197	substance-dependent	_	
40-21	7198-7209	individuals	_	
40-22	7209-7210	,	_	
40-23	7211-7220	including	_	
40-24	7221-7224	the	_	
40-25	7225-7235	processing	_	
40-26	7236-7238	of	_	
40-27	7239-7248	evocative	_	
40-28	7249-7252	and	_	
40-29	7253-7261	negative	_	
40-30	7262-7271	emotional	_	
40-31	7272-7278	images	_	
40-32	7278-7279	,	_	
40-33	7280-7282	we	_	
40-34	7283-7295	hypothesized	_	
40-35	7296-7300	that	_	
40-36	7301-7304	the	_	
40-37	7305-7314	dependent	_	
40-38	7315-7321	groups	_	
40-39	7322-7327	would	_	
40-40	7328-7332	show	_	
40-41	7333-7342	increased	_	
40-42	7343-7353	activation	_	
40-43	7354-7356	in	_	
40-44	7357-7360	the	_	
40-45	7361-7369	amygdala	_	
40-46	7369-7370	,	_	
40-47	7371-7374	the	_	
40-48	7375-7379	mPFC	_	
40-49	7380-7383	and	_	
40-50	7384-7387	the	_	
40-51	7388-7399	hippocampus	_	
40-52	7400-7402	in	_	
40-53	7403-7411	response	_	
40-54	7412-7414	to	_	
40-55	7415-7423	aversive	_	
40-56	7424-7430	images	_	
40-57	7430-7431	.	_	

#Text=In light of preclinical evidence, we further hypothesized that these effects would be modulated by naltrexone depending on the degree of childhood adversity experienced.
41-1	7432-7434	In	_	
41-2	7435-7440	light	_	
41-3	7441-7443	of	_	
41-4	7444-7455	preclinical	_	
41-5	7456-7464	evidence	_	
41-6	7464-7465	,	_	
41-7	7466-7468	we	_	
41-8	7469-7476	further	_	
41-9	7477-7489	hypothesized	_	
41-10	7490-7494	that	_	
41-11	7495-7500	these	_	
41-12	7501-7508	effects	_	
41-13	7509-7514	would	_	
41-14	7515-7517	be	_	
41-15	7518-7527	modulated	_	
41-16	7528-7530	by	_	
41-17	7531-7541	naltrexone	_	
41-18	7542-7551	depending	_	
41-19	7552-7554	on	_	
41-20	7555-7558	the	_	
41-21	7559-7565	degree	_	
41-22	7566-7568	of	_	
41-23	7569-7578	childhood	_	
41-24	7579-7588	adversity	_	
41-25	7589-7600	experienced	_	
41-26	7600-7601	.	_	

#Text=Materials and methods
#Text=Participants
#Text=This was a double-blind, placebo-controlled, randomized, crossover study involving three sites (Imperial College London, University of Cambridge, University of Manchester; ICCAM).
42-1	7602-7611	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
42-2	7612-7615	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
42-3	7616-7623	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
42-4	7624-7636	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-5	7637-7641	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-6	7642-7645	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-7	7646-7647	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-8	7648-7660	double-blind	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-9	7660-7661	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-10	7662-7680	placebo-controlled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-11	7680-7681	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-12	7682-7692	randomized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-13	7692-7693	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-14	7694-7703	crossover	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-15	7704-7709	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-16	7710-7719	involving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-17	7720-7725	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-18	7726-7731	sites	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-19	7732-7733	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-20	7733-7741	Imperial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-21	7742-7749	College	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-22	7750-7756	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-23	7756-7757	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-24	7758-7768	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-25	7769-7771	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-26	7772-7781	Cambridge	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-27	7781-7782	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-28	7783-7793	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-29	7794-7796	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-30	7797-7807	Manchester	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-31	7807-7808	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-32	7809-7814	ICCAM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-33	7814-7815	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
42-34	7815-7816	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Full details of the ICCAM platform are reported elsewhere.
43-1	7817-7821	Full	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-2	7822-7829	details	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-3	7830-7832	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-4	7833-7836	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-5	7837-7842	ICCAM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-6	7843-7851	platform	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-7	7852-7855	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-8	7856-7864	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-9	7865-7874	elsewhere	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-10	7874-7875	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Briefly, inclusion criteria were fluency in English; age 20–64; meeting DSM-IV criteria for alcohol, cocaine, amphetamine or opiate dependence; and abstinence from alcohol or drugs for at least 4 weeks prior to the experimental medicine sessions.
44-1	7876-7883	Briefly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-2	7883-7884	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-3	7885-7894	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-4	7895-7903	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-5	7904-7908	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-6	7909-7916	fluency	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-7	7917-7919	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-8	7920-7927	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-9	7927-7928	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-10	7929-7932	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-11	7933-7935	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-12	7935-7936	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-13	7936-7938	64	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-14	7938-7939	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-15	7940-7947	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-16	7948-7954	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-17	7955-7963	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-18	7964-7967	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-19	7968-7975	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[11]	
44-20	7975-7976	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-21	7977-7984	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[12]	
44-22	7984-7985	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
44-23	7986-7997	amphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence[14]	
44-24	7998-8000	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-25	8001-8007	opiate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[15]	
44-26	8008-8018	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[15]	
44-27	8018-8019	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-28	8020-8023	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-29	8024-8034	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[16]	
44-30	8035-8039	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[16]	
44-31	8040-8047	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[16]	
44-32	8048-8050	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[16]	
44-33	8051-8056	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[16]	
44-34	8057-8060	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-35	8061-8063	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-36	8064-8069	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-37	8070-8071	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-38	8072-8077	weeks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-39	8078-8083	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-40	8084-8086	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-41	8087-8090	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-42	8091-8103	experimental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-43	8104-8112	medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-44	8113-8121	sessions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-45	8121-8122	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Control participants did not meet DSM-IV criteria for any disorder.
45-1	8123-8130	Control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[18]	
45-2	8131-8143	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[18]	
45-3	8144-8147	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-4	8148-8151	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-5	8152-8156	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-6	8157-8163	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-7	8164-8172	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-8	8173-8176	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-9	8177-8180	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-10	8181-8189	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-11	8189-8190	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=Exclusion criteria for all participants were use of medication that could not be paused for the study duration; current primary Axis I or neurological diagnosis; current or past psychiatric history (excluding lifetime or secondary history of anxiety or depression); and MRI contraindications.
46-1	8191-8200	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-2	8201-8209	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-3	8210-8213	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-4	8214-8217	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-5	8218-8230	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-6	8231-8235	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-7	8236-8239	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-8	8240-8242	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-9	8243-8253	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-10	8254-8258	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-11	8259-8264	could	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-12	8265-8268	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-13	8269-8271	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-14	8272-8278	paused	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-15	8279-8282	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-16	8283-8286	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-17	8287-8292	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-18	8293-8301	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-19	8301-8302	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-20	8303-8310	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-21	8311-8318	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-22	8319-8323	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-23	8324-8325	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-24	8326-8328	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-25	8329-8341	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-26	8342-8351	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-27	8351-8352	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-28	8353-8360	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-29	8361-8363	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-30	8364-8368	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-31	8369-8380	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-32	8381-8388	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-33	8389-8390	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-34	8390-8399	excluding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-35	8400-8408	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-36	8409-8411	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-37	8412-8421	secondary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-38	8422-8429	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-39	8430-8432	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-40	8433-8440	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-41	8441-8443	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-42	8444-8454	depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-43	8454-8455	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-44	8455-8456	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-45	8457-8460	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-46	8461-8464	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-47	8465-8482	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
46-48	8482-8483	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	

#Text=All participants screened negative (using urine samples) for amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
47-1	8484-8487	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-2	8488-8500	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-3	8501-8509	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-4	8510-8518	negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-5	8519-8520	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-6	8520-8525	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-7	8526-8531	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-8	8532-8539	samples	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-9	8539-8540	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-10	8541-8544	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-11	8545-8557	amphetamines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-12	8557-8558	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-13	8559-8571	barbiturates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-14	8571-8572	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-15	8573-8580	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-16	8580-8581	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-17	8582-8589	opiates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-18	8589-8590	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-19	8591-8603	cannabinoids	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-20	8604-8607	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-21	8608-8623	benzodiazepines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
47-22	8623-8624	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=Here, we compared the effects of naltrexone between individuals who were only dependent on alcohol from individuals who in addition to alcohol were also dependent on cocaine and/or opiates.
48-1	8625-8629	Here	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-2	8629-8630	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-3	8631-8633	we	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-4	8634-8642	compared	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-5	8643-8646	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-6	8647-8654	effects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-7	8655-8657	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-8	8658-8668	naltrexone	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-9	8669-8676	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-10	8677-8688	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-11	8689-8692	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-12	8693-8697	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-13	8698-8702	only	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-14	8703-8712	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-15	8713-8715	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-16	8716-8723	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-17	8724-8728	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-18	8729-8740	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-19	8741-8744	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-20	8745-8747	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-21	8748-8756	addition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-22	8757-8759	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-23	8760-8767	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-24	8768-8772	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-25	8773-8777	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-26	8778-8787	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-27	8788-8790	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-28	8791-8798	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-29	8799-8802	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-30	8802-8803	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-31	8803-8805	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-32	8806-8813	opiates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
48-33	8813-8814	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	

#Text=This distinction was made due to evidence showing that individuals dependent on alcohol and drugs have more severe psychopathology, and differences in brain function and structure compared with individuals dependent on alcohol alone.
49-1	8815-8819	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-2	8820-8831	distinction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-3	8832-8835	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-4	8836-8840	made	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-5	8841-8844	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-6	8845-8847	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-7	8848-8856	evidence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-8	8857-8864	showing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-9	8865-8869	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-10	8870-8881	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-11	8882-8891	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-12	8892-8894	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-13	8895-8902	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-14	8903-8906	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-15	8907-8912	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-16	8913-8917	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-17	8918-8922	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-18	8923-8929	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-19	8930-8945	psychopathology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-20	8945-8946	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-21	8947-8950	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-22	8951-8962	differences	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-23	8963-8965	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-24	8966-8971	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-25	8972-8980	function	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-26	8981-8984	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-27	8985-8994	structure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-28	8995-9003	compared	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-29	9004-9008	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-30	9009-9020	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-31	9021-9030	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-32	9031-9033	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-33	9034-9041	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-34	9042-9047	alone	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-35	9047-9048	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	

#Text=Control participants with a history of heavy alcohol or drug use were also excluded due to known associated functional and structural abnormalities.
50-1	9049-9056	Control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[25]	
50-2	9057-9069	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[25]	
50-3	9070-9074	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-4	9075-9076	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-5	9077-9084	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-6	9085-9087	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-7	9088-9093	heavy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-8	9094-9101	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-9	9102-9104	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-10	9105-9109	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-11	9110-9113	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-12	9114-9118	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-13	9119-9123	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-14	9124-9132	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-15	9133-9136	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-16	9137-9139	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-17	9140-9145	known	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-18	9146-9156	associated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-19	9157-9167	functional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-20	9168-9171	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-21	9172-9182	structural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-22	9183-9196	abnormalities	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
50-23	9196-9197	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	

#Text=Heavy alcohol use was defined as a score higher than eight on the Alcohol Use Disorders Identification Test (AUDIT).
51-1	9198-9203	Heavy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
51-2	9204-9211	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
51-3	9212-9215	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
51-4	9216-9219	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
51-5	9220-9227	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
51-6	9228-9230	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
51-7	9231-9232	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
51-8	9233-9238	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
51-9	9239-9245	higher	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
51-10	9246-9250	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
51-11	9251-9256	eight	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
51-12	9257-9259	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
51-13	9260-9263	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
51-14	9264-9271	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[27]	
51-15	9272-9275	Use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[27]	
51-16	9276-9285	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[27]	
51-17	9286-9300	Identification	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[27]	
51-18	9301-9305	Test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[27]	
51-19	9306-9307	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[27]	
51-20	9307-9312	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[27]	
51-21	9312-9313	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[27]	
51-22	9313-9314	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[27]	

#Text=Heavy drug use was defined by clinicians of the ICCAM team using the following criteria: more than 300 pills (lifetime) for MDMA; daily/almost daily THC use for more than one year and more than 2 spliffs; and more than once a week for more than six months and more than 1 g for amphetamines.
52-1	9315-9320	Heavy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-2	9321-9325	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-3	9326-9329	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-4	9330-9333	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-5	9334-9341	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-6	9342-9344	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-7	9345-9355	clinicians	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-8	9356-9358	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-9	9359-9362	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-10	9363-9368	ICCAM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-11	9369-9373	team	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-12	9374-9379	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-13	9380-9383	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-14	9384-9393	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-15	9394-9402	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-16	9402-9403	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-17	9404-9408	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-18	9409-9413	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-19	9414-9417	300	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-20	9418-9423	pills	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-21	9424-9425	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-22	9425-9433	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-23	9433-9434	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-24	9435-9438	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-25	9439-9443	MDMA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-26	9443-9444	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-27	9445-9450	daily	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-28	9450-9451	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-29	9451-9457	almost	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-30	9458-9463	daily	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-31	9464-9467	THC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-32	9468-9471	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-33	9472-9475	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-34	9476-9480	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-35	9481-9485	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-36	9486-9489	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-37	9490-9494	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-38	9495-9498	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-39	9499-9503	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-40	9504-9508	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-41	9509-9510	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-42	9511-9518	spliffs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-43	9518-9519	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-44	9520-9523	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-45	9524-9528	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-46	9529-9533	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-47	9534-9538	once	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-48	9539-9540	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-49	9541-9545	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-50	9546-9549	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-51	9550-9554	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-52	9555-9559	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-53	9560-9563	six	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-54	9564-9570	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-55	9571-9574	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-56	9575-9579	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-57	9580-9584	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-58	9585-9586	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-59	9587-9588	g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-60	9589-9592	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-61	9593-9605	amphetamines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
52-62	9605-9606	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	

#Text=On the basis of these criteria, patients with drug dependence but without alcohol dependence (n=11) and control participants with a history of heavy alcohol or drug use (n=9) were excluded.
53-1	9607-9609	On	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-2	9610-9613	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-3	9614-9619	basis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-4	9620-9622	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-5	9623-9628	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-6	9629-9637	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-7	9637-9638	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-8	9639-9647	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-9	9648-9652	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-10	9653-9657	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-11	9658-9668	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-12	9669-9672	but	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-13	9673-9680	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-14	9681-9688	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-15	9689-9699	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-16	9700-9701	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-17	9701-9702	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-18	9702-9703	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-19	9703-9705	11	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-20	9705-9706	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-21	9707-9710	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-22	9711-9718	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-23	9719-9731	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-24	9732-9736	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-25	9737-9738	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-26	9739-9746	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-27	9747-9749	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-28	9750-9755	heavy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-29	9756-9763	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-30	9764-9766	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-31	9767-9771	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-32	9772-9775	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-33	9776-9777	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-34	9777-9778	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-35	9778-9779	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-36	9779-9780	9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-37	9780-9781	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-38	9782-9786	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-39	9787-9795	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
53-40	9795-9796	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	

#Text=The final alcohol group (alcohol) comprised 18 individuals meeting criteria for alcohol dependence only.
54-1	9797-9800	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-2	9801-9806	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-3	9807-9814	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-4	9815-9820	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-5	9821-9822	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-6	9822-9829	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-7	9829-9830	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-8	9831-9840	comprised	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-9	9841-9843	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-10	9844-9855	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-11	9856-9863	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-12	9864-9872	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-13	9873-9876	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-14	9877-9884	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[29]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[30]	
54-15	9885-9895	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[29]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[30]	
54-16	9896-9900	only	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-17	9900-9901	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	

#Text=The alcohol and drugs group (alcohol/drugs) comprised 21 individuals meeting criteria for alcohol dependence and the following drug dependencies: cocaine (42.9%); cocaine and opiates (47.6%); amphetamines (4.8%); and opiates (4.8%).
55-1	9902-9905	The	_	
55-2	9906-9913	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[31]	
55-3	9914-9917	and	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[31]	
55-4	9918-9923	drugs	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[31]	
55-5	9924-9929	group	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[31]	
55-6	9930-9931	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[31]	
55-7	9931-9938	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[31]	
55-8	9938-9939	/	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[31]	
55-9	9939-9944	drugs	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[31]	
55-10	9944-9945	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[31]	
55-11	9946-9955	comprised	_	
55-12	9956-9958	21	_	
55-13	9959-9970	individuals	_	
55-14	9971-9978	meeting	_	
55-15	9979-9987	criteria	_	
55-16	9988-9991	for	_	
55-17	9992-9999	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[32]	
55-18	10000-10010	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[32]	
55-19	10011-10014	and	_	
55-20	10015-10018	the	_	
55-21	10019-10028	following	_	
55-22	10029-10033	drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-23	10034-10046	dependencies	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-24	10046-10047	:	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-25	10048-10055	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[34]	
55-26	10056-10057	(	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-27	10057-10062	42.9%	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-28	10062-10063	)	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-29	10063-10064	;	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-30	10065-10072	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-31	10073-10076	and	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-32	10077-10084	opiates	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-33	10085-10086	(	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-34	10086-10091	47.6%	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-35	10091-10092	)	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-36	10092-10093	;	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-37	10094-10106	amphetamines	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]|http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence[35]	
55-38	10107-10108	(	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-39	10108-10112	4.8%	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-40	10112-10113	)	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-41	10113-10114	;	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-42	10115-10118	and	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-43	10119-10126	opiates	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[36]	
55-44	10127-10128	(	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-45	10128-10132	4.8%	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-46	10132-10133	)	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	
55-47	10133-10134	.	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[33]	

#Text=The control group comprised 21 individuals without a history of alcohol or drug dependence.
56-1	10135-10138	The	_	
56-2	10139-10146	control	_	
56-3	10147-10152	group	_	
56-4	10153-10162	comprised	_	
56-5	10163-10165	21	_	
56-6	10166-10177	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[37]	
56-7	10178-10185	without	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[37]	
56-8	10186-10187	a	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[37]	
56-9	10188-10195	history	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[37]	
56-10	10196-10198	of	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[37]	
56-11	10199-10206	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[37]	
56-12	10207-10209	or	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[37]	
56-13	10210-10214	drug	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[37]	
56-14	10215-10225	dependence	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[37]	
56-15	10225-10226	.	_	

#Text=Baseline assessment
#Text=All participants completed the Wechsler Test of Adult Reading (WTAR) to measure verbal intelligence and control volunteers also completed the AUDIT to screen for harmful drinking patterns.
57-1	10227-10235	Baseline	_	
57-2	10236-10246	assessment	_	
57-3	10247-10250	All	_	
57-4	10251-10263	participants	_	
57-5	10264-10273	completed	_	
57-6	10274-10277	the	_	
57-7	10278-10286	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[38]	
57-8	10287-10291	Test	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[38]	
57-9	10292-10294	of	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[38]	
57-10	10295-10300	Adult	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[38]	
57-11	10301-10308	Reading	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[38]	
57-12	10309-10310	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[38]	
57-13	10310-10314	WTAR	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[38]	
57-14	10314-10315	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[38]	
57-15	10316-10318	to	_	
57-16	10319-10326	measure	_	
57-17	10327-10333	verbal	_	
57-18	10334-10346	intelligence	_	
57-19	10347-10350	and	_	
57-20	10351-10358	control	_	
57-21	10359-10369	volunteers	_	
57-22	10370-10374	also	_	
57-23	10375-10384	completed	_	
57-24	10385-10388	the	_	
57-25	10389-10394	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest	
57-26	10395-10397	to	_	
57-27	10398-10404	screen	_	
57-28	10405-10408	for	_	
57-29	10409-10416	harmful	_	
57-30	10417-10425	drinking	_	
57-31	10426-10434	patterns	_	
57-32	10434-10435	.	_	

#Text=To investigate the effects of individual variations of perceived stress and adverse childhood experiences on emotional processing, participants completed the Perceived Stress Scale (PSS-14) and the Childhood Trauma Questionnaire (CTQ).
58-1	10436-10438	To	_	
58-2	10439-10450	investigate	_	
58-3	10451-10454	the	_	
58-4	10455-10462	effects	_	
58-5	10463-10465	of	_	
58-6	10466-10476	individual	_	
58-7	10477-10487	variations	_	
58-8	10488-10490	of	_	
58-9	10491-10500	perceived	_	
58-10	10501-10507	stress	_	
58-11	10508-10511	and	_	
58-12	10512-10519	adverse	_	
58-13	10520-10529	childhood	_	
58-14	10530-10541	experiences	_	
58-15	10542-10544	on	_	
58-16	10545-10554	emotional	_	
58-17	10555-10565	processing	_	
58-18	10565-10566	,	_	
58-19	10567-10579	participants	_	
58-20	10580-10589	completed	_	
58-21	10590-10593	the	_	
58-22	10594-10603	Perceived	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[39]	
58-23	10604-10610	Stress	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[39]	
58-24	10611-10616	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[39]	
58-25	10617-10618	(	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[39]	
58-26	10618-10621	PSS	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[39]	
58-27	10621-10622	-	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[39]	
58-28	10622-10624	14	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[39]	
58-29	10624-10625	)	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[39]	
58-30	10626-10629	and	_	
58-31	10630-10633	the	_	
58-32	10634-10643	Childhood	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[40]	
58-33	10644-10650	Trauma	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[40]	
58-34	10651-10664	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[40]	
58-35	10665-10666	(	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[40]	
58-36	10666-10669	CTQ	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[40]	
58-37	10669-10670	)	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[40]	
58-38	10670-10671	.	_	

#Text=For the PSS-14, we used the total score and for the CTQ we calculated an abuse composite score from three abuse subscales, that is, physical, sexual and emotional abuse.
59-1	10672-10675	For	_	
59-2	10676-10679	the	_	
59-3	10680-10683	PSS	_	
59-4	10683-10684	-	_	
59-5	10684-10686	14	_	
59-6	10686-10687	,	_	
59-7	10688-10690	we	_	
59-8	10691-10695	used	_	
59-9	10696-10699	the	_	
59-10	10700-10705	total	_	
59-11	10706-10711	score	_	
59-12	10712-10715	and	_	
59-13	10716-10719	for	_	
59-14	10720-10723	the	_	
59-15	10724-10727	CTQ	_	
59-16	10728-10730	we	_	
59-17	10731-10741	calculated	_	
59-18	10742-10744	an	_	
59-19	10745-10750	abuse	_	
59-20	10751-10760	composite	_	
59-21	10761-10766	score	_	
59-22	10767-10771	from	_	
59-23	10772-10777	three	_	
59-24	10778-10783	abuse	_	
59-25	10784-10793	subscales	_	
59-26	10793-10794	,	_	
59-27	10795-10799	that	_	
59-28	10800-10802	is	_	
59-29	10802-10803	,	_	
59-30	10804-10812	physical	_	
59-31	10812-10813	,	_	
59-32	10814-10820	sexual	_	
59-33	10821-10824	and	_	
59-34	10825-10834	emotional	_	
59-35	10835-10840	abuse	_	
59-36	10840-10841	.	_	

#Text=In light of prior research suggesting the effects of naltrexone might be modulated by variations in locus of control beliefs, participants completed Rotter's locus of control scale and a drug-related version.
60-1	10842-10844	In	_	
60-2	10845-10850	light	_	
60-3	10851-10853	of	_	
60-4	10854-10859	prior	_	
60-5	10860-10868	research	_	
60-6	10869-10879	suggesting	_	
60-7	10880-10883	the	_	
60-8	10884-10891	effects	_	
60-9	10892-10894	of	_	
60-10	10895-10905	naltrexone	_	
60-11	10906-10911	might	_	
60-12	10912-10914	be	_	
60-13	10915-10924	modulated	_	
60-14	10925-10927	by	_	
60-15	10928-10938	variations	_	
60-16	10939-10941	in	_	
60-17	10942-10947	locus	_	
60-18	10948-10950	of	_	
60-19	10951-10958	control	_	
60-20	10959-10966	beliefs	_	
60-21	10966-10967	,	_	
60-22	10968-10980	participants	_	
60-23	10981-10990	completed	_	
60-24	10991-10999	Rotter's	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[41]	
60-25	11000-11005	locus	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[41]	
60-26	11006-11008	of	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[41]	
60-27	11009-11016	control	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[41]	
60-28	11017-11022	scale	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[41]	
60-29	11023-11026	and	_	
60-30	11027-11028	a	_	
60-31	11029-11041	drug-related	_	
60-32	11042-11049	version	_	
60-33	11049-11050	.	_	

#Text=Procedure
#Text=This study received ethical approval from the West London and Gene Therapy Advisory Committee National Research Ethics Service committee (11/H0707/9).
61-1	11051-11060	Procedure	_	
61-2	11061-11065	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-3	11066-11071	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-4	11072-11080	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-5	11081-11088	ethical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-6	11089-11097	approval	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-7	11098-11102	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-8	11103-11106	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-9	11107-11111	West	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-10	11112-11118	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-11	11119-11122	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-12	11123-11127	Gene	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-13	11128-11135	Therapy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-14	11136-11144	Advisory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-15	11145-11154	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-16	11155-11163	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-17	11164-11172	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-18	11173-11179	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-19	11180-11187	Service	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-20	11188-11197	committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-21	11198-11199	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-22	11199-11201	11	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-23	11201-11202	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-24	11202-11207	H0707	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-25	11207-11208	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-26	11208-11209	9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-27	11209-11210	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	
61-28	11210-11211	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]	

#Text=Participants provided consent, basic demographic information and baseline assessment measures.
62-1	11212-11224	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
62-2	11225-11233	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
62-3	11234-11241	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
62-4	11241-11242	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
62-5	11243-11248	basic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
62-6	11249-11260	demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
62-7	11261-11272	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
62-8	11273-11276	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
62-9	11277-11285	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
62-10	11286-11296	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
62-11	11297-11305	measures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
62-12	11305-11306	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	

#Text=For the experimental medicine sessions, participants completed a urine screen and alcohol breath and pregnancy tests.
63-1	11307-11310	For	_	
63-2	11311-11314	the	_	
63-3	11315-11327	experimental	_	
63-4	11328-11336	medicine	_	
63-5	11337-11345	sessions	_	
63-6	11345-11346	,	_	
63-7	11347-11359	participants	_	
63-8	11360-11369	completed	_	
63-9	11370-11371	a	_	
63-10	11372-11377	urine	_	
63-11	11378-11384	screen	_	
63-12	11385-11388	and	_	
63-13	11389-11396	alcohol	_	
63-14	11397-11403	breath	_	
63-15	11404-11407	and	_	
63-16	11408-11417	pregnancy	_	
63-17	11418-11423	tests	_	
63-18	11423-11424	.	_	

#Text=Participants screening negative were dosed 2 h prior to the MRI scan.
64-1	11425-11437	Participants	_	
64-2	11438-11447	screening	_	
64-3	11448-11456	negative	_	
64-4	11457-11461	were	_	
64-5	11462-11467	dosed	_	
64-6	11468-11469	2	_	
64-7	11470-11471	h	_	
64-8	11472-11477	prior	_	
64-9	11478-11480	to	_	
64-10	11481-11484	the	_	
64-11	11485-11488	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[44]	
64-12	11489-11493	scan	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[44]	
64-13	11493-11494	.	_	

#Text=The experimental medicine sessions consisted of administering placebo or 50 mg of naltrexone in a counterbalanced order.
65-1	11495-11498	The	_	
65-2	11499-11511	experimental	_	
65-3	11512-11520	medicine	_	
65-4	11521-11529	sessions	_	
65-5	11530-11539	consisted	_	
65-6	11540-11542	of	_	
65-7	11543-11556	administering	_	
65-8	11557-11564	placebo	_	
65-9	11565-11567	or	_	
65-10	11568-11570	50	_	
65-11	11571-11573	mg	_	
65-12	11574-11576	of	_	
65-13	11577-11587	naltrexone	_	
65-14	11588-11590	in	_	
65-15	11591-11592	a	_	
65-16	11593-11608	counterbalanced	_	
65-17	11609-11614	order	_	
65-18	11614-11615	.	_	

#Text=The Beck Depression Inventory (BDI-II) and the Spielberger-State Anxiety Inventory (STAI) were administered to evaluate current mood on the day of testing.
66-1	11616-11619	The	_	
66-2	11620-11624	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[45]	
66-3	11625-11635	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[45]	
66-4	11636-11645	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[45]	
66-5	11646-11647	(	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[45]	
66-6	11647-11653	BDI-II	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[45]	
66-7	11653-11654	)	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[45]	
66-8	11655-11658	and	_	
66-9	11659-11662	the	_	
66-10	11663-11680	Spielberger-State	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[46]	
66-11	11681-11688	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[46]	
66-12	11689-11698	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[46]	
66-13	11699-11700	(	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[46]	
66-14	11700-11704	STAI	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[46]	
66-15	11704-11705	)	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[46]	
66-16	11706-11710	were	_	
66-17	11711-11723	administered	_	
66-18	11724-11726	to	_	
66-19	11727-11735	evaluate	_	
66-20	11736-11743	current	_	
66-21	11744-11748	mood	_	
66-22	11749-11751	on	_	
66-23	11752-11755	the	_	
66-24	11756-11759	day	_	
66-25	11760-11762	of	_	
66-26	11763-11770	testing	_	
66-27	11770-11771	.	_	

#Text=Smoking was permitted up to 1 h before scanning; caffeine was only permitted in the morning.
67-1	11772-11779	Smoking	_	
67-2	11780-11783	was	_	
67-3	11784-11793	permitted	_	
67-4	11794-11796	up	_	
67-5	11797-11799	to	_	
67-6	11800-11801	1	_	
67-7	11802-11803	h	_	
67-8	11804-11810	before	_	
67-9	11811-11819	scanning	_	
67-10	11819-11820	;	_	
67-11	11821-11829	caffeine	_	
67-12	11830-11833	was	_	
67-13	11834-11838	only	_	
67-14	11839-11848	permitted	_	
67-15	11849-11851	in	_	
67-16	11852-11855	the	_	
67-17	11856-11863	morning	_	
67-18	11863-11864	.	_	

#Text=Participants were given a snack on arrival but subsequent food intake was restricted to ensure full drug absorption.
68-1	11865-11877	Participants	_	
68-2	11878-11882	were	_	
68-3	11883-11888	given	_	
68-4	11889-11890	a	_	
68-5	11891-11896	snack	_	
68-6	11897-11899	on	_	
68-7	11900-11907	arrival	_	
68-8	11908-11911	but	_	
68-9	11912-11922	subsequent	_	
68-10	11923-11927	food	_	
68-11	11928-11934	intake	_	
68-12	11935-11938	was	_	
68-13	11939-11949	restricted	_	
68-14	11950-11952	to	_	
68-15	11953-11959	ensure	_	
68-16	11960-11964	full	_	
68-17	11965-11969	drug	_	
68-18	11970-11980	absorption	_	
68-19	11980-11981	.	_	

#Text=The experimental medicine sessions were separated by at least 1 week.
69-1	11982-11985	The	_	
69-2	11986-11998	experimental	_	
69-3	11999-12007	medicine	_	
69-4	12008-12016	sessions	_	
69-5	12017-12021	were	_	
69-6	12022-12031	separated	_	
69-7	12032-12034	by	_	
69-8	12035-12037	at	_	
69-9	12038-12043	least	_	
69-10	12044-12045	1	_	
69-11	12046-12050	week	_	
69-12	12050-12051	.	_	

#Text=Evocative images task
#Text=The evocative images task probes negative arousal to aversive stimuli.
70-1	12052-12061	Evocative	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	
70-2	12062-12068	images	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	
70-3	12069-12073	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	
70-4	12074-12077	The	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	
70-5	12078-12087	evocative	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	
70-6	12088-12094	images	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	
70-7	12095-12099	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	
70-8	12100-12106	probes	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	
70-9	12107-12115	negative	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	
70-10	12116-12123	arousal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	
70-11	12124-12126	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	
70-12	12127-12135	aversive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	
70-13	12136-12143	stimuli	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	
70-14	12143-12144	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[47]	

#Text=Aversive images of threat or injury were contrasted with neutral images of human or inanimate objects selected from the International Affective Picture System (IAPS: https://csea.phhp.ufl.edu/media/iapsmessage.html).
71-1	12145-12153	Aversive	_	
71-2	12154-12160	images	_	
71-3	12161-12163	of	_	
71-4	12164-12170	threat	_	
71-5	12171-12173	or	_	
71-6	12174-12180	injury	_	
71-7	12181-12185	were	_	
71-8	12186-12196	contrasted	_	
71-9	12197-12201	with	_	
71-10	12202-12209	neutral	_	
71-11	12210-12216	images	_	
71-12	12217-12219	of	_	
71-13	12220-12225	human	_	
71-14	12226-12228	or	_	
71-15	12229-12238	inanimate	_	
71-16	12239-12246	objects	_	
71-17	12247-12255	selected	_	
71-18	12256-12260	from	_	
71-19	12261-12264	the	_	
71-20	12265-12278	International	_	
71-21	12279-12288	Affective	_	
71-22	12289-12296	Picture	_	
71-23	12297-12303	System	_	
71-24	12304-12305	(	_	
71-25	12305-12309	IAPS	_	
71-26	12309-12310	:	_	
71-27	12311-12316	https	_	
71-28	12316-12317	:	_	
71-29	12317-12318	/	_	
71-30	12318-12319	/	_	
71-31	12319-12336	csea.phhp.ufl.edu	_	
71-32	12336-12337	/	_	
71-33	12337-12342	media	_	
71-34	12342-12343	/	_	
71-35	12343-12359	iapsmessage.html	_	
71-36	12359-12360	)	_	
71-37	12360-12361	.	_	

#Text=Any images with alcohol or drugs in them were not included.
72-1	12362-12365	Any	_	
72-2	12366-12372	images	_	
72-3	12373-12377	with	_	
72-4	12378-12385	alcohol	_	
72-5	12386-12388	or	_	
72-6	12389-12394	drugs	_	
72-7	12395-12397	in	_	
72-8	12398-12402	them	_	
72-9	12403-12407	were	_	
72-10	12408-12411	not	_	
72-11	12412-12420	included	_	
72-12	12420-12421	.	_	

#Text=Similar tasks have been used to demonstrate functional activation in alcohol- and drug-dependent groups in response to negative IAPS images.
73-1	12422-12429	Similar	_	
73-2	12430-12435	tasks	_	
73-3	12436-12440	have	_	
73-4	12441-12445	been	_	
73-5	12446-12450	used	_	
73-6	12451-12453	to	_	
73-7	12454-12465	demonstrate	_	
73-8	12466-12476	functional	_	
73-9	12477-12487	activation	_	
73-10	12488-12490	in	_	
73-11	12491-12498	alcohol	_	
73-12	12498-12499	-	_	
73-13	12500-12503	and	_	
73-14	12504-12518	drug-dependent	_	
73-15	12519-12525	groups	_	
73-16	12526-12528	in	_	
73-17	12529-12537	response	_	
73-18	12538-12540	to	_	
73-19	12541-12549	negative	_	
73-20	12550-12554	IAPS	_	
73-21	12555-12561	images	_	
73-22	12561-12562	.	_	

#Text=A total of 240 images (120 aversive, 120 neutral) were presented in a block design consisting of two runs.
74-1	12563-12564	A	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-2	12565-12570	total	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-3	12571-12573	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-4	12574-12577	240	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-5	12578-12584	images	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-6	12585-12586	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-7	12586-12589	120	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-8	12590-12598	aversive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-9	12598-12599	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-10	12600-12603	120	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-11	12604-12611	neutral	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-12	12611-12612	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-13	12613-12617	were	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-14	12618-12627	presented	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-15	12628-12630	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-16	12631-12632	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-17	12633-12638	block	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-18	12639-12645	design	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-19	12646-12656	consisting	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-20	12657-12659	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-21	12660-12663	two	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-22	12664-12668	runs	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	
74-23	12668-12669	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[48]	

#Text=Each run contained eight blocks of six images presented for 5 s each, followed by a 400 ms inter-stimulus interval that consisted of a fixation cross.
75-1	12670-12674	Each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-2	12675-12678	run	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-3	12679-12688	contained	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-4	12689-12694	eight	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-5	12695-12701	blocks	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-6	12702-12704	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-7	12705-12708	six	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-8	12709-12715	images	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-9	12716-12725	presented	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-10	12726-12729	for	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-11	12730-12731	5	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-12	12732-12733	s	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-13	12734-12738	each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-14	12738-12739	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-15	12740-12748	followed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-16	12749-12751	by	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-17	12752-12753	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-18	12754-12757	400	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-19	12758-12760	ms	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-20	12761-12775	inter-stimulus	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-21	12776-12784	interval	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-22	12785-12789	that	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-23	12790-12799	consisted	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-24	12800-12802	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-25	12803-12804	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-26	12805-12813	fixation	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-27	12814-12819	cross	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	
75-28	12819-12820	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[49]	

#Text=Participants were given the implicit task to press a response button when the next image appeared on the screen.
76-1	12821-12833	Participants	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-2	12834-12838	were	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-3	12839-12844	given	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-4	12845-12848	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-5	12849-12857	implicit	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-6	12858-12862	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-7	12863-12865	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-8	12866-12871	press	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-9	12872-12873	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-10	12874-12882	response	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-11	12883-12889	button	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-12	12890-12894	when	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-13	12895-12898	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-14	12899-12903	next	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-15	12904-12909	image	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-16	12910-12918	appeared	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-17	12919-12921	on	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-18	12922-12925	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-19	12926-12932	screen	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	
76-20	12932-12933	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[50]	

#Text=Images were counterbalanced for valence and arousal between sessions and between blocks and were presented in a pseudorandomized order, with a neutral image always presented first.
77-1	12934-12940	Images	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-2	12941-12945	were	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-3	12946-12961	counterbalanced	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-4	12962-12965	for	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-5	12966-12973	valence	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-6	12974-12977	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-7	12978-12985	arousal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-8	12986-12993	between	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-9	12994-13002	sessions	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-10	13003-13006	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-11	13007-13014	between	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-12	13015-13021	blocks	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-13	13022-13025	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-14	13026-13030	were	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-15	13031-13040	presented	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-16	13041-13043	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-17	13044-13045	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-18	13046-13062	pseudorandomized	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-19	13063-13068	order	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-20	13068-13069	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-21	13070-13074	with	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-22	13075-13076	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-23	13077-13084	neutral	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-24	13085-13090	image	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-25	13091-13097	always	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-26	13098-13107	presented	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-27	13108-13113	first	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[51]	
77-28	13113-13114	.	_	

#Text=Each block was separated by a 15 s rest period to prevent habituation effects.
78-1	13115-13119	Each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-2	13120-13125	block	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-3	13126-13129	was	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-4	13130-13139	separated	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-5	13140-13142	by	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-6	13143-13144	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-7	13145-13147	15	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-8	13148-13149	s	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-9	13150-13154	rest	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-10	13155-13161	period	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-11	13162-13164	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-12	13165-13172	prevent	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-13	13173-13184	habituation	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-14	13185-13192	effects	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[52]	
78-15	13192-13193	.	_	

#Text=Response latency (in ms) was recorded for each participant in response to all images presented.
79-1	13194-13202	Response	_	
79-2	13203-13210	latency	_	
79-3	13211-13212	(	_	
79-4	13212-13214	in	_	
79-5	13215-13217	ms	_	
79-6	13217-13218	)	_	
79-7	13219-13222	was	_	
79-8	13223-13231	recorded	_	
79-9	13232-13235	for	_	
79-10	13236-13240	each	_	
79-11	13241-13252	participant	_	
79-12	13253-13255	in	_	
79-13	13256-13264	response	_	
79-14	13265-13267	to	_	
79-15	13268-13271	all	_	
79-16	13272-13278	images	_	
79-17	13279-13288	presented	_	
79-18	13288-13289	.	_	

#Text=Statistical analysis
#Text=Demographic, baseline assessment and behavioral measures
#Text=Demographic and baseline assessment measures were analyzed using univariate analysis of variance (ANOVAs) for continuous variables and chi-square for categorical variables.
80-1	13290-13301	Statistical	_	
80-2	13302-13310	analysis	_	
80-3	13311-13322	Demographic	_	
80-4	13322-13323	,	_	
80-5	13324-13332	baseline	_	
80-6	13333-13343	assessment	_	
80-7	13344-13347	and	_	
80-8	13348-13358	behavioral	_	
80-9	13359-13367	measures	_	
80-10	13368-13379	Demographic	_	
80-11	13380-13383	and	_	
80-12	13384-13392	baseline	_	
80-13	13393-13403	assessment	_	
80-14	13404-13412	measures	_	
80-15	13413-13417	were	_	
80-16	13418-13426	analyzed	_	
80-17	13427-13432	using	_	
80-18	13433-13443	univariate	_	
80-19	13444-13452	analysis	_	
80-20	13453-13455	of	_	
80-21	13456-13464	variance	_	
80-22	13465-13466	(	_	
80-23	13466-13472	ANOVAs	_	
80-24	13472-13473	)	_	
80-25	13474-13477	for	_	
80-26	13478-13488	continuous	_	
80-27	13489-13498	variables	_	
80-28	13499-13502	and	_	
80-29	13503-13513	chi-square	_	
80-30	13514-13517	for	_	
80-31	13518-13529	categorical	_	
80-32	13530-13539	variables	_	
80-33	13539-13540	.	_	

#Text=Post-hoc Tukey tests were used to identify pairwise differences for continuous variables.
81-1	13541-13549	Post-hoc	_	
81-2	13550-13555	Tukey	_	
81-3	13556-13561	tests	_	
81-4	13562-13566	were	_	
81-5	13567-13571	used	_	
81-6	13572-13574	to	_	
81-7	13575-13583	identify	_	
81-8	13584-13592	pairwise	_	
81-9	13593-13604	differences	_	
81-10	13605-13608	for	_	
81-11	13609-13619	continuous	_	
81-12	13620-13629	variables	_	
81-13	13629-13630	.	_	

#Text=Mean response latencies during emotional processing were square-root transformed to stabilize variances relative to the mean (untransformed scores presented in Table 1).
82-1	13631-13635	Mean	_	
82-2	13636-13644	response	_	
82-3	13645-13654	latencies	_	
82-4	13655-13661	during	_	
82-5	13662-13671	emotional	_	
82-6	13672-13682	processing	_	
82-7	13683-13687	were	_	
82-8	13688-13699	square-root	_	
82-9	13700-13711	transformed	_	
82-10	13712-13714	to	_	
82-11	13715-13724	stabilize	_	
82-12	13725-13734	variances	_	
82-13	13735-13743	relative	_	
82-14	13744-13746	to	_	
82-15	13747-13750	the	_	
82-16	13751-13755	mean	_	
82-17	13756-13757	(	_	
82-18	13757-13770	untransformed	_	
82-19	13771-13777	scores	_	
82-20	13778-13787	presented	_	
82-21	13788-13790	in	_	
82-22	13791-13796	Table	_	
82-23	13797-13798	1	_	
82-24	13798-13799	)	_	
82-25	13799-13800	.	_	

#Text=Repeated-measures ANOVAs were used with the two within-subject factors condition (neutral, aversive) and treatment (placebo, naltrexone) and the between-subject factor group (control, alcohol, alcohol/drugs) to examine response latencies.
83-1	13801-13818	Repeated-measures	_	
83-2	13819-13825	ANOVAs	_	
83-3	13826-13830	were	_	
83-4	13831-13835	used	_	
83-5	13836-13840	with	_	
83-6	13841-13844	the	_	
83-7	13845-13848	two	_	
83-8	13849-13863	within-subject	_	
83-9	13864-13871	factors	_	
83-10	13872-13881	condition	_	
83-11	13882-13883	(	_	
83-12	13883-13890	neutral	_	
83-13	13890-13891	,	_	
83-14	13892-13900	aversive	_	
83-15	13900-13901	)	_	
83-16	13902-13905	and	_	
83-17	13906-13915	treatment	_	
83-18	13916-13917	(	_	
83-19	13917-13924	placebo	_	
83-20	13924-13925	,	_	
83-21	13926-13936	naltrexone	_	
83-22	13936-13937	)	_	
83-23	13938-13941	and	_	
83-24	13942-13945	the	_	
83-25	13946-13961	between-subject	_	
83-26	13962-13968	factor	_	
83-27	13969-13974	group	_	
83-28	13975-13976	(	_	
83-29	13976-13983	control	_	
83-30	13983-13984	,	_	
83-31	13985-13992	alcohol	_	
83-32	13992-13993	,	_	
83-33	13994-14001	alcohol	_	
83-34	14001-14002	/	_	
83-35	14002-14007	drugs	_	
83-36	14007-14008	)	_	
83-37	14009-14011	to	_	
83-38	14012-14019	examine	_	
83-39	14020-14028	response	_	
83-40	14029-14038	latencies	_	
83-41	14038-14039	.	_	

#Text=Repeated-measures ANOVAs were also used to evaluate changes in affective states between the experimental medicine visits.
84-1	14040-14057	Repeated-measures	_	
84-2	14058-14064	ANOVAs	_	
84-3	14065-14069	were	_	
84-4	14070-14074	also	_	
84-5	14075-14079	used	_	
84-6	14080-14082	to	_	
84-7	14083-14091	evaluate	_	
84-8	14092-14099	changes	_	
84-9	14100-14102	in	_	
84-10	14103-14112	affective	_	
84-11	14113-14119	states	_	
84-12	14120-14127	between	_	
84-13	14128-14131	the	_	
84-14	14132-14144	experimental	_	
84-15	14145-14153	medicine	_	
84-16	14154-14160	visits	_	
84-17	14160-14161	.	_	

#Text=To determine the influence of naltrexone on task performance, we calculated a change score for each individual by subtracting mean latencies from each condition (aversive minus neutral) following placebo and naltrexone.
85-1	14162-14164	To	_	
85-2	14165-14174	determine	_	
85-3	14175-14178	the	_	
85-4	14179-14188	influence	_	
85-5	14189-14191	of	_	
85-6	14192-14202	naltrexone	_	
85-7	14203-14205	on	_	
85-8	14206-14210	task	_	
85-9	14211-14222	performance	_	
85-10	14222-14223	,	_	
85-11	14224-14226	we	_	
85-12	14227-14237	calculated	_	
85-13	14238-14239	a	_	
85-14	14240-14246	change	_	
85-15	14247-14252	score	_	
85-16	14253-14256	for	_	
85-17	14257-14261	each	_	
85-18	14262-14272	individual	_	
85-19	14273-14275	by	_	
85-20	14276-14287	subtracting	_	
85-21	14288-14292	mean	_	
85-22	14293-14302	latencies	_	
85-23	14303-14307	from	_	
85-24	14308-14312	each	_	
85-25	14313-14322	condition	_	
85-26	14323-14324	(	_	
85-27	14324-14332	aversive	_	
85-28	14333-14338	minus	_	
85-29	14339-14346	neutral	_	
85-30	14346-14347	)	_	
85-31	14348-14357	following	_	
85-32	14358-14365	placebo	_	
85-33	14366-14369	and	_	
85-34	14370-14380	naltrexone	_	
85-35	14380-14381	.	_	

#Text=We then used Pearson's r coefficients to test for associations between change scores and individual variations in affective states.
86-1	14382-14384	We	_	
86-2	14385-14389	then	_	
86-3	14390-14394	used	_	
86-4	14395-14404	Pearson's	_	
86-5	14405-14406	r	_	
86-6	14407-14419	coefficients	_	
86-7	14420-14422	to	_	
86-8	14423-14427	test	_	
86-9	14428-14431	for	_	
86-10	14432-14444	associations	_	
86-11	14445-14452	between	_	
86-12	14453-14459	change	_	
86-13	14460-14466	scores	_	
86-14	14467-14470	and	_	
86-15	14471-14481	individual	_	
86-16	14482-14492	variations	_	
86-17	14493-14495	in	_	
86-18	14496-14505	affective	_	
86-19	14506-14512	states	_	
86-20	14512-14513	.	_	

#Text=Neuroimaging data acquisition, processing and analysis
#Text=Volumetric MRI data was acquired with 3 T systems at three sites (Imanova, London; Wolfson Brain Imaging Centre, Cambridge; and the Translational Imaging Unit, Manchester).
87-1	14514-14526	Neuroimaging	_	
87-2	14527-14531	data	_	
87-3	14532-14543	acquisition	_	
87-4	14543-14544	,	_	
87-5	14545-14555	processing	_	
87-6	14556-14559	and	_	
87-7	14560-14568	analysis	_	
87-8	14569-14579	Volumetric	_	
87-9	14580-14583	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
87-10	14584-14588	data	_	
87-11	14589-14592	was	_	
87-12	14593-14601	acquired	_	
87-13	14602-14606	with	_	
87-14	14607-14608	3	_	
87-15	14609-14610	T	_	
87-16	14611-14618	systems	_	
87-17	14619-14621	at	_	
87-18	14622-14627	three	_	
87-19	14628-14633	sites	_	
87-20	14634-14635	(	_	
87-21	14635-14642	Imanova	_	
87-22	14642-14643	,	_	
87-23	14644-14650	London	_	
87-24	14650-14651	;	_	
87-25	14652-14659	Wolfson	_	
87-26	14660-14665	Brain	_	
87-27	14666-14673	Imaging	_	
87-28	14674-14680	Centre	_	
87-29	14680-14681	,	_	
87-30	14682-14691	Cambridge	_	
87-31	14691-14692	;	_	
87-32	14693-14696	and	_	
87-33	14697-14700	the	_	
87-34	14701-14714	Translational	_	
87-35	14715-14722	Imaging	_	
87-36	14723-14727	Unit	_	
87-37	14727-14728	,	_	
87-38	14729-14739	Manchester	_	
87-39	14739-14740	)	_	
87-40	14740-14741	.	_	

#Text=London and Cambridge operated nominally identical 3 T Siemens Tim Trio systems and Manchester operated a 3 T Philips Achieva.
#Text=fMRI data were preprocessed using SPM8.
88-1	14742-14748	London	_	
88-2	14749-14752	and	_	
88-3	14753-14762	Cambridge	_	
88-4	14763-14771	operated	_	
88-5	14772-14781	nominally	_	
88-6	14782-14791	identical	_	
88-7	14792-14793	3	_	
88-8	14794-14795	T	_	
88-9	14796-14803	Siemens	_	
88-10	14804-14807	Tim	_	
88-11	14808-14812	Trio	_	
88-12	14813-14820	systems	_	
88-13	14821-14824	and	_	
88-14	14825-14835	Manchester	_	
88-15	14836-14844	operated	_	
88-16	14845-14846	a	_	
88-17	14847-14848	3	_	
88-18	14849-14850	T	_	
88-19	14851-14858	Philips	_	
88-20	14859-14866	Achieva	_	
88-21	14866-14867	.	_	
88-22	14868-14872	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
88-23	14873-14877	data	_	
88-24	14878-14882	were	_	
88-25	14883-14895	preprocessed	_	
88-26	14896-14901	using	_	
88-27	14902-14906	SPM8	_	
88-28	14906-14907	.	_	

#Text=Mean echo-planar imaging (EPI) was first computed for each participant and visually inspected in the orbitofrontal cortex and temporal lobe to ensure that none showed excessive signal dropout.
89-1	14908-14912	Mean	_	
89-2	14913-14924	echo-planar	_	
89-3	14925-14932	imaging	_	
89-4	14933-14934	(	_	
89-5	14934-14937	EPI	_	
89-6	14937-14938	)	_	
89-7	14939-14942	was	_	
89-8	14943-14948	first	_	
89-9	14949-14957	computed	_	
89-10	14958-14961	for	_	
89-11	14962-14966	each	_	
89-12	14967-14978	participant	_	
89-13	14979-14982	and	_	
89-14	14983-14991	visually	_	
89-15	14992-15001	inspected	_	
89-16	15002-15004	in	_	
89-17	15005-15008	the	_	
89-18	15009-15022	orbitofrontal	_	
89-19	15023-15029	cortex	_	
89-20	15030-15033	and	_	
89-21	15034-15042	temporal	_	
89-22	15043-15047	lobe	_	
89-23	15048-15050	to	_	
89-24	15051-15057	ensure	_	
89-25	15058-15062	that	_	
89-26	15063-15067	none	_	
89-27	15068-15074	showed	_	
89-28	15075-15084	excessive	_	
89-29	15085-15091	signal	_	
89-30	15092-15099	dropout	_	
89-31	15099-15100	.	_	

#Text=All EPIs were then realigned to the first scan by rigid body transformations to correct for head movements.
90-1	15101-15104	All	_	
90-2	15105-15109	EPIs	_	
90-3	15110-15114	were	_	
90-4	15115-15119	then	_	
90-5	15120-15129	realigned	_	
90-6	15130-15132	to	_	
90-7	15133-15136	the	_	
90-8	15137-15142	first	_	
90-9	15143-15147	scan	_	
90-10	15148-15150	by	_	
90-11	15151-15156	rigid	_	
90-12	15157-15161	body	_	
90-13	15162-15177	transformations	_	
90-14	15178-15180	to	_	
90-15	15181-15188	correct	_	
90-16	15189-15192	for	_	
90-17	15193-15197	head	_	
90-18	15198-15207	movements	_	
90-19	15207-15208	.	_	

#Text=Next, EPIs were normalized to the standard template in the Montreal Neurological Institute (MNI) space using linear and nonlinear transformations and smoothed with a Gaussian kernel of full width at half maximum of 8 mm.
91-1	15209-15213	Next	_	
91-2	15213-15214	,	_	
91-3	15215-15219	EPIs	_	
91-4	15220-15224	were	_	
91-5	15225-15235	normalized	_	
91-6	15236-15238	to	_	
91-7	15239-15242	the	_	
91-8	15243-15251	standard	_	
91-9	15252-15260	template	_	
91-10	15261-15263	in	_	
91-11	15264-15267	the	_	
91-12	15268-15276	Montreal	_	
91-13	15277-15289	Neurological	_	
91-14	15290-15299	Institute	_	
91-15	15300-15301	(	_	
91-16	15301-15304	MNI	_	
91-17	15304-15305	)	_	
91-18	15306-15311	space	_	
91-19	15312-15317	using	_	
91-20	15318-15324	linear	_	
91-21	15325-15328	and	_	
91-22	15329-15338	nonlinear	_	
91-23	15339-15354	transformations	_	
91-24	15355-15358	and	_	
91-25	15359-15367	smoothed	_	
91-26	15368-15372	with	_	
91-27	15373-15374	a	_	
91-28	15375-15383	Gaussian	_	
91-29	15384-15390	kernel	_	
91-30	15391-15393	of	_	
91-31	15394-15398	full	_	
91-32	15399-15404	width	_	
91-33	15405-15407	at	_	
91-34	15408-15412	half	_	
91-35	15413-15420	maximum	_	
91-36	15421-15423	of	_	
91-37	15424-15425	8	_	
91-38	15426-15428	mm	_	
91-39	15428-15429	.	_	

#Text=Realignment parameters were then inspected for each subject to make sure that movements of translation and rotation were <2 mm and 2°, respectively.
92-1	15430-15441	Realignment	_	
92-2	15442-15452	parameters	_	
92-3	15453-15457	were	_	
92-4	15458-15462	then	_	
92-5	15463-15472	inspected	_	
92-6	15473-15476	for	_	
92-7	15477-15481	each	_	
92-8	15482-15489	subject	_	
92-9	15490-15492	to	_	
92-10	15493-15497	make	_	
92-11	15498-15502	sure	_	
92-12	15503-15507	that	_	
92-13	15508-15517	movements	_	
92-14	15518-15520	of	_	
92-15	15521-15532	translation	_	
92-16	15533-15536	and	_	
92-17	15537-15545	rotation	_	
92-18	15546-15550	were	_	
92-19	15551-15552	<	_	
92-20	15552-15553	2	_	
92-21	15554-15556	mm	_	
92-22	15557-15560	and	_	
92-23	15561-15562	2	_	
92-24	15562-15563	°	_	
92-25	15563-15564	,	_	
92-26	15565-15577	respectively	_	
92-27	15577-15578	.	_	

#Text=To identify significant differences across groups in regional responses of brain areas, a general linear model (GLM) was employed.
93-1	15579-15581	To	_	
93-2	15582-15590	identify	_	
93-3	15591-15602	significant	_	
93-4	15603-15614	differences	_	
93-5	15615-15621	across	_	
93-6	15622-15628	groups	_	
93-7	15629-15631	in	_	
93-8	15632-15640	regional	_	
93-9	15641-15650	responses	_	
93-10	15651-15653	of	_	
93-11	15654-15659	brain	_	
93-12	15660-15665	areas	_	
93-13	15665-15666	,	_	
93-14	15667-15668	a	_	
93-15	15669-15676	general	_	
93-16	15677-15683	linear	_	
93-17	15684-15689	model	_	
93-18	15690-15691	(	_	
93-19	15691-15694	GLM	_	
93-20	15694-15695	)	_	
93-21	15696-15699	was	_	
93-22	15700-15708	employed	_	
93-23	15708-15709	.	_	

#Text=Subject-specific GLMs included three experimental factors (aversive images, neutral images and fixation cross) and six realignment parameters as effects of no interest to account for residual motion-related variance.
94-1	15710-15726	Subject-specific	_	
94-2	15727-15731	GLMs	_	
94-3	15732-15740	included	_	
94-4	15741-15746	three	_	
94-5	15747-15759	experimental	_	
94-6	15760-15767	factors	_	
94-7	15768-15769	(	_	
94-8	15769-15777	aversive	_	
94-9	15778-15784	images	_	
94-10	15784-15785	,	_	
94-11	15786-15793	neutral	_	
94-12	15794-15800	images	_	
94-13	15801-15804	and	_	
94-14	15805-15813	fixation	_	
94-15	15814-15819	cross	_	
94-16	15819-15820	)	_	
94-17	15821-15824	and	_	
94-18	15825-15828	six	_	
94-19	15829-15840	realignment	_	
94-20	15841-15851	parameters	_	
94-21	15852-15854	as	_	
94-22	15855-15862	effects	_	
94-23	15863-15865	of	_	
94-24	15866-15868	no	_	
94-25	15869-15877	interest	_	
94-26	15878-15880	to	_	
94-27	15881-15888	account	_	
94-28	15889-15892	for	_	
94-29	15893-15901	residual	_	
94-30	15902-15916	motion-related	_	
94-31	15917-15925	variance	_	
94-32	15925-15926	.	_	

#Text=Low-frequency signal drift was removed using a high-pass filter (cut-off 128 s).
95-1	15927-15940	Low-frequency	_	
95-2	15941-15947	signal	_	
95-3	15948-15953	drift	_	
95-4	15954-15957	was	_	
95-5	15958-15965	removed	_	
95-6	15966-15971	using	_	
95-7	15972-15973	a	_	
95-8	15974-15983	high-pass	_	
95-9	15984-15990	filter	_	
95-10	15991-15992	(	_	
95-11	15992-15999	cut-off	_	
95-12	16000-16003	128	_	
95-13	16004-16005	s	_	
95-14	16005-16006	)	_	
95-15	16006-16007	.	_	

#Text=An autoregressive modeling of temporal autocorrelations was applied.
96-1	16008-16010	An	_	
96-2	16011-16025	autoregressive	_	
96-3	16026-16034	modeling	_	
96-4	16035-16037	of	_	
96-5	16038-16046	temporal	_	
96-6	16047-16063	autocorrelations	_	
96-7	16064-16067	was	_	
96-8	16068-16075	applied	_	
96-9	16075-16076	.	_	

#Text=The following contrasts were generated for the second-level analysis: (1) aversive images versus neutral images, (2) aversive images versus fixation cross and (3) neutral images versus fixation cross.
97-1	16077-16080	The	_	
97-2	16081-16090	following	_	
97-3	16091-16100	contrasts	_	
97-4	16101-16105	were	_	
97-5	16106-16115	generated	_	
97-6	16116-16119	for	_	
97-7	16120-16123	the	_	
97-8	16124-16136	second-level	_	
97-9	16137-16145	analysis	_	
97-10	16145-16146	:	_	
97-11	16147-16148	(	_	
97-12	16148-16149	1	_	
97-13	16149-16150	)	_	
97-14	16151-16159	aversive	_	
97-15	16160-16166	images	_	
97-16	16167-16173	versus	_	
97-17	16174-16181	neutral	_	
97-18	16182-16188	images	_	
97-19	16188-16189	,	_	
97-20	16190-16191	(	_	
97-21	16191-16192	2	_	
97-22	16192-16193	)	_	
97-23	16194-16202	aversive	_	
97-24	16203-16209	images	_	
97-25	16210-16216	versus	_	
97-26	16217-16225	fixation	_	
97-27	16226-16231	cross	_	
97-28	16232-16235	and	_	
97-29	16236-16237	(	_	
97-30	16237-16238	3	_	
97-31	16238-16239	)	_	
97-32	16240-16247	neutral	_	
97-33	16248-16254	images	_	
97-34	16255-16261	versus	_	
97-35	16262-16270	fixation	_	
97-36	16271-16276	cross	_	
97-37	16276-16277	.	_	

#Text=Group differences in brain responses were assessed via: (1) a full factorial analysis for the contrast ‘aversive versus neutral' including three groups (control, alcohol, alcohol/drugs) and two pharmacological treatments (placebo, naltrexone) as main factors and (2) a full factorial analysis including three groups (control, alcohol, alcohol/drugs), two pharmacological treatments (placebo, naltrexone) and two task conditions (aversive images versus fixation cross, neutral images versus fixation cross) as main factors.
98-1	16278-16283	Group	_	
98-2	16284-16295	differences	_	
98-3	16296-16298	in	_	
98-4	16299-16304	brain	_	
98-5	16305-16314	responses	_	
98-6	16315-16319	were	_	
98-7	16320-16328	assessed	_	
98-8	16329-16332	via	_	
98-9	16332-16333	:	_	
98-10	16334-16335	(	_	
98-11	16335-16336	1	_	
98-12	16336-16337	)	_	
98-13	16338-16339	a	_	
98-14	16340-16344	full	_	
98-15	16345-16354	factorial	_	
98-16	16355-16363	analysis	_	
98-17	16364-16367	for	_	
98-18	16368-16371	the	_	
98-19	16372-16380	contrast	_	
98-20	16381-16382	‘	_	
98-21	16382-16390	aversive	_	
98-22	16391-16397	versus	_	
98-23	16398-16405	neutral	_	
98-24	16405-16406	'	_	
98-25	16407-16416	including	_	
98-26	16417-16422	three	_	
98-27	16423-16429	groups	_	
98-28	16430-16431	(	_	
98-29	16431-16438	control	_	
98-30	16438-16439	,	_	
98-31	16440-16447	alcohol	_	
98-32	16447-16448	,	_	
98-33	16449-16456	alcohol	_	
98-34	16456-16457	/	_	
98-35	16457-16462	drugs	_	
98-36	16462-16463	)	_	
98-37	16464-16467	and	_	
98-38	16468-16471	two	_	
98-39	16472-16487	pharmacological	_	
98-40	16488-16498	treatments	_	
98-41	16499-16500	(	_	
98-42	16500-16507	placebo	_	
98-43	16507-16508	,	_	
98-44	16509-16519	naltrexone	_	
98-45	16519-16520	)	_	
98-46	16521-16523	as	_	
98-47	16524-16528	main	_	
98-48	16529-16536	factors	_	
98-49	16537-16540	and	_	
98-50	16541-16542	(	_	
98-51	16542-16543	2	_	
98-52	16543-16544	)	_	
98-53	16545-16546	a	_	
98-54	16547-16551	full	_	
98-55	16552-16561	factorial	_	
98-56	16562-16570	analysis	_	
98-57	16571-16580	including	_	
98-58	16581-16586	three	_	
98-59	16587-16593	groups	_	
98-60	16594-16595	(	_	
98-61	16595-16602	control	_	
98-62	16602-16603	,	_	
98-63	16604-16611	alcohol	_	
98-64	16611-16612	,	_	
98-65	16613-16620	alcohol	_	
98-66	16620-16621	/	_	
98-67	16621-16626	drugs	_	
98-68	16626-16627	)	_	
98-69	16627-16628	,	_	
98-70	16629-16632	two	_	
98-71	16633-16648	pharmacological	_	
98-72	16649-16659	treatments	_	
98-73	16660-16661	(	_	
98-74	16661-16668	placebo	_	
98-75	16668-16669	,	_	
98-76	16670-16680	naltrexone	_	
98-77	16680-16681	)	_	
98-78	16682-16685	and	_	
98-79	16686-16689	two	_	
98-80	16690-16694	task	_	
98-81	16695-16705	conditions	_	
98-82	16706-16707	(	_	
98-83	16707-16715	aversive	_	
98-84	16716-16722	images	_	
98-85	16723-16729	versus	_	
98-86	16730-16738	fixation	_	
98-87	16739-16744	cross	_	
98-88	16744-16745	,	_	
98-89	16746-16753	neutral	_	
98-90	16754-16760	images	_	
98-91	16761-16767	versus	_	
98-92	16768-16776	fixation	_	
98-93	16777-16782	cross	_	
98-94	16782-16783	)	_	
98-95	16784-16786	as	_	
98-96	16787-16791	main	_	
98-97	16792-16799	factors	_	
98-98	16799-16800	.	_	

#Text=For each model, SPM-F-maps assessing the main effect of group, the main effect of treatment, the group-by-treatment interaction and the group-by-treatment-by-condition interaction were generated, respectively.
99-1	16801-16804	For	_	
99-2	16805-16809	each	_	
99-3	16810-16815	model	_	
99-4	16815-16816	,	_	
99-5	16817-16827	SPM-F-maps	_	
99-6	16828-16837	assessing	_	
99-7	16838-16841	the	_	
99-8	16842-16846	main	_	
99-9	16847-16853	effect	_	
99-10	16854-16856	of	_	
99-11	16857-16862	group	_	
99-12	16862-16863	,	_	
99-13	16864-16867	the	_	
99-14	16868-16872	main	_	
99-15	16873-16879	effect	_	
99-16	16880-16882	of	_	
99-17	16883-16892	treatment	_	
99-18	16892-16893	,	_	
99-19	16894-16897	the	_	
99-20	16898-16916	group-by-treatment	_	
99-21	16917-16928	interaction	_	
99-22	16929-16932	and	_	
99-23	16933-16936	the	_	
99-24	16937-16968	group-by-treatment-by-condition	_	
99-25	16969-16980	interaction	_	
99-26	16981-16985	were	_	
99-27	16986-16995	generated	_	
99-28	16995-16996	,	_	
99-29	16997-17009	respectively	_	
99-30	17009-17010	.	_	

#Text=An additional covariate of site was added to remove the effect of the different scan sites.
100-1	17011-17013	An	_	
100-2	17014-17024	additional	_	
100-3	17025-17034	covariate	_	
100-4	17035-17037	of	_	
100-5	17038-17042	site	_	
100-6	17043-17046	was	_	
100-7	17047-17052	added	_	
100-8	17053-17055	to	_	
100-9	17056-17062	remove	_	
100-10	17063-17066	the	_	
100-11	17067-17073	effect	_	
100-12	17074-17076	of	_	
100-13	17077-17080	the	_	
100-14	17081-17090	different	_	
100-15	17091-17095	scan	_	
100-16	17096-17101	sites	_	
100-17	17101-17102	.	_	

#Text=In the first model, we also included the abuse composite score as a covariate-of-interest to test for associations between brain response and childhood adversity as a function of pharmacological treatment.
101-1	17103-17105	In	_	
101-2	17106-17109	the	_	
101-3	17110-17115	first	_	
101-4	17116-17121	model	_	
101-5	17121-17122	,	_	
101-6	17123-17125	we	_	
101-7	17126-17130	also	_	
101-8	17131-17139	included	_	
101-9	17140-17143	the	_	
101-10	17144-17149	abuse	_	
101-11	17150-17159	composite	_	
101-12	17160-17165	score	_	
101-13	17166-17168	as	_	
101-14	17169-17170	a	_	
101-15	17171-17192	covariate-of-interest	_	
101-16	17193-17195	to	_	
101-17	17196-17200	test	_	
101-18	17201-17204	for	_	
101-19	17205-17217	associations	_	
101-20	17218-17225	between	_	
101-21	17226-17231	brain	_	
101-22	17232-17240	response	_	
101-23	17241-17244	and	_	
101-24	17245-17254	childhood	_	
101-25	17255-17264	adversity	_	
101-26	17265-17267	as	_	
101-27	17268-17269	a	_	
101-28	17270-17278	function	_	
101-29	17279-17281	of	_	
101-30	17282-17297	pharmacological	_	
101-31	17298-17307	treatment	_	
101-32	17307-17308	.	_	

#Text=To threshold the second-level maps, we used a priori regions of interest (ROIs) based on a functional definition of the brain regions as previously recommended (P<0.05, family-wise error (FWE) correction for multiple comparisons after a small volume correction).
102-1	17309-17311	To	_	
102-2	17312-17321	threshold	_	
102-3	17322-17325	the	_	
102-4	17326-17338	second-level	_	
102-5	17339-17343	maps	_	
102-6	17343-17344	,	_	
102-7	17345-17347	we	_	
102-8	17348-17352	used	_	
102-9	17353-17354	a	_	
102-10	17355-17361	priori	_	
102-11	17362-17369	regions	_	
102-12	17370-17372	of	_	
102-13	17373-17381	interest	_	
102-14	17382-17383	(	_	
102-15	17383-17387	ROIs	_	
102-16	17387-17388	)	_	
102-17	17389-17394	based	_	
102-18	17395-17397	on	_	
102-19	17398-17399	a	_	
102-20	17400-17410	functional	_	
102-21	17411-17421	definition	_	
102-22	17422-17424	of	_	
102-23	17425-17428	the	_	
102-24	17429-17434	brain	_	
102-25	17435-17442	regions	_	
102-26	17443-17445	as	_	
102-27	17446-17456	previously	_	
102-28	17457-17468	recommended	_	
102-29	17469-17470	(	_	
102-30	17470-17471	P	_	
102-31	17471-17472	<	_	
102-32	17472-17476	0.05	_	
102-33	17476-17477	,	_	
102-34	17478-17489	family-wise	_	
102-35	17490-17495	error	_	
102-36	17496-17497	(	_	
102-37	17497-17500	FWE	_	
102-38	17500-17501	)	_	
102-39	17502-17512	correction	_	
102-40	17513-17516	for	_	
102-41	17517-17525	multiple	_	
102-42	17526-17537	comparisons	_	
102-43	17538-17543	after	_	
102-44	17544-17545	a	_	
102-45	17546-17551	small	_	
102-46	17552-17558	volume	_	
102-47	17559-17569	correction	_	
102-48	17569-17570	)	_	
102-49	17570-17571	.	_	

#Text=This commonly employed statistical procedure not only ensures a robust protection against type I errors but also prevents false negative results.
103-1	17572-17576	This	_	
103-2	17577-17585	commonly	_	
103-3	17586-17594	employed	_	
103-4	17595-17606	statistical	_	
103-5	17607-17616	procedure	_	
103-6	17617-17620	not	_	
103-7	17621-17625	only	_	
103-8	17626-17633	ensures	_	
103-9	17634-17635	a	_	
103-10	17636-17642	robust	_	
103-11	17643-17653	protection	_	
103-12	17654-17661	against	_	
103-13	17662-17666	type	_	
103-14	17667-17668	I	_	
103-15	17669-17675	errors	_	
103-16	17676-17679	but	_	
103-17	17680-17684	also	_	
103-18	17685-17693	prevents	_	
103-19	17694-17699	false	_	
103-20	17700-17708	negative	_	
103-21	17709-17716	results	_	
103-22	17716-17717	.	_	

#Text=Here, the following anatomical ROIs were selected because of their functional role in negative emotional processing in substance use disorders: the amygdala, the mPFC and the hippocampus.
104-1	17718-17722	Here	_	
104-2	17722-17723	,	_	
104-3	17724-17727	the	_	
104-4	17728-17737	following	_	
104-5	17738-17748	anatomical	_	
104-6	17749-17753	ROIs	_	
104-7	17754-17758	were	_	
104-8	17759-17767	selected	_	
104-9	17768-17775	because	_	
104-10	17776-17778	of	_	
104-11	17779-17784	their	_	
104-12	17785-17795	functional	_	
104-13	17796-17800	role	_	
104-14	17801-17803	in	_	
104-15	17804-17812	negative	_	
104-16	17813-17822	emotional	_	
104-17	17823-17833	processing	_	
104-18	17834-17836	in	_	
104-19	17837-17846	substance	_	
104-20	17847-17850	use	_	
104-21	17851-17860	disorders	_	
104-22	17860-17861	:	_	
104-23	17862-17865	the	_	
104-24	17866-17874	amygdala	_	
104-25	17874-17875	,	_	
104-26	17876-17879	the	_	
104-27	17880-17884	mPFC	_	
104-28	17885-17888	and	_	
104-29	17889-17892	the	_	
104-30	17893-17904	hippocampus	_	
104-31	17904-17905	.	_	

#Text=Each ROI was defined using a sphere centered on MNI coordinates obtained from previous studies.
105-1	17906-17910	Each	_	
105-2	17911-17914	ROI	_	
105-3	17915-17918	was	_	
105-4	17919-17926	defined	_	
105-5	17927-17932	using	_	
105-6	17933-17934	a	_	
105-7	17935-17941	sphere	_	
105-8	17942-17950	centered	_	
105-9	17951-17953	on	_	
105-10	17954-17957	MNI	_	
105-11	17958-17969	coordinates	_	
105-12	17970-17978	obtained	_	
105-13	17979-17983	from	_	
105-14	17984-17992	previous	_	
105-15	17993-18000	studies	_	
105-16	18000-18001	.	_	

#Text=Specifically, a sphere with a radius of 5 mm was centered on the right amygdala (x,y,z: 25,−3,−27), a sphere with a radius of 10 mm was centered on the right mPFC (x,y,z: 14,62,1) and a sphere with a radius of 8 mm was centered on the right hippocampus (x,y,z: 29,−14,−14).
106-1	18002-18014	Specifically	_	
106-2	18014-18015	,	_	
106-3	18016-18017	a	_	
106-4	18018-18024	sphere	_	
106-5	18025-18029	with	_	
106-6	18030-18031	a	_	
106-7	18032-18038	radius	_	
106-8	18039-18041	of	_	
106-9	18042-18043	5	_	
106-10	18044-18046	mm	_	
106-11	18047-18050	was	_	
106-12	18051-18059	centered	_	
106-13	18060-18062	on	_	
106-14	18063-18066	the	_	
106-15	18067-18072	right	_	
106-16	18073-18081	amygdala	_	
106-17	18082-18083	(	_	
106-18	18083-18084	x	_	
106-19	18084-18085	,	_	
106-20	18085-18086	y	_	
106-21	18086-18087	,	_	
106-22	18087-18088	z	_	
106-23	18088-18089	:	_	
106-24	18090-18092	25	_	
106-25	18092-18093	,	_	
106-26	18093-18094	−	_	
106-27	18094-18095	3	_	
106-28	18095-18096	,	_	
106-29	18096-18097	−	_	
106-30	18097-18099	27	_	
106-31	18099-18100	)	_	
106-32	18100-18101	,	_	
106-33	18102-18103	a	_	
106-34	18104-18110	sphere	_	
106-35	18111-18115	with	_	
106-36	18116-18117	a	_	
106-37	18118-18124	radius	_	
106-38	18125-18127	of	_	
106-39	18128-18130	10	_	
106-40	18131-18133	mm	_	
106-41	18134-18137	was	_	
106-42	18138-18146	centered	_	
106-43	18147-18149	on	_	
106-44	18150-18153	the	_	
106-45	18154-18159	right	_	
106-46	18160-18164	mPFC	_	
106-47	18165-18166	(	_	
106-48	18166-18167	x	_	
106-49	18167-18168	,	_	
106-50	18168-18169	y	_	
106-51	18169-18170	,	_	
106-52	18170-18171	z	_	
106-53	18171-18172	:	_	
106-54	18173-18180	14,62,1	_	
106-55	18180-18181	)	_	
106-56	18182-18185	and	_	
106-57	18186-18187	a	_	
106-58	18188-18194	sphere	_	
106-59	18195-18199	with	_	
106-60	18200-18201	a	_	
106-61	18202-18208	radius	_	
106-62	18209-18211	of	_	
106-63	18212-18213	8	_	
106-64	18214-18216	mm	_	
106-65	18217-18220	was	_	
106-66	18221-18229	centered	_	
106-67	18230-18232	on	_	
106-68	18233-18236	the	_	
106-69	18237-18242	right	_	
106-70	18243-18254	hippocampus	_	
106-71	18255-18256	(	_	
106-72	18256-18257	x	_	
106-73	18257-18258	,	_	
106-74	18258-18259	y	_	
106-75	18259-18260	,	_	
106-76	18260-18261	z	_	
106-77	18261-18262	:	_	
106-78	18263-18265	29	_	
106-79	18265-18266	,	_	
106-80	18266-18267	−	_	
106-81	18267-18269	14	_	
106-82	18269-18270	,	_	
106-83	18270-18271	−	_	
106-84	18271-18273	14	_	
106-85	18273-18274	)	_	
106-86	18274-18275	.	_	

#Text=The different size of the spheres was chosen to reflect the actual size of the regions.
107-1	18276-18279	The	_	
107-2	18280-18289	different	_	
107-3	18290-18294	size	_	
107-4	18295-18297	of	_	
107-5	18298-18301	the	_	
107-6	18302-18309	spheres	_	
107-7	18310-18313	was	_	
107-8	18314-18320	chosen	_	
107-9	18321-18323	to	_	
107-10	18324-18331	reflect	_	
107-11	18332-18335	the	_	
107-12	18336-18342	actual	_	
107-13	18343-18347	size	_	
107-14	18348-18350	of	_	
107-15	18351-18354	the	_	
107-16	18355-18362	regions	_	
107-17	18362-18363	.	_	

#Text=Brain regions that were not predicted a priori but met a threshold of P<0.05, whole-brain corrected, were also reported.
108-1	18364-18369	Brain	_	
108-2	18370-18377	regions	_	
108-3	18378-18382	that	_	
108-4	18383-18387	were	_	
108-5	18388-18391	not	_	
108-6	18392-18401	predicted	_	
108-7	18402-18403	a	_	
108-8	18404-18410	priori	_	
108-9	18411-18414	but	_	
108-10	18415-18418	met	_	
108-11	18419-18420	a	_	
108-12	18421-18430	threshold	_	
108-13	18431-18433	of	_	
108-14	18434-18435	P	_	
108-15	18435-18436	<	_	
108-16	18436-18440	0.05	_	
108-17	18440-18441	,	_	
108-18	18442-18453	whole-brain	_	
108-19	18454-18463	corrected	_	
108-20	18463-18464	,	_	
108-21	18465-18469	were	_	
108-22	18470-18474	also	_	
108-23	18475-18483	reported	_	
108-24	18483-18484	.	_	

#Text=Functional connectivity: psycho-physiological interaction analyses
#Text=Psycho-physiological interaction (PPI) represents the change in connectivity between a seed region and the rest of the brain that is induced by a specific psychological context.
109-1	18485-18495	Functional	_	
109-2	18496-18508	connectivity	_	
109-3	18508-18509	:	_	
109-4	18510-18530	psycho-physiological	_	
109-5	18531-18542	interaction	_	
109-6	18543-18551	analyses	_	
109-7	18552-18572	Psycho-physiological	_	
109-8	18573-18584	interaction	_	
109-9	18585-18586	(	_	
109-10	18586-18589	PPI	_	
109-11	18589-18590	)	_	
109-12	18591-18601	represents	_	
109-13	18602-18605	the	_	
109-14	18606-18612	change	_	
109-15	18613-18615	in	_	
109-16	18616-18628	connectivity	_	
109-17	18629-18636	between	_	
109-18	18637-18638	a	_	
109-19	18639-18643	seed	_	
109-20	18644-18650	region	_	
109-21	18651-18654	and	_	
109-22	18655-18658	the	_	
109-23	18659-18663	rest	_	
109-24	18664-18666	of	_	
109-25	18667-18670	the	_	
109-26	18671-18676	brain	_	
109-27	18677-18681	that	_	
109-28	18682-18684	is	_	
109-29	18685-18692	induced	_	
109-30	18693-18695	by	_	
109-31	18696-18697	a	_	
109-32	18698-18706	specific	_	
109-33	18707-18720	psychological	_	
109-34	18721-18728	context	_	
109-35	18728-18729	.	_	

#Text=The ACC was chosen as a seed due to the high density of MORs in this region that potentially reflects higher binding potential associated with greater capacity to modulate negative emotional processing.
110-1	18730-18733	The	_	
110-2	18734-18737	ACC	_	
110-3	18738-18741	was	_	
110-4	18742-18748	chosen	_	
110-5	18749-18751	as	_	
110-6	18752-18753	a	_	
110-7	18754-18758	seed	_	
110-8	18759-18762	due	_	
110-9	18763-18765	to	_	
110-10	18766-18769	the	_	
110-11	18770-18774	high	_	
110-12	18775-18782	density	_	
110-13	18783-18785	of	_	
110-14	18786-18790	MORs	_	
110-15	18791-18793	in	_	
110-16	18794-18798	this	_	
110-17	18799-18805	region	_	
110-18	18806-18810	that	_	
110-19	18811-18822	potentially	_	
110-20	18823-18831	reflects	_	
110-21	18832-18838	higher	_	
110-22	18839-18846	binding	_	
110-23	18847-18856	potential	_	
110-24	18857-18867	associated	_	
110-25	18868-18872	with	_	
110-26	18873-18880	greater	_	
110-27	18881-18889	capacity	_	
110-28	18890-18892	to	_	
110-29	18893-18901	modulate	_	
110-30	18902-18910	negative	_	
110-31	18911-18920	emotional	_	
110-32	18921-18931	processing	_	
110-33	18931-18932	.	_	

#Text=We sought to identify brain regions that had a differential functional connectivity pattern with the seed region during the processing of aversive versus neutral images.
111-1	18933-18935	We	_	
111-2	18936-18942	sought	_	
111-3	18943-18945	to	_	
111-4	18946-18954	identify	_	
111-5	18955-18960	brain	_	
111-6	18961-18968	regions	_	
111-7	18969-18973	that	_	
111-8	18974-18977	had	_	
111-9	18978-18979	a	_	
111-10	18980-18992	differential	_	
111-11	18993-19003	functional	_	
111-12	19004-19016	connectivity	_	
111-13	19017-19024	pattern	_	
111-14	19025-19029	with	_	
111-15	19030-19033	the	_	
111-16	19034-19038	seed	_	
111-17	19039-19045	region	_	
111-18	19046-19052	during	_	
111-19	19053-19056	the	_	
111-20	19057-19067	processing	_	
111-21	19068-19070	of	_	
111-22	19071-19079	aversive	_	
111-23	19080-19086	versus	_	
111-24	19087-19094	neutral	_	
111-25	19095-19101	images	_	
111-26	19101-19102	.	_	

#Text=For each participant, a 15 mm sphere was centered on the right anterior cingulate cortex (x,y,z: 6,60,4; extracted from the first model).
112-1	19103-19106	For	_	
112-2	19107-19111	each	_	
112-3	19112-19123	participant	_	
112-4	19123-19124	,	_	
112-5	19125-19126	a	_	
112-6	19127-19129	15	_	
112-7	19130-19132	mm	_	
112-8	19133-19139	sphere	_	
112-9	19140-19143	was	_	
112-10	19144-19152	centered	_	
112-11	19153-19155	on	_	
112-12	19156-19159	the	_	
112-13	19160-19165	right	_	
112-14	19166-19174	anterior	_	
112-15	19175-19184	cingulate	_	
112-16	19185-19191	cortex	_	
112-17	19192-19193	(	_	
112-18	19193-19194	x	_	
112-19	19194-19195	,	_	
112-20	19195-19196	y	_	
112-21	19196-19197	,	_	
112-22	19197-19198	z	_	
112-23	19198-19199	:	_	
112-24	19200-19206	6,60,4	_	
112-25	19206-19207	;	_	
112-26	19208-19217	extracted	_	
112-27	19218-19222	from	_	
112-28	19223-19226	the	_	
112-29	19227-19232	first	_	
112-30	19233-19238	model	_	
112-31	19238-19239	)	_	
112-32	19239-19240	.	_	

#Text=The time series of the BOLD response for each participant was then computed using the first eigenvariate from all voxels' time series in the sphere.
113-1	19241-19244	The	_	
113-2	19245-19249	time	_	
113-3	19250-19256	series	_	
113-4	19257-19259	of	_	
113-5	19260-19263	the	_	
113-6	19264-19268	BOLD	_	
113-7	19269-19277	response	_	
113-8	19278-19281	for	_	
113-9	19282-19286	each	_	
113-10	19287-19298	participant	_	
113-11	19299-19302	was	_	
113-12	19303-19307	then	_	
113-13	19308-19316	computed	_	
113-14	19317-19322	using	_	
113-15	19323-19326	the	_	
113-16	19327-19332	first	_	
113-17	19333-19345	eigenvariate	_	
113-18	19346-19350	from	_	
113-19	19351-19354	all	_	
113-20	19355-19361	voxels	_	
113-21	19361-19362	'	_	
113-22	19363-19367	time	_	
113-23	19368-19374	series	_	
113-24	19375-19377	in	_	
113-25	19378-19381	the	_	
113-26	19382-19388	sphere	_	
113-27	19388-19389	.	_	

#Text=The BOLD time series for each individual was deconvolved to estimate a neuronal time series for the source, using the PPIs deconvolution parameter defaults in SPM8.
114-1	19390-19393	The	_	
114-2	19394-19398	BOLD	_	
114-3	19399-19403	time	_	
114-4	19404-19410	series	_	
114-5	19411-19414	for	_	
114-6	19415-19419	each	_	
114-7	19420-19430	individual	_	
114-8	19431-19434	was	_	
114-9	19435-19446	deconvolved	_	
114-10	19447-19449	to	_	
114-11	19450-19458	estimate	_	
114-12	19459-19460	a	_	
114-13	19461-19469	neuronal	_	
114-14	19470-19474	time	_	
114-15	19475-19481	series	_	
114-16	19482-19485	for	_	
114-17	19486-19489	the	_	
114-18	19490-19496	source	_	
114-19	19496-19497	,	_	
114-20	19498-19503	using	_	
114-21	19504-19507	the	_	
114-22	19508-19512	PPIs	_	
114-23	19513-19526	deconvolution	_	
114-24	19527-19536	parameter	_	
114-25	19537-19545	defaults	_	
114-26	19546-19548	in	_	
114-27	19549-19553	SPM8	_	
114-28	19553-19554	.	_	

#Text=The PPI regressor was calculated as the element-by-element product of the seed neuronal time series and a vector coding for the main effect of task (1 for aversive images, −1 for neutral images).
115-1	19555-19558	The	_	
115-2	19559-19562	PPI	_	
115-3	19563-19572	regressor	_	
115-4	19573-19576	was	_	
115-5	19577-19587	calculated	_	
115-6	19588-19590	as	_	
115-7	19591-19594	the	_	
115-8	19595-19613	element-by-element	_	
115-9	19614-19621	product	_	
115-10	19622-19624	of	_	
115-11	19625-19628	the	_	
115-12	19629-19633	seed	_	
115-13	19634-19642	neuronal	_	
115-14	19643-19647	time	_	
115-15	19648-19654	series	_	
115-16	19655-19658	and	_	
115-17	19659-19660	a	_	
115-18	19661-19667	vector	_	
115-19	19668-19674	coding	_	
115-20	19675-19678	for	_	
115-21	19679-19682	the	_	
115-22	19683-19687	main	_	
115-23	19688-19694	effect	_	
115-24	19695-19697	of	_	
115-25	19698-19702	task	_	
115-26	19703-19704	(	_	
115-27	19704-19705	1	_	
115-28	19706-19709	for	_	
115-29	19710-19718	aversive	_	
115-30	19719-19725	images	_	
115-31	19725-19726	,	_	
115-32	19727-19728	−	_	
115-33	19728-19729	1	_	
115-34	19730-19733	for	_	
115-35	19734-19741	neutral	_	
115-36	19742-19748	images	_	
115-37	19748-19749	)	_	
115-38	19749-19750	.	_	

#Text=This product was reconvolved by the canonical haemodynamic response function.
116-1	19751-19755	This	_	
116-2	19756-19763	product	_	
116-3	19764-19767	was	_	
116-4	19768-19779	reconvolved	_	
116-5	19780-19782	by	_	
116-6	19783-19786	the	_	
116-7	19787-19796	canonical	_	
116-8	19797-19809	haemodynamic	_	
116-9	19810-19818	response	_	
116-10	19819-19827	function	_	
116-11	19827-19828	.	_	

#Text=The statistical model also included the main effect of the task convolved by the haemodynamic response function, the seed neuronal time series and the six movement parameters as effects of no interest.
117-1	19829-19832	The	_	
117-2	19833-19844	statistical	_	
117-3	19845-19850	model	_	
117-4	19851-19855	also	_	
117-5	19856-19864	included	_	
117-6	19865-19868	the	_	
117-7	19869-19873	main	_	
117-8	19874-19880	effect	_	
117-9	19881-19883	of	_	
117-10	19884-19887	the	_	
117-11	19888-19892	task	_	
117-12	19893-19902	convolved	_	
117-13	19903-19905	by	_	
117-14	19906-19909	the	_	
117-15	19910-19922	haemodynamic	_	
117-16	19923-19931	response	_	
117-17	19932-19940	function	_	
117-18	19940-19941	,	_	
117-19	19942-19945	the	_	
117-20	19946-19950	seed	_	
117-21	19951-19959	neuronal	_	
117-22	19960-19964	time	_	
117-23	19965-19971	series	_	
117-24	19972-19975	and	_	
117-25	19976-19979	the	_	
117-26	19980-19983	six	_	
117-27	19984-19992	movement	_	
117-28	19993-20003	parameters	_	
117-29	20004-20006	as	_	
117-30	20007-20014	effects	_	
117-31	20015-20017	of	_	
117-32	20018-20020	no	_	
117-33	20021-20029	interest	_	
117-34	20029-20030	.	_	

#Text=Subject-specific PPI models were run, and contrast images were generated such that the identified target regions were those that showed a change in connectivity with the ACC during the processing of aversive versus neutral images.
118-1	20031-20047	Subject-specific	_	
118-2	20048-20051	PPI	_	
118-3	20052-20058	models	_	
118-4	20059-20063	were	_	
118-5	20064-20067	run	_	
118-6	20067-20068	,	_	
118-7	20069-20072	and	_	
118-8	20073-20081	contrast	_	
118-9	20082-20088	images	_	
118-10	20089-20093	were	_	
118-11	20094-20103	generated	_	
118-12	20104-20108	such	_	
118-13	20109-20113	that	_	
118-14	20114-20117	the	_	
118-15	20118-20128	identified	_	
118-16	20129-20135	target	_	
118-17	20136-20143	regions	_	
118-18	20144-20148	were	_	
118-19	20149-20154	those	_	
118-20	20155-20159	that	_	
118-21	20160-20166	showed	_	
118-22	20167-20168	a	_	
118-23	20169-20175	change	_	
118-24	20176-20178	in	_	
118-25	20179-20191	connectivity	_	
118-26	20192-20196	with	_	
118-27	20197-20200	the	_	
118-28	20201-20204	ACC	_	
118-29	20205-20211	during	_	
118-30	20212-20215	the	_	
118-31	20216-20226	processing	_	
118-32	20227-20229	of	_	
118-33	20230-20238	aversive	_	
118-34	20239-20245	versus	_	
118-35	20246-20253	neutral	_	
118-36	20254-20260	images	_	
118-37	20260-20261	.	_	

#Text=Subject-specific PPI contrast images were entered into second-level GLMs to assess if change in connectivity between the ACC and other regions in the brain were associated with childhood adversity as a function of pharmacological treatment.
119-1	20262-20278	Subject-specific	_	
119-2	20279-20282	PPI	_	
119-3	20283-20291	contrast	_	
119-4	20292-20298	images	_	
119-5	20299-20303	were	_	
119-6	20304-20311	entered	_	
119-7	20312-20316	into	_	
119-8	20317-20329	second-level	_	
119-9	20330-20334	GLMs	_	
119-10	20335-20337	to	_	
119-11	20338-20344	assess	_	
119-12	20345-20347	if	_	
119-13	20348-20354	change	_	
119-14	20355-20357	in	_	
119-15	20358-20370	connectivity	_	
119-16	20371-20378	between	_	
119-17	20379-20382	the	_	
119-18	20383-20386	ACC	_	
119-19	20387-20390	and	_	
119-20	20391-20396	other	_	
119-21	20397-20404	regions	_	
119-22	20405-20407	in	_	
119-23	20408-20411	the	_	
119-24	20412-20417	brain	_	
119-25	20418-20422	were	_	
119-26	20423-20433	associated	_	
119-27	20434-20438	with	_	
119-28	20439-20448	childhood	_	
119-29	20449-20458	adversity	_	
119-30	20459-20461	as	_	
119-31	20462-20463	a	_	
119-32	20464-20472	function	_	
119-33	20473-20475	of	_	
119-34	20476-20491	pharmacological	_	
119-35	20492-20501	treatment	_	
119-36	20501-20502	.	_	

#Text=The same statistical approaches previously described were employed to threshold the second-level PPI maps.
120-1	20503-20506	The	_	
120-2	20507-20511	same	_	
120-3	20512-20523	statistical	_	
120-4	20524-20534	approaches	_	
120-5	20535-20545	previously	_	
120-6	20546-20555	described	_	
120-7	20556-20560	were	_	
120-8	20561-20569	employed	_	
120-9	20570-20572	to	_	
120-10	20573-20582	threshold	_	
120-11	20583-20586	the	_	
120-12	20587-20599	second-level	_	
120-13	20600-20603	PPI	_	
120-14	20604-20608	maps	_	
120-15	20608-20609	.	_	

#Text=Results
#Text=Demographic information and baseline assessment
#Text=As shown in Table 2, the three groups did not differ with regard to gender, age, verbal intelligence, handedness, smoking status and locus of control beliefs (all P's>0.05).
121-1	20610-20617	Results	_	
121-2	20618-20629	Demographic	_	
121-3	20630-20641	information	_	
121-4	20642-20645	and	_	
121-5	20646-20654	baseline	_	
121-6	20655-20665	assessment	_	
121-7	20666-20668	As	_	
121-8	20669-20674	shown	_	
121-9	20675-20677	in	_	
121-10	20678-20683	Table	_	
121-11	20684-20685	2	_	
121-12	20685-20686	,	_	
121-13	20687-20690	the	_	
121-14	20691-20696	three	_	
121-15	20697-20703	groups	_	
121-16	20704-20707	did	_	
121-17	20708-20711	not	_	
121-18	20712-20718	differ	_	
121-19	20719-20723	with	_	
121-20	20724-20730	regard	_	
121-21	20731-20733	to	_	
121-22	20734-20740	gender	_	
121-23	20740-20741	,	_	
121-24	20742-20745	age	_	
121-25	20745-20746	,	_	
121-26	20747-20753	verbal	_	
121-27	20754-20766	intelligence	_	
121-28	20766-20767	,	_	
121-29	20768-20778	handedness	_	
121-30	20778-20779	,	_	
121-31	20780-20787	smoking	_	
121-32	20788-20794	status	_	
121-33	20795-20798	and	_	
121-34	20799-20804	locus	_	
121-35	20805-20807	of	_	
121-36	20808-20815	control	_	
121-37	20816-20823	beliefs	_	
121-38	20824-20825	(	_	
121-39	20825-20828	all	_	
121-40	20829-20832	P's	_	
121-41	20832-20833	>	_	
121-42	20833-20837	0.05	_	
121-43	20837-20838	)	_	
121-44	20838-20839	.	_	

#Text=However, significant group differences emerged with regard to stress sensitivity (F2,57=5.71, P=0.005) and childhood adversity (F2,57=6.63, P=0.003), such that the alcohol/drugs group reported significantly higher sensitivity to stress compared with the control group (Tukey's P=0.004) and significantly higher levels of childhood adversity compared with the control (Tukey's P=0.005) and alcohol (Tukey's P=0.012) groups.
122-1	20840-20847	However	_	
122-2	20847-20848	,	_	
122-3	20849-20860	significant	_	
122-4	20861-20866	group	_	
122-5	20867-20878	differences	_	
122-6	20879-20886	emerged	_	
122-7	20887-20891	with	_	
122-8	20892-20898	regard	_	
122-9	20899-20901	to	_	
122-10	20902-20908	stress	_	
122-11	20909-20920	sensitivity	_	
122-12	20921-20922	(	_	
122-13	20922-20927	F2,57	_	
122-14	20927-20928	=	_	
122-15	20928-20932	5.71	_	
122-16	20932-20933	,	_	
122-17	20934-20935	P	_	
122-18	20935-20936	=	_	
122-19	20936-20941	0.005	_	
122-20	20941-20942	)	_	
122-21	20943-20946	and	_	
122-22	20947-20956	childhood	_	
122-23	20957-20966	adversity	_	
122-24	20967-20968	(	_	
122-25	20968-20973	F2,57	_	
122-26	20973-20974	=	_	
122-27	20974-20978	6.63	_	
122-28	20978-20979	,	_	
122-29	20980-20981	P	_	
122-30	20981-20982	=	_	
122-31	20982-20987	0.003	_	
122-32	20987-20988	)	_	
122-33	20988-20989	,	_	
122-34	20990-20994	such	_	
122-35	20995-20999	that	_	
122-36	21000-21003	the	_	
122-37	21004-21011	alcohol	_	
122-38	21011-21012	/	_	
122-39	21012-21017	drugs	_	
122-40	21018-21023	group	_	
122-41	21024-21032	reported	_	
122-42	21033-21046	significantly	_	
122-43	21047-21053	higher	_	
122-44	21054-21065	sensitivity	_	
122-45	21066-21068	to	_	
122-46	21069-21075	stress	_	
122-47	21076-21084	compared	_	
122-48	21085-21089	with	_	
122-49	21090-21093	the	_	
122-50	21094-21101	control	_	
122-51	21102-21107	group	_	
122-52	21108-21109	(	_	
122-53	21109-21116	Tukey's	_	
122-54	21117-21118	P	_	
122-55	21118-21119	=	_	
122-56	21119-21124	0.004	_	
122-57	21124-21125	)	_	
122-58	21126-21129	and	_	
122-59	21130-21143	significantly	_	
122-60	21144-21150	higher	_	
122-61	21151-21157	levels	_	
122-62	21158-21160	of	_	
122-63	21161-21170	childhood	_	
122-64	21171-21180	adversity	_	
122-65	21181-21189	compared	_	
122-66	21190-21194	with	_	
122-67	21195-21198	the	_	
122-68	21199-21206	control	_	
122-69	21207-21208	(	_	
122-70	21208-21215	Tukey's	_	
122-71	21216-21217	P	_	
122-72	21217-21218	=	_	
122-73	21218-21223	0.005	_	
122-74	21223-21224	)	_	
122-75	21225-21228	and	_	
122-76	21229-21236	alcohol	_	
122-77	21237-21238	(	_	
122-78	21238-21245	Tukey's	_	
122-79	21246-21247	P	_	
122-80	21247-21248	=	_	
122-81	21248-21253	0.012	_	
122-82	21253-21254	)	_	
122-83	21255-21261	groups	_	
122-84	21261-21262	.	_	

#Text=The groups also differed with regard to affective states (BDI-II, STAI-State) on the day of testing, as assessed prior to scanning on placebo (F2,57=6.37, P=0.003; F2,57=8.42, P=0.001) and naltrexone (F2,57=5.04, P=0.010; F2,57=3.93, P=0.025).
123-1	21263-21266	The	_	
123-2	21267-21273	groups	_	
123-3	21274-21278	also	_	
123-4	21279-21287	differed	_	
123-5	21288-21292	with	_	
123-6	21293-21299	regard	_	
123-7	21300-21302	to	_	
123-8	21303-21312	affective	_	
123-9	21313-21319	states	_	
123-10	21320-21321	(	_	
123-11	21321-21327	BDI-II	_	
123-12	21327-21328	,	_	
123-13	21329-21339	STAI-State	_	
123-14	21339-21340	)	_	
123-15	21341-21343	on	_	
123-16	21344-21347	the	_	
123-17	21348-21351	day	_	
123-18	21352-21354	of	_	
123-19	21355-21362	testing	_	
123-20	21362-21363	,	_	
123-21	21364-21366	as	_	
123-22	21367-21375	assessed	_	
123-23	21376-21381	prior	_	
123-24	21382-21384	to	_	
123-25	21385-21393	scanning	_	
123-26	21394-21396	on	_	
123-27	21397-21404	placebo	_	
123-28	21405-21406	(	_	
123-29	21406-21411	F2,57	_	
123-30	21411-21412	=	_	
123-31	21412-21416	6.37	_	
123-32	21416-21417	,	_	
123-33	21418-21419	P	_	
123-34	21419-21420	=	_	
123-35	21420-21425	0.003	_	
123-36	21425-21426	;	_	
123-37	21427-21432	F2,57	_	
123-38	21432-21433	=	_	
123-39	21433-21437	8.42	_	
123-40	21437-21438	,	_	
123-41	21439-21440	P	_	
123-42	21440-21441	=	_	
123-43	21441-21446	0.001	_	
123-44	21446-21447	)	_	
123-45	21448-21451	and	_	
123-46	21452-21462	naltrexone	_	
123-47	21463-21464	(	_	
123-48	21464-21469	F2,57	_	
123-49	21469-21470	=	_	
123-50	21470-21474	5.04	_	
123-51	21474-21475	,	_	
123-52	21476-21477	P	_	
123-53	21477-21478	=	_	
123-54	21478-21483	0.010	_	
123-55	21483-21484	;	_	
123-56	21485-21490	F2,57	_	
123-57	21490-21491	=	_	
123-58	21491-21495	3.93	_	
123-59	21495-21496	,	_	
123-60	21497-21498	P	_	
123-61	21498-21499	=	_	
123-62	21499-21504	0.025	_	
123-63	21504-21505	)	_	
123-64	21505-21506	.	_	

#Text=The alcohol/drugs group scored significantly higher than the control group on total scores for both measures (both Tukey's P=0.002).
124-1	21507-21510	The	_	
124-2	21511-21518	alcohol	_	
124-3	21518-21519	/	_	
124-4	21519-21524	drugs	_	
124-5	21525-21530	group	_	
124-6	21531-21537	scored	_	
124-7	21538-21551	significantly	_	
124-8	21552-21558	higher	_	
124-9	21559-21563	than	_	
124-10	21564-21567	the	_	
124-11	21568-21575	control	_	
124-12	21576-21581	group	_	
124-13	21582-21584	on	_	
124-14	21585-21590	total	_	
124-15	21591-21597	scores	_	
124-16	21598-21601	for	_	
124-17	21602-21606	both	_	
124-18	21607-21615	measures	_	
124-19	21616-21617	(	_	
124-20	21617-21621	both	_	
124-21	21622-21629	Tukey's	_	
124-22	21630-21631	P	_	
124-23	21631-21632	=	_	
124-24	21632-21637	0.002	_	
124-25	21637-21638	)	_	
124-26	21638-21639	.	_	

#Text=However, affective state did not significantly fluctuate between the two experimental medicine sessions, as reflected by non-significant group-by-session interactions (BDI-II: F2,57=.64, P=0.534; STAI-State: F2,57=2.13, P=0.129), and the main effects of treatment were not significant for either measure (BDI-II: F1,57=1.41, P=0.240; STAI-State: F1,57=1.72, P=0.194).
125-1	21640-21647	However	_	
125-2	21647-21648	,	_	
125-3	21649-21658	affective	_	
125-4	21659-21664	state	_	
125-5	21665-21668	did	_	
125-6	21669-21672	not	_	
125-7	21673-21686	significantly	_	
125-8	21687-21696	fluctuate	_	
125-9	21697-21704	between	_	
125-10	21705-21708	the	_	
125-11	21709-21712	two	_	
125-12	21713-21725	experimental	_	
125-13	21726-21734	medicine	_	
125-14	21735-21743	sessions	_	
125-15	21743-21744	,	_	
125-16	21745-21747	as	_	
125-17	21748-21757	reflected	_	
125-18	21758-21760	by	_	
125-19	21761-21776	non-significant	_	
125-20	21777-21793	group-by-session	_	
125-21	21794-21806	interactions	_	
125-22	21807-21808	(	_	
125-23	21808-21814	BDI-II	_	
125-24	21814-21815	:	_	
125-25	21816-21821	F2,57	_	
125-26	21821-21822	=	_	
125-27	21822-21825	.64	_	
125-28	21825-21826	,	_	
125-29	21827-21828	P	_	
125-30	21828-21829	=	_	
125-31	21829-21834	0.534	_	
125-32	21834-21835	;	_	
125-33	21836-21846	STAI-State	_	
125-34	21846-21847	:	_	
125-35	21848-21853	F2,57	_	
125-36	21853-21854	=	_	
125-37	21854-21858	2.13	_	
125-38	21858-21859	,	_	
125-39	21860-21861	P	_	
125-40	21861-21862	=	_	
125-41	21862-21867	0.129	_	
125-42	21867-21868	)	_	
125-43	21868-21869	,	_	
125-44	21870-21873	and	_	
125-45	21874-21877	the	_	
125-46	21878-21882	main	_	
125-47	21883-21890	effects	_	
125-48	21891-21893	of	_	
125-49	21894-21903	treatment	_	
125-50	21904-21908	were	_	
125-51	21909-21912	not	_	
125-52	21913-21924	significant	_	
125-53	21925-21928	for	_	
125-54	21929-21935	either	_	
125-55	21936-21943	measure	_	
125-56	21944-21945	(	_	
125-57	21945-21951	BDI-II	_	
125-58	21951-21952	:	_	
125-59	21953-21958	F1,57	_	
125-60	21958-21959	=	_	
125-61	21959-21963	1.41	_	
125-62	21963-21964	,	_	
125-63	21965-21966	P	_	
125-64	21966-21967	=	_	
125-65	21967-21972	0.240	_	
125-66	21972-21973	;	_	
125-67	21974-21984	STAI-State	_	
125-68	21984-21985	:	_	
125-69	21986-21991	F1,57	_	
125-70	21991-21992	=	_	
125-71	21992-21996	1.72	_	
125-72	21996-21997	,	_	
125-73	21998-21999	P	_	
125-74	21999-22000	=	_	
125-75	22000-22005	0.194	_	
125-76	22005-22006	)	_	
125-77	22006-22007	.	_	

#Text=Total scores of the BDI-II and STAI-State did not correlate significantly with behavioral change scores (all P's>0.05) and consequently were not used as covariates in subsequent behavioral analyses.
126-1	22008-22013	Total	_	
126-2	22014-22020	scores	_	
126-3	22021-22023	of	_	
126-4	22024-22027	the	_	
126-5	22028-22034	BDI-II	_	
126-6	22035-22038	and	_	
126-7	22039-22049	STAI-State	_	
126-8	22050-22053	did	_	
126-9	22054-22057	not	_	
126-10	22058-22067	correlate	_	
126-11	22068-22081	significantly	_	
126-12	22082-22086	with	_	
126-13	22087-22097	behavioral	_	
126-14	22098-22104	change	_	
126-15	22105-22111	scores	_	
126-16	22112-22113	(	_	
126-17	22113-22116	all	_	
126-18	22117-22120	P's	_	
126-19	22120-22121	>	_	
126-20	22121-22125	0.05	_	
126-21	22125-22126	)	_	
126-22	22127-22130	and	_	
126-23	22131-22143	consequently	_	
126-24	22144-22148	were	_	
126-25	22149-22152	not	_	
126-26	22153-22157	used	_	
126-27	22158-22160	as	_	
126-28	22161-22171	covariates	_	
126-29	22172-22174	in	_	
126-30	22175-22185	subsequent	_	
126-31	22186-22196	behavioral	_	
126-32	22197-22205	analyses	_	
126-33	22205-22206	.	_	

#Text=As we did not identify differences in demographics between participants recruited at the three different sites (all P's>0.2), we did not include scanning site as a covariate in behavioral analyses.
127-1	22207-22209	As	_	
127-2	22210-22212	we	_	
127-3	22213-22216	did	_	
127-4	22217-22220	not	_	
127-5	22221-22229	identify	_	
127-6	22230-22241	differences	_	
127-7	22242-22244	in	_	
127-8	22245-22257	demographics	_	
127-9	22258-22265	between	_	
127-10	22266-22278	participants	_	
127-11	22279-22288	recruited	_	
127-12	22289-22291	at	_	
127-13	22292-22295	the	_	
127-14	22296-22301	three	_	
127-15	22302-22311	different	_	
127-16	22312-22317	sites	_	
127-17	22318-22319	(	_	
127-18	22319-22322	all	_	
127-19	22323-22326	P's	_	
127-20	22326-22327	>	_	
127-21	22327-22330	0.2	_	
127-22	22330-22331	)	_	
127-23	22331-22332	,	_	
127-24	22333-22335	we	_	
127-25	22336-22339	did	_	
127-26	22340-22343	not	_	
127-27	22344-22351	include	_	
127-28	22352-22360	scanning	_	
127-29	22361-22365	site	_	
127-30	22366-22368	as	_	
127-31	22369-22370	a	_	
127-32	22371-22380	covariate	_	
127-33	22381-22383	in	_	
127-34	22384-22394	behavioral	_	
127-35	22395-22403	analyses	_	
127-36	22403-22404	.	_	

#Text=Task-related performance during evocative image processing
#Text=As shown in Table 1, participants in both the alcohol and alcohol/drugs groups tended to respond more slowly in general, but there was considerable variability and differences between the groups failed to reach significance (F2,57=3.04, P=0.056).
128-1	22405-22417	Task-related	_	
128-2	22418-22429	performance	_	
128-3	22430-22436	during	_	
128-4	22437-22446	evocative	_	
128-5	22447-22452	image	_	
128-6	22453-22463	processing	_	
128-7	22464-22466	As	_	
128-8	22467-22472	shown	_	
128-9	22473-22475	in	_	
128-10	22476-22481	Table	_	
128-11	22482-22483	1	_	
128-12	22483-22484	,	_	
128-13	22485-22497	participants	_	
128-14	22498-22500	in	_	
128-15	22501-22505	both	_	
128-16	22506-22509	the	_	
128-17	22510-22517	alcohol	_	
128-18	22518-22521	and	_	
128-19	22522-22529	alcohol	_	
128-20	22529-22530	/	_	
128-21	22530-22535	drugs	_	
128-22	22536-22542	groups	_	
128-23	22543-22549	tended	_	
128-24	22550-22552	to	_	
128-25	22553-22560	respond	_	
128-26	22561-22565	more	_	
128-27	22566-22572	slowly	_	
128-28	22573-22575	in	_	
128-29	22576-22583	general	_	
128-30	22583-22584	,	_	
128-31	22585-22588	but	_	
128-32	22589-22594	there	_	
128-33	22595-22598	was	_	
128-34	22599-22611	considerable	_	
128-35	22612-22623	variability	_	
128-36	22624-22627	and	_	
128-37	22628-22639	differences	_	
128-38	22640-22647	between	_	
128-39	22648-22651	the	_	
128-40	22652-22658	groups	_	
128-41	22659-22665	failed	_	
128-42	22666-22668	to	_	
128-43	22669-22674	reach	_	
128-44	22675-22687	significance	_	
128-45	22688-22689	(	_	
128-46	22689-22694	F2,57	_	
128-47	22694-22695	=	_	
128-48	22695-22699	3.04	_	
128-49	22699-22700	,	_	
128-50	22701-22702	P	_	
128-51	22702-22703	=	_	
128-52	22703-22708	0.056	_	
128-53	22708-22709	)	_	
128-54	22709-22710	.	_	

#Text=There was a main effect of condition (aversive versus neutral images; F1,57=11.27, P=0.001), such that response latency to aversive images (818.87 ms s.d. ±343.55) was significantly longer than response latency to neutral images (758.11 ms ±271.47) (t59=−3.36, P=0.001) across groups.
129-1	22711-22716	There	_	
129-2	22717-22720	was	_	
129-3	22721-22722	a	_	
129-4	22723-22727	main	_	
129-5	22728-22734	effect	_	
129-6	22735-22737	of	_	
129-7	22738-22747	condition	_	
129-8	22748-22749	(	_	
129-9	22749-22757	aversive	_	
129-10	22758-22764	versus	_	
129-11	22765-22772	neutral	_	
129-12	22773-22779	images	_	
129-13	22779-22780	;	_	
129-14	22781-22786	F1,57	_	
129-15	22786-22787	=	_	
129-16	22787-22792	11.27	_	
129-17	22792-22793	,	_	
129-18	22794-22795	P	_	
129-19	22795-22796	=	_	
129-20	22796-22801	0.001	_	
129-21	22801-22802	)	_	
129-22	22802-22803	,	_	
129-23	22804-22808	such	_	
129-24	22809-22813	that	_	
129-25	22814-22822	response	_	
129-26	22823-22830	latency	_	
129-27	22831-22833	to	_	
129-28	22834-22842	aversive	_	
129-29	22843-22849	images	_	
129-30	22850-22851	(	_	
129-31	22851-22857	818.87	_	
129-32	22858-22860	ms	_	
129-33	22861-22864	s.d	_	
129-34	22864-22865	.	_	
129-35	22866-22867	±	_	
129-36	22867-22873	343.55	_	
129-37	22873-22874	)	_	
129-38	22875-22878	was	_	
129-39	22879-22892	significantly	_	
129-40	22893-22899	longer	_	
129-41	22900-22904	than	_	
129-42	22905-22913	response	_	
129-43	22914-22921	latency	_	
129-44	22922-22924	to	_	
129-45	22925-22932	neutral	_	
129-46	22933-22939	images	_	
129-47	22940-22941	(	_	
129-48	22941-22947	758.11	_	
129-49	22948-22950	ms	_	
129-50	22951-22952	±	_	
129-51	22952-22958	271.47	_	
129-52	22958-22959	)	_	
129-53	22960-22961	(	_	
129-54	22961-22964	t59	_	
129-55	22964-22965	=	_	
129-56	22965-22966	−	_	
129-57	22966-22970	3.36	_	
129-58	22970-22971	,	_	
129-59	22972-22973	P	_	
129-60	22973-22974	=	_	
129-61	22974-22979	0.001	_	
129-62	22979-22980	)	_	
129-63	22981-22987	across	_	
129-64	22988-22994	groups	_	
129-65	22994-22995	.	_	

#Text=However, there was no main effect of treatment (F1,57=0.006, P=0.941) and the group-by-treatment (F2,57=0.90, P=0.915) and the group-by-treatment-by-condition (F2,57=0.45, P=0.640) interactions were also not significant.
130-1	22996-23003	However	_	
130-2	23003-23004	,	_	
130-3	23005-23010	there	_	
130-4	23011-23014	was	_	
130-5	23015-23017	no	_	
130-6	23018-23022	main	_	
130-7	23023-23029	effect	_	
130-8	23030-23032	of	_	
130-9	23033-23042	treatment	_	
130-10	23043-23044	(	_	
130-11	23044-23049	F1,57	_	
130-12	23049-23050	=	_	
130-13	23050-23055	0.006	_	
130-14	23055-23056	,	_	
130-15	23057-23058	P	_	
130-16	23058-23059	=	_	
130-17	23059-23064	0.941	_	
130-18	23064-23065	)	_	
130-19	23066-23069	and	_	
130-20	23070-23073	the	_	
130-21	23074-23092	group-by-treatment	_	
130-22	23093-23094	(	_	
130-23	23094-23099	F2,57	_	
130-24	23099-23100	=	_	
130-25	23100-23104	0.90	_	
130-26	23104-23105	,	_	
130-27	23106-23107	P	_	
130-28	23107-23108	=	_	
130-29	23108-23113	0.915	_	
130-30	23113-23114	)	_	
130-31	23115-23118	and	_	
130-32	23119-23122	the	_	
130-33	23123-23154	group-by-treatment-by-condition	_	
130-34	23155-23156	(	_	
130-35	23156-23161	F2,57	_	
130-36	23161-23162	=	_	
130-37	23162-23166	0.45	_	
130-38	23166-23167	,	_	
130-39	23168-23169	P	_	
130-40	23169-23170	=	_	
130-41	23170-23175	0.640	_	
130-42	23175-23176	)	_	
130-43	23177-23189	interactions	_	
130-44	23190-23194	were	_	
130-45	23195-23199	also	_	
130-46	23200-23203	not	_	
130-47	23204-23215	significant	_	
130-48	23215-23216	.	_	

#Text=Task-related brain activation during evocative image processing
#Text=Significant correlations between the ROIs and childhood adversity were found during the processing of aversive versus neutral images as a function of pharmacological treatment.
131-1	23217-23229	Task-related	_	
131-2	23230-23235	brain	_	
131-3	23236-23246	activation	_	
131-4	23247-23253	during	_	
131-5	23254-23263	evocative	_	
131-6	23264-23269	image	_	
131-7	23270-23280	processing	_	
131-8	23281-23292	Significant	_	
131-9	23293-23305	correlations	_	
131-10	23306-23313	between	_	
131-11	23314-23317	the	_	
131-12	23318-23322	ROIs	_	
131-13	23323-23326	and	_	
131-14	23327-23336	childhood	_	
131-15	23337-23346	adversity	_	
131-16	23347-23351	were	_	
131-17	23352-23357	found	_	
131-18	23358-23364	during	_	
131-19	23365-23368	the	_	
131-20	23369-23379	processing	_	
131-21	23380-23382	of	_	
131-22	23383-23391	aversive	_	
131-23	23392-23398	versus	_	
131-24	23399-23406	neutral	_	
131-25	23407-23413	images	_	
131-26	23414-23416	as	_	
131-27	23417-23418	a	_	
131-28	23419-23427	function	_	
131-29	23428-23430	of	_	
131-30	23431-23446	pharmacological	_	
131-31	23447-23456	treatment	_	
131-32	23456-23457	.	_	

#Text=Figure 1a shows a positive association between activity in the right mPFC (x,y,z: 20,60,0) and childhood adversity (z-score=3.71, P=0.004 FWE for multiple comparisons after small volume correction) and, similarly, Figure 1b shows a positive association between functional connectivity between the right ACC and the right hippocampus (x,y,z: 22,−16,−10) and childhood adversity (z-score=3.11; P=0.002, FWE for multiple comparisons after small volume correction) in the placebo relative to the naltrexone session.
132-1	23458-23464	Figure	_	
132-2	23465-23467	1a	_	
132-3	23468-23473	shows	_	
132-4	23474-23475	a	_	
132-5	23476-23484	positive	_	
132-6	23485-23496	association	_	
132-7	23497-23504	between	_	
132-8	23505-23513	activity	_	
132-9	23514-23516	in	_	
132-10	23517-23520	the	_	
132-11	23521-23526	right	_	
132-12	23527-23531	mPFC	_	
132-13	23532-23533	(	_	
132-14	23533-23534	x	_	
132-15	23534-23535	,	_	
132-16	23535-23536	y	_	
132-17	23536-23537	,	_	
132-18	23537-23538	z	_	
132-19	23538-23539	:	_	
132-20	23540-23547	20,60,0	_	
132-21	23547-23548	)	_	
132-22	23549-23552	and	_	
132-23	23553-23562	childhood	_	
132-24	23563-23572	adversity	_	
132-25	23573-23574	(	_	
132-26	23574-23581	z-score	_	
132-27	23581-23582	=	_	
132-28	23582-23586	3.71	_	
132-29	23586-23587	,	_	
132-30	23588-23589	P	_	
132-31	23589-23590	=	_	
132-32	23590-23595	0.004	_	
132-33	23596-23599	FWE	_	
132-34	23600-23603	for	_	
132-35	23604-23612	multiple	_	
132-36	23613-23624	comparisons	_	
132-37	23625-23630	after	_	
132-38	23631-23636	small	_	
132-39	23637-23643	volume	_	
132-40	23644-23654	correction	_	
132-41	23654-23655	)	_	
132-42	23656-23659	and	_	
132-43	23659-23660	,	_	
132-44	23661-23670	similarly	_	
132-45	23670-23671	,	_	
132-46	23672-23678	Figure	_	
132-47	23679-23681	1b	_	
132-48	23682-23687	shows	_	
132-49	23688-23689	a	_	
132-50	23690-23698	positive	_	
132-51	23699-23710	association	_	
132-52	23711-23718	between	_	
132-53	23719-23729	functional	_	
132-54	23730-23742	connectivity	_	
132-55	23743-23750	between	_	
132-56	23751-23754	the	_	
132-57	23755-23760	right	_	
132-58	23761-23764	ACC	_	
132-59	23765-23768	and	_	
132-60	23769-23772	the	_	
132-61	23773-23778	right	_	
132-62	23779-23790	hippocampus	_	
132-63	23791-23792	(	_	
132-64	23792-23793	x	_	
132-65	23793-23794	,	_	
132-66	23794-23795	y	_	
132-67	23795-23796	,	_	
132-68	23796-23797	z	_	
132-69	23797-23798	:	_	
132-70	23799-23801	22	_	
132-71	23801-23802	,	_	
132-72	23802-23803	−	_	
132-73	23803-23805	16	_	
132-74	23805-23806	,	_	
132-75	23806-23807	−	_	
132-76	23807-23809	10	_	
132-77	23809-23810	)	_	
132-78	23811-23814	and	_	
132-79	23815-23824	childhood	_	
132-80	23825-23834	adversity	_	
132-81	23835-23836	(	_	
132-82	23836-23843	z-score	_	
132-83	23843-23844	=	_	
132-84	23844-23848	3.11	_	
132-85	23848-23849	;	_	
132-86	23850-23851	P	_	
132-87	23851-23852	=	_	
132-88	23852-23857	0.002	_	
132-89	23857-23858	,	_	
132-90	23859-23862	FWE	_	
132-91	23863-23866	for	_	
132-92	23867-23875	multiple	_	
132-93	23876-23887	comparisons	_	
132-94	23888-23893	after	_	
132-95	23894-23899	small	_	
132-96	23900-23906	volume	_	
132-97	23907-23917	correction	_	
132-98	23917-23918	)	_	
132-99	23919-23921	in	_	
132-100	23922-23925	the	_	
132-101	23926-23933	placebo	_	
132-102	23934-23942	relative	_	
132-103	23943-23945	to	_	
132-104	23946-23949	the	_	
132-105	23950-23960	naltrexone	_	
132-106	23961-23968	session	_	
132-107	23968-23969	.	_	

#Text=This pattern of association was found irrespective of group.
133-1	23970-23974	This	_	
133-2	23975-23982	pattern	_	
133-3	23983-23985	of	_	
133-4	23986-23997	association	_	
133-5	23998-24001	was	_	
133-6	24002-24007	found	_	
133-7	24008-24020	irrespective	_	
133-8	24021-24023	of	_	
133-9	24024-24029	group	_	
133-10	24029-24030	.	_	

#Text=As shown in Table 3, there was a main effect of group and a main effect of condition in temporal–occipital regions.
134-1	24031-24033	As	_	
134-2	24034-24039	shown	_	
134-3	24040-24042	in	_	
134-4	24043-24048	Table	_	
134-5	24049-24050	3	_	
134-6	24050-24051	,	_	
134-7	24052-24057	there	_	
134-8	24058-24061	was	_	
134-9	24062-24063	a	_	
134-10	24064-24068	main	_	
134-11	24069-24075	effect	_	
134-12	24076-24078	of	_	
134-13	24079-24084	group	_	
134-14	24085-24088	and	_	
134-15	24089-24090	a	_	
134-16	24091-24095	main	_	
134-17	24096-24102	effect	_	
134-18	24103-24105	of	_	
134-19	24106-24115	condition	_	
134-20	24116-24118	in	_	
134-21	24119-24137	temporal–occipital	_	
134-22	24138-24145	regions	_	
134-23	24145-24146	.	_	

#Text=There was a significant group-by-treatment-by-condition interaction (z-score=2.66; P=0.032 FWE for multiple comparisons after small volume correction) in the right amygdala (x,y,z: 26,2,−24; Figure 2) while viewing aversive and neutral images relative to baseline.
135-1	24147-24152	There	_	
135-2	24153-24156	was	_	
135-3	24157-24158	a	_	
135-4	24159-24170	significant	_	
135-5	24171-24202	group-by-treatment-by-condition	_	
135-6	24203-24214	interaction	_	
135-7	24215-24216	(	_	
135-8	24216-24223	z-score	_	
135-9	24223-24224	=	_	
135-10	24224-24228	2.66	_	
135-11	24228-24229	;	_	
135-12	24230-24231	P	_	
135-13	24231-24232	=	_	
135-14	24232-24237	0.032	_	
135-15	24238-24241	FWE	_	
135-16	24242-24245	for	_	
135-17	24246-24254	multiple	_	
135-18	24255-24266	comparisons	_	
135-19	24267-24272	after	_	
135-20	24273-24278	small	_	
135-21	24279-24285	volume	_	
135-22	24286-24296	correction	_	
135-23	24296-24297	)	_	
135-24	24298-24300	in	_	
135-25	24301-24304	the	_	
135-26	24305-24310	right	_	
135-27	24311-24319	amygdala	_	
135-28	24320-24321	(	_	
135-29	24321-24322	x	_	
135-30	24322-24323	,	_	
135-31	24323-24324	y	_	
135-32	24324-24325	,	_	
135-33	24325-24326	z	_	
135-34	24326-24327	:	_	
135-35	24328-24332	26,2	_	
135-36	24332-24333	,	_	
135-37	24333-24334	−	_	
135-38	24334-24336	24	_	
135-39	24336-24337	;	_	
135-40	24338-24344	Figure	_	
135-41	24345-24346	2	_	
135-42	24346-24347	)	_	
135-43	24348-24353	while	_	
135-44	24354-24361	viewing	_	
135-45	24362-24370	aversive	_	
135-46	24371-24374	and	_	
135-47	24375-24382	neutral	_	
135-48	24383-24389	images	_	
135-49	24390-24398	relative	_	
135-50	24399-24401	to	_	
135-51	24402-24410	baseline	_	
135-52	24410-24411	.	_	

#Text=Figure 2a shows that the alcohol and control groups had higher activation in the amygdala when processing aversive relative to neutral images on placebo, thus demonstrating increased activation to threat-related stimuli.
136-1	24412-24418	Figure	_	
136-2	24419-24421	2a	_	
136-3	24422-24427	shows	_	
136-4	24428-24432	that	_	
136-5	24433-24436	the	_	
136-6	24437-24444	alcohol	_	
136-7	24445-24448	and	_	
136-8	24449-24456	control	_	
136-9	24457-24463	groups	_	
136-10	24464-24467	had	_	
136-11	24468-24474	higher	_	
136-12	24475-24485	activation	_	
136-13	24486-24488	in	_	
136-14	24489-24492	the	_	
136-15	24493-24501	amygdala	_	
136-16	24502-24506	when	_	
136-17	24507-24517	processing	_	
136-18	24518-24526	aversive	_	
136-19	24527-24535	relative	_	
136-20	24536-24538	to	_	
136-21	24539-24546	neutral	_	
136-22	24547-24553	images	_	
136-23	24554-24556	on	_	
136-24	24557-24564	placebo	_	
136-25	24564-24565	,	_	
136-26	24566-24570	thus	_	
136-27	24571-24584	demonstrating	_	
136-28	24585-24594	increased	_	
136-29	24595-24605	activation	_	
136-30	24606-24608	to	_	
136-31	24609-24623	threat-related	_	
136-32	24624-24631	stimuli	_	
136-33	24631-24632	.	_	

#Text=However, activation in the amygdala increased to both aversive and neutral images in the alcohol/drugs group, irrespective of emotional valence.
137-1	24633-24640	However	_	
137-2	24640-24641	,	_	
137-3	24642-24652	activation	_	
137-4	24653-24655	in	_	
137-5	24656-24659	the	_	
137-6	24660-24668	amygdala	_	
137-7	24669-24678	increased	_	
137-8	24679-24681	to	_	
137-9	24682-24686	both	_	
137-10	24687-24695	aversive	_	
137-11	24696-24699	and	_	
137-12	24700-24707	neutral	_	
137-13	24708-24714	images	_	
137-14	24715-24717	in	_	
137-15	24718-24721	the	_	
137-16	24722-24729	alcohol	_	
137-17	24729-24730	/	_	
137-18	24730-24735	drugs	_	
137-19	24736-24741	group	_	
137-20	24741-24742	,	_	
137-21	24743-24755	irrespective	_	
137-22	24756-24758	of	_	
137-23	24759-24768	emotional	_	
137-24	24769-24776	valence	_	
137-25	24776-24777	.	_	

#Text=Figure 2b shows that the group-by-treatment-by-condition interaction was mainly driven by a normalization of response in the amygdala for aversive relative to neutral images under naltrexone in the alcohol/drugs group, whereas the pattern of activation did not change in the alcohol and control groups.
138-1	24778-24784	Figure	_	
138-2	24785-24787	2b	_	
138-3	24788-24793	shows	_	
138-4	24794-24798	that	_	
138-5	24799-24802	the	_	
138-6	24803-24834	group-by-treatment-by-condition	_	
138-7	24835-24846	interaction	_	
138-8	24847-24850	was	_	
138-9	24851-24857	mainly	_	
138-10	24858-24864	driven	_	
138-11	24865-24867	by	_	
138-12	24868-24869	a	_	
138-13	24870-24883	normalization	_	
138-14	24884-24886	of	_	
138-15	24887-24895	response	_	
138-16	24896-24898	in	_	
138-17	24899-24902	the	_	
138-18	24903-24911	amygdala	_	
138-19	24912-24915	for	_	
138-20	24916-24924	aversive	_	
138-21	24925-24933	relative	_	
138-22	24934-24936	to	_	
138-23	24937-24944	neutral	_	
138-24	24945-24951	images	_	
138-25	24952-24957	under	_	
138-26	24958-24968	naltrexone	_	
138-27	24969-24971	in	_	
138-28	24972-24975	the	_	
138-29	24976-24983	alcohol	_	
138-30	24983-24984	/	_	
138-31	24984-24989	drugs	_	
138-32	24990-24995	group	_	
138-33	24995-24996	,	_	
138-34	24997-25004	whereas	_	
138-35	25005-25008	the	_	
138-36	25009-25016	pattern	_	
138-37	25017-25019	of	_	
138-38	25020-25030	activation	_	
138-39	25031-25034	did	_	
138-40	25035-25038	not	_	
138-41	25039-25045	change	_	
138-42	25046-25048	in	_	
138-43	25049-25052	the	_	
138-44	25053-25060	alcohol	_	
138-45	25061-25064	and	_	
138-46	25065-25072	control	_	
138-47	25073-25079	groups	_	
138-48	25079-25080	.	_	

#Text=There was no main effect of treatment and the group-by-treatment interaction was not significant.
139-1	25081-25086	There	_	
139-2	25087-25090	was	_	
139-3	25091-25093	no	_	
139-4	25094-25098	main	_	
139-5	25099-25105	effect	_	
139-6	25106-25108	of	_	
139-7	25109-25118	treatment	_	
139-8	25119-25122	and	_	
139-9	25123-25126	the	_	
139-10	25127-25145	group-by-treatment	_	
139-11	25146-25157	interaction	_	
139-12	25158-25161	was	_	
139-13	25162-25165	not	_	
139-14	25166-25177	significant	_	
139-15	25177-25178	.	_	

#Text=Discussion
#Text=Influence of childhood adversity on naltrexone
#Text=Childhood adversity was highly prevalent in our alcohol/drugs group and significantly differed between the patient groups.
140-1	25179-25189	Discussion	_	
140-2	25190-25199	Influence	_	
140-3	25200-25202	of	_	
140-4	25203-25212	childhood	_	
140-5	25213-25222	adversity	_	
140-6	25223-25225	on	_	
140-7	25226-25236	naltrexone	_	
140-8	25237-25246	Childhood	_	
140-9	25247-25256	adversity	_	
140-10	25257-25260	was	_	
140-11	25261-25267	highly	_	
140-12	25268-25277	prevalent	_	
140-13	25278-25280	in	_	
140-14	25281-25284	our	_	
140-15	25285-25292	alcohol	_	
140-16	25292-25293	/	_	
140-17	25293-25298	drugs	_	
140-18	25299-25304	group	_	
140-19	25305-25308	and	_	
140-20	25309-25322	significantly	_	
140-21	25323-25331	differed	_	
140-22	25332-25339	between	_	
140-23	25340-25343	the	_	
140-24	25344-25351	patient	_	
140-25	25352-25358	groups	_	
140-26	25358-25359	.	_	

#Text=This is in line with previous studies showing that individuals with a history of childhood abuse are more prone to combined alcohol and drug taking in adulthood.
141-1	25360-25364	This	_	
141-2	25365-25367	is	_	
141-3	25368-25370	in	_	
141-4	25371-25375	line	_	
141-5	25376-25380	with	_	
141-6	25381-25389	previous	_	
141-7	25390-25397	studies	_	
141-8	25398-25405	showing	_	
141-9	25406-25410	that	_	
141-10	25411-25422	individuals	_	
141-11	25423-25427	with	_	
141-12	25428-25429	a	_	
141-13	25430-25437	history	_	
141-14	25438-25440	of	_	
141-15	25441-25450	childhood	_	
141-16	25451-25456	abuse	_	
141-17	25457-25460	are	_	
141-18	25461-25465	more	_	
141-19	25466-25471	prone	_	
141-20	25472-25474	to	_	
141-21	25475-25483	combined	_	
141-22	25484-25491	alcohol	_	
141-23	25492-25495	and	_	
141-24	25496-25500	drug	_	
141-25	25501-25507	taking	_	
141-26	25508-25510	in	_	
141-27	25511-25520	adulthood	_	
141-28	25520-25521	.	_	

#Text=Sensitivity to stress was also high in our alcohol/drugs group compared with the control group.
142-1	25522-25533	Sensitivity	_	
142-2	25534-25536	to	_	
142-3	25537-25543	stress	_	
142-4	25544-25547	was	_	
142-5	25548-25552	also	_	
142-6	25553-25557	high	_	
142-7	25558-25560	in	_	
142-8	25561-25564	our	_	
142-9	25565-25572	alcohol	_	
142-10	25572-25573	/	_	
142-11	25573-25578	drugs	_	
142-12	25579-25584	group	_	
142-13	25585-25593	compared	_	
142-14	25594-25598	with	_	
142-15	25599-25602	the	_	
142-16	25603-25610	control	_	
142-17	25611-25616	group	_	
142-18	25616-25617	.	_	

#Text=These differences support that aversive emotional states contribute to negatively reinforced drug seeking, consistent with the ‘dark side' view of addiction.
143-1	25618-25623	These	_	
143-2	25624-25635	differences	_	
143-3	25636-25643	support	_	
143-4	25644-25648	that	_	
143-5	25649-25657	aversive	_	
143-6	25658-25667	emotional	_	
143-7	25668-25674	states	_	
143-8	25675-25685	contribute	_	
143-9	25686-25688	to	_	
143-10	25689-25699	negatively	_	
143-11	25700-25710	reinforced	_	
143-12	25711-25715	drug	_	
143-13	25716-25723	seeking	_	
143-14	25723-25724	,	_	
143-15	25725-25735	consistent	_	
143-16	25736-25740	with	_	
143-17	25741-25744	the	_	
143-18	25745-25746	‘	_	
143-19	25746-25750	dark	_	
143-20	25751-25755	side	_	
143-21	25755-25756	'	_	
143-22	25757-25761	view	_	
143-23	25762-25764	of	_	
143-24	25765-25774	addiction	_	
143-25	25774-25775	.	_	

#Text=Negative reinforcement thus acts to increase more compulsive drug-seeking behavior, particularly during the withdrawal/negative affect stage of the addiction cycle.
144-1	25776-25784	Negative	_	
144-2	25785-25798	reinforcement	_	
144-3	25799-25803	thus	_	
144-4	25804-25808	acts	_	
144-5	25809-25811	to	_	
144-6	25812-25820	increase	_	
144-7	25821-25825	more	_	
144-8	25826-25836	compulsive	_	
144-9	25837-25849	drug-seeking	_	
144-10	25850-25858	behavior	_	
144-11	25858-25859	,	_	
144-12	25860-25872	particularly	_	
144-13	25873-25879	during	_	
144-14	25880-25883	the	_	
144-15	25884-25894	withdrawal	_	
144-16	25894-25895	/	_	
144-17	25895-25903	negative	_	
144-18	25904-25910	affect	_	
144-19	25911-25916	stage	_	
144-20	25917-25919	of	_	
144-21	25920-25923	the	_	
144-22	25924-25933	addiction	_	
144-23	25934-25939	cycle	_	
144-24	25939-25940	.	_	

#Text=Similarities between the effects of childhood maltreatment, one form of early adversity, and impairments in emotion regulation systems underlying vulnerability to substance use disorders have been identified, but are poorly understood.
145-1	25941-25953	Similarities	_	
145-2	25954-25961	between	_	
145-3	25962-25965	the	_	
145-4	25966-25973	effects	_	
145-5	25974-25976	of	_	
145-6	25977-25986	childhood	_	
145-7	25987-25999	maltreatment	_	
145-8	25999-26000	,	_	
145-9	26001-26004	one	_	
145-10	26005-26009	form	_	
145-11	26010-26012	of	_	
145-12	26013-26018	early	_	
145-13	26019-26028	adversity	_	
145-14	26028-26029	,	_	
145-15	26030-26033	and	_	
145-16	26034-26045	impairments	_	
145-17	26046-26048	in	_	
145-18	26049-26056	emotion	_	
145-19	26057-26067	regulation	_	
145-20	26068-26075	systems	_	
145-21	26076-26086	underlying	_	
145-22	26087-26100	vulnerability	_	
145-23	26101-26103	to	_	
145-24	26104-26113	substance	_	
145-25	26114-26117	use	_	
145-26	26118-26127	disorders	_	
145-27	26128-26132	have	_	
145-28	26133-26137	been	_	
145-29	26138-26148	identified	_	
145-30	26148-26149	,	_	
145-31	26150-26153	but	_	
145-32	26154-26157	are	_	
145-33	26158-26164	poorly	_	
145-34	26165-26175	understood	_	
145-35	26175-26176	.	_	

#Text=In maltreated adolescents, increased activation in prefrontal regions has been found during effortful control of emotion regulation.
146-1	26177-26179	In	_	
146-2	26180-26190	maltreated	_	
146-3	26191-26202	adolescents	_	
146-4	26202-26203	,	_	
146-5	26204-26213	increased	_	
146-6	26214-26224	activation	_	
146-7	26225-26227	in	_	
146-8	26228-26238	prefrontal	_	
146-9	26239-26246	regions	_	
146-10	26247-26250	has	_	
146-11	26251-26255	been	_	
146-12	26256-26261	found	_	
146-13	26262-26268	during	_	
146-14	26269-26278	effortful	_	
146-15	26279-26286	control	_	
146-16	26287-26289	of	_	
146-17	26290-26297	emotion	_	
146-18	26298-26308	regulation	_	
146-19	26308-26309	.	_	

#Text=However, surprisingly few fMRI studies have investigated brain response to emotional stimuli in substance-dependent groups abused in childhood.
147-1	26310-26317	However	_	
147-2	26317-26318	,	_	
147-3	26319-26331	surprisingly	_	
147-4	26332-26335	few	_	
147-5	26336-26340	fMRI	_	
147-6	26341-26348	studies	_	
147-7	26349-26353	have	_	
147-8	26354-26366	investigated	_	
147-9	26367-26372	brain	_	
147-10	26373-26381	response	_	
147-11	26382-26384	to	_	
147-12	26385-26394	emotional	_	
147-13	26395-26402	stimuli	_	
147-14	26403-26405	in	_	
147-15	26406-26425	substance-dependent	_	
147-16	26426-26432	groups	_	
147-17	26433-26439	abused	_	
147-18	26440-26442	in	_	
147-19	26443-26452	childhood	_	
147-20	26452-26453	.	_	

#Text=It has been shown that functional alterations in mPFC activity are associated with greater maltreatment severity in response to drug- and stress-related cues in individuals with cocaine dependence.
148-1	26454-26456	It	_	
148-2	26457-26460	has	_	
148-3	26461-26465	been	_	
148-4	26466-26471	shown	_	
148-5	26472-26476	that	_	
148-6	26477-26487	functional	_	
148-7	26488-26499	alterations	_	
148-8	26500-26502	in	_	
148-9	26503-26507	mPFC	_	
148-10	26508-26516	activity	_	
148-11	26517-26520	are	_	
148-12	26521-26531	associated	_	
148-13	26532-26536	with	_	
148-14	26537-26544	greater	_	
148-15	26545-26557	maltreatment	_	
148-16	26558-26566	severity	_	
148-17	26567-26569	in	_	
148-18	26570-26578	response	_	
148-19	26579-26581	to	_	
148-20	26582-26586	drug	_	
148-21	26586-26587	-	_	
148-22	26588-26591	and	_	
148-23	26592-26606	stress-related	_	
148-24	26607-26611	cues	_	
148-25	26612-26614	in	_	
148-26	26615-26626	individuals	_	
148-27	26627-26631	with	_	
148-28	26632-26639	cocaine	_	
148-29	26640-26650	dependence	_	
148-30	26650-26651	.	_	

#Text=Heighted mesolimbic response has also been found in response to drug-related and evocative cues in cocaine-dependent individuals reporting a history of emotional, physical and sexual abuse.
149-1	26652-26660	Heighted	_	
149-2	26661-26671	mesolimbic	_	
149-3	26672-26680	response	_	
149-4	26681-26684	has	_	
149-5	26685-26689	also	_	
149-6	26690-26694	been	_	
149-7	26695-26700	found	_	
149-8	26701-26703	in	_	
149-9	26704-26712	response	_	
149-10	26713-26715	to	_	
149-11	26716-26728	drug-related	_	
149-12	26729-26732	and	_	
149-13	26733-26742	evocative	_	
149-14	26743-26747	cues	_	
149-15	26748-26750	in	_	
149-16	26751-26768	cocaine-dependent	_	
149-17	26769-26780	individuals	_	
149-18	26781-26790	reporting	_	
149-19	26791-26792	a	_	
149-20	26793-26800	history	_	
149-21	26801-26803	of	_	
149-22	26804-26813	emotional	_	
149-23	26813-26814	,	_	
149-24	26815-26823	physical	_	
149-25	26824-26827	and	_	
149-26	26828-26834	sexual	_	
149-27	26835-26840	abuse	_	
149-28	26840-26841	.	_	

#Text=Consistent with preclinical evidence demonstrating that the therapeutic efficacy of naltrexone is associated with early adverse experiences, we found that naltrexone modulated task-related activation in the mPFC, one key region associated with emotion dysregulation in both substance use disorders and adults with histories of childhood adversity, depending on the degree of abuse experienced.
150-1	26842-26852	Consistent	_	
150-2	26853-26857	with	_	
150-3	26858-26869	preclinical	_	
150-4	26870-26878	evidence	_	
150-5	26879-26892	demonstrating	_	
150-6	26893-26897	that	_	
150-7	26898-26901	the	_	
150-8	26902-26913	therapeutic	_	
150-9	26914-26922	efficacy	_	
150-10	26923-26925	of	_	
150-11	26926-26936	naltrexone	_	
150-12	26937-26939	is	_	
150-13	26940-26950	associated	_	
150-14	26951-26955	with	_	
150-15	26956-26961	early	_	
150-16	26962-26969	adverse	_	
150-17	26970-26981	experiences	_	
150-18	26981-26982	,	_	
150-19	26983-26985	we	_	
150-20	26986-26991	found	_	
150-21	26992-26996	that	_	
150-22	26997-27007	naltrexone	_	
150-23	27008-27017	modulated	_	
150-24	27018-27030	task-related	_	
150-25	27031-27041	activation	_	
150-26	27042-27044	in	_	
150-27	27045-27048	the	_	
150-28	27049-27053	mPFC	_	
150-29	27053-27054	,	_	
150-30	27055-27058	one	_	
150-31	27059-27062	key	_	
150-32	27063-27069	region	_	
150-33	27070-27080	associated	_	
150-34	27081-27085	with	_	
150-35	27086-27093	emotion	_	
150-36	27094-27107	dysregulation	_	
150-37	27108-27110	in	_	
150-38	27111-27115	both	_	
150-39	27116-27125	substance	_	
150-40	27126-27129	use	_	
150-41	27130-27139	disorders	_	
150-42	27140-27143	and	_	
150-43	27144-27150	adults	_	
150-44	27151-27155	with	_	
150-45	27156-27165	histories	_	
150-46	27166-27168	of	_	
150-47	27169-27178	childhood	_	
150-48	27179-27188	adversity	_	
150-49	27188-27189	,	_	
150-50	27190-27199	depending	_	
150-51	27200-27202	on	_	
150-52	27203-27206	the	_	
150-53	27207-27213	degree	_	
150-54	27214-27216	of	_	
150-55	27217-27222	abuse	_	
150-56	27223-27234	experienced	_	
150-57	27234-27235	.	_	

#Text=Naltrexone also modulated ACC–hippocampal connectivity, two regions integral to mood regulation, depending on childhood adversity.
151-1	27236-27246	Naltrexone	_	
151-2	27247-27251	also	_	
151-3	27252-27261	modulated	_	
151-4	27262-27277	ACC–hippocampal	_	
151-5	27278-27290	connectivity	_	
151-6	27290-27291	,	_	
151-7	27292-27295	two	_	
151-8	27296-27303	regions	_	
151-9	27304-27312	integral	_	
151-10	27313-27315	to	_	
151-11	27316-27320	mood	_	
151-12	27321-27331	regulation	_	
151-13	27331-27332	,	_	
151-14	27333-27342	depending	_	
151-15	27343-27345	on	_	
151-16	27346-27355	childhood	_	
151-17	27356-27365	adversity	_	
151-18	27365-27366	.	_	

#Text=In fMRI studies, hippocampal activation and network connectivity has been shown to predict cocaine relapse.
152-1	27367-27369	In	_	
152-2	27370-27374	fMRI	_	
152-3	27375-27382	studies	_	
152-4	27382-27383	,	_	
152-5	27384-27395	hippocampal	_	
152-6	27396-27406	activation	_	
152-7	27407-27410	and	_	
152-8	27411-27418	network	_	
152-9	27419-27431	connectivity	_	
152-10	27432-27435	has	_	
152-11	27436-27440	been	_	
152-12	27441-27446	shown	_	
152-13	27447-27449	to	_	
152-14	27450-27457	predict	_	
152-15	27458-27465	cocaine	_	
152-16	27466-27473	relapse	_	
152-17	27473-27474	.	_	

#Text=Limbic connectivity between the hippocampus and the amygdala is also associated with reduced adaptive emotional processing in maltreated individuals with methamphetamine dependence.
153-1	27475-27481	Limbic	_	
153-2	27482-27494	connectivity	_	
153-3	27495-27502	between	_	
153-4	27503-27506	the	_	
153-5	27507-27518	hippocampus	_	
153-6	27519-27522	and	_	
153-7	27523-27526	the	_	
153-8	27527-27535	amygdala	_	
153-9	27536-27538	is	_	
153-10	27539-27543	also	_	
153-11	27544-27554	associated	_	
153-12	27555-27559	with	_	
153-13	27560-27567	reduced	_	
153-14	27568-27576	adaptive	_	
153-15	27577-27586	emotional	_	
153-16	27587-27597	processing	_	
153-17	27598-27600	in	_	
153-18	27601-27611	maltreated	_	
153-19	27612-27623	individuals	_	
153-20	27624-27628	with	_	
153-21	27629-27644	methamphetamine	_	
153-22	27645-27655	dependence	_	
153-23	27655-27656	.	_	

#Text=Interplay between the ACC and the hippocampus has been implicated in the reconsolidation and expression of fear memories, with alterations in ACC–hippocampal connectivity found in patients with posttraumatic stress disorder.
154-1	27657-27666	Interplay	_	
154-2	27667-27674	between	_	
154-3	27675-27678	the	_	
154-4	27679-27682	ACC	_	
154-5	27683-27686	and	_	
154-6	27687-27690	the	_	
154-7	27691-27702	hippocampus	_	
154-8	27703-27706	has	_	
154-9	27707-27711	been	_	
154-10	27712-27722	implicated	_	
154-11	27723-27725	in	_	
154-12	27726-27729	the	_	
154-13	27730-27745	reconsolidation	_	
154-14	27746-27749	and	_	
154-15	27750-27760	expression	_	
154-16	27761-27763	of	_	
154-17	27764-27768	fear	_	
154-18	27769-27777	memories	_	
154-19	27777-27778	,	_	
154-20	27779-27783	with	_	
154-21	27784-27795	alterations	_	
154-22	27796-27798	in	_	
154-23	27799-27814	ACC–hippocampal	_	
154-24	27815-27827	connectivity	_	
154-25	27828-27833	found	_	
154-26	27834-27836	in	_	
154-27	27837-27845	patients	_	
154-28	27846-27850	with	_	
154-29	27851-27864	posttraumatic	_	
154-30	27865-27871	stress	_	
154-31	27872-27880	disorder	_	
154-32	27880-27881	.	_	

#Text=These findings, together with our data, suggests that opioid receptors in the ACC and the hippocampus are important pharmacological targets in individuals with a history of abuse, which, although not specific to our substance-dependent groups, may be of relevance to other disorders characterized by childhood adversity, such as trauma-related or psychotic disorders.
155-1	27882-27887	These	_	
155-2	27888-27896	findings	_	
155-3	27896-27897	,	_	
155-4	27898-27906	together	_	
155-5	27907-27911	with	_	
155-6	27912-27915	our	_	
155-7	27916-27920	data	_	
155-8	27920-27921	,	_	
155-9	27922-27930	suggests	_	
155-10	27931-27935	that	_	
155-11	27936-27942	opioid	_	
155-12	27943-27952	receptors	_	
155-13	27953-27955	in	_	
155-14	27956-27959	the	_	
155-15	27960-27963	ACC	_	
155-16	27964-27967	and	_	
155-17	27968-27971	the	_	
155-18	27972-27983	hippocampus	_	
155-19	27984-27987	are	_	
155-20	27988-27997	important	_	
155-21	27998-28013	pharmacological	_	
155-22	28014-28021	targets	_	
155-23	28022-28024	in	_	
155-24	28025-28036	individuals	_	
155-25	28037-28041	with	_	
155-26	28042-28043	a	_	
155-27	28044-28051	history	_	
155-28	28052-28054	of	_	
155-29	28055-28060	abuse	_	
155-30	28060-28061	,	_	
155-31	28062-28067	which	_	
155-32	28067-28068	,	_	
155-33	28069-28077	although	_	
155-34	28078-28081	not	_	
155-35	28082-28090	specific	_	
155-36	28091-28093	to	_	
155-37	28094-28097	our	_	
155-38	28098-28117	substance-dependent	_	
155-39	28118-28124	groups	_	
155-40	28124-28125	,	_	
155-41	28126-28129	may	_	
155-42	28130-28132	be	_	
155-43	28133-28135	of	_	
155-44	28136-28145	relevance	_	
155-45	28146-28148	to	_	
155-46	28149-28154	other	_	
155-47	28155-28164	disorders	_	
155-48	28165-28178	characterized	_	
155-49	28179-28181	by	_	
155-50	28182-28191	childhood	_	
155-51	28192-28201	adversity	_	
155-52	28201-28202	,	_	
155-53	28203-28207	such	_	
155-54	28208-28210	as	_	
155-55	28211-28225	trauma-related	_	
155-56	28226-28228	or	_	
155-57	28229-28238	psychotic	_	
155-58	28239-28248	disorders	_	
155-59	28248-28249	.	_	

#Text=The neurobiological effects of childhood adversity on emotional processing are under-investigated in addiction.
156-1	28250-28253	The	_	
156-2	28254-28269	neurobiological	_	
156-3	28270-28277	effects	_	
156-4	28278-28280	of	_	
156-5	28281-28290	childhood	_	
156-6	28291-28300	adversity	_	
156-7	28301-28303	on	_	
156-8	28304-28313	emotional	_	
156-9	28314-28324	processing	_	
156-10	28325-28328	are	_	
156-11	28329-28347	under-investigated	_	
156-12	28348-28350	in	_	
156-13	28351-28360	addiction	_	
156-14	28360-28361	.	_	

#Text=Our data confirm that environmental factors, specifically early adverse experiences, influence variations in naltrexone response.
157-1	28362-28365	Our	_	
157-2	28366-28370	data	_	
157-3	28371-28378	confirm	_	
157-4	28379-28383	that	_	
157-5	28384-28397	environmental	_	
157-6	28398-28405	factors	_	
157-7	28405-28406	,	_	
157-8	28407-28419	specifically	_	
157-9	28420-28425	early	_	
157-10	28426-28433	adverse	_	
157-11	28434-28445	experiences	_	
157-12	28445-28446	,	_	
157-13	28447-28456	influence	_	
157-14	28457-28467	variations	_	
157-15	28468-28470	in	_	
157-16	28471-28481	naltrexone	_	
157-17	28482-28490	response	_	
157-18	28490-28491	.	_	

#Text=It is possible that differences in childhood adversity might account for some of the variability in outcome in alcohol-dependent patients treated with naltrexone.
158-1	28492-28494	It	_	
158-2	28495-28497	is	_	
158-3	28498-28506	possible	_	
158-4	28507-28511	that	_	
158-5	28512-28523	differences	_	
158-6	28524-28526	in	_	
158-7	28527-28536	childhood	_	
158-8	28537-28546	adversity	_	
158-9	28547-28552	might	_	
158-10	28553-28560	account	_	
158-11	28561-28564	for	_	
158-12	28565-28569	some	_	
158-13	28570-28572	of	_	
158-14	28573-28576	the	_	
158-15	28577-28588	variability	_	
158-16	28589-28591	in	_	
158-17	28592-28599	outcome	_	
158-18	28600-28602	in	_	
158-19	28603-28620	alcohol-dependent	_	
158-20	28621-28629	patients	_	
158-21	28630-28637	treated	_	
158-22	28638-28642	with	_	
158-23	28643-28653	naltrexone	_	
158-24	28653-28654	.	_	

#Text=Early life experiences have been shown to affect the endogenous opioid system in preclinical models, and the present data offer convergent evidence that the effects of childhood adversity on endogenous opioids are an important indicator of responsiveness to pharmacological treatments acting on MOR transmission in humans.
159-1	28655-28660	Early	_	
159-2	28661-28665	life	_	
159-3	28666-28677	experiences	_	
159-4	28678-28682	have	_	
159-5	28683-28687	been	_	
159-6	28688-28693	shown	_	
159-7	28694-28696	to	_	
159-8	28697-28703	affect	_	
159-9	28704-28707	the	_	
159-10	28708-28718	endogenous	_	
159-11	28719-28725	opioid	_	
159-12	28726-28732	system	_	
159-13	28733-28735	in	_	
159-14	28736-28747	preclinical	_	
159-15	28748-28754	models	_	
159-16	28754-28755	,	_	
159-17	28756-28759	and	_	
159-18	28760-28763	the	_	
159-19	28764-28771	present	_	
159-20	28772-28776	data	_	
159-21	28777-28782	offer	_	
159-22	28783-28793	convergent	_	
159-23	28794-28802	evidence	_	
159-24	28803-28807	that	_	
159-25	28808-28811	the	_	
159-26	28812-28819	effects	_	
159-27	28820-28822	of	_	
159-28	28823-28832	childhood	_	
159-29	28833-28842	adversity	_	
159-30	28843-28845	on	_	
159-31	28846-28856	endogenous	_	
159-32	28857-28864	opioids	_	
159-33	28865-28868	are	_	
159-34	28869-28871	an	_	
159-35	28872-28881	important	_	
159-36	28882-28891	indicator	_	
159-37	28892-28894	of	_	
159-38	28895-28909	responsiveness	_	
159-39	28910-28912	to	_	
159-40	28913-28928	pharmacological	_	
159-41	28929-28939	treatments	_	
159-42	28940-28946	acting	_	
159-43	28947-28949	on	_	
159-44	28950-28953	MOR	_	
159-45	28954-28966	transmission	_	
159-46	28967-28969	in	_	
159-47	28970-28976	humans	_	
159-48	28976-28977	.	_	

#Text=We suggest that behavioral interventions that promote emotion regulation strategies for traumatic experiences or pharmacological interventions that normalize cortical–limbic connectivity may be effective in groups with high levels of childhood adversity.
160-1	28978-28980	We	_	
160-2	28981-28988	suggest	_	
160-3	28989-28993	that	_	
160-4	28994-29004	behavioral	_	
160-5	29005-29018	interventions	_	
160-6	29019-29023	that	_	
160-7	29024-29031	promote	_	
160-8	29032-29039	emotion	_	
160-9	29040-29050	regulation	_	
160-10	29051-29061	strategies	_	
160-11	29062-29065	for	_	
160-12	29066-29075	traumatic	_	
160-13	29076-29087	experiences	_	
160-14	29088-29090	or	_	
160-15	29091-29106	pharmacological	_	
160-16	29107-29120	interventions	_	
160-17	29121-29125	that	_	
160-18	29126-29135	normalize	_	
160-19	29136-29151	cortical–limbic	_	
160-20	29152-29164	connectivity	_	
160-21	29165-29168	may	_	
160-22	29169-29171	be	_	
160-23	29172-29181	effective	_	
160-24	29182-29184	in	_	
160-25	29185-29191	groups	_	
160-26	29192-29196	with	_	
160-27	29197-29201	high	_	
160-28	29202-29208	levels	_	
160-29	29209-29211	of	_	
160-30	29212-29221	childhood	_	
160-31	29222-29231	adversity	_	
160-32	29231-29232	.	_	

#Text=Effects of MOR blockade on different types of substance dependence
#Text=Previous fMRI studies have shown altered limbic activation in response to naturally evocative, negative emotional and substance-related stimuli in substance-dependent groups.
161-1	29233-29240	Effects	_	
161-2	29241-29243	of	_	
161-3	29244-29247	MOR	_	
161-4	29248-29256	blockade	_	
161-5	29257-29259	on	_	
161-6	29260-29269	different	_	
161-7	29270-29275	types	_	
161-8	29276-29278	of	_	
161-9	29279-29288	substance	_	
161-10	29289-29299	dependence	_	
161-11	29300-29308	Previous	_	
161-12	29309-29313	fMRI	_	
161-13	29314-29321	studies	_	
161-14	29322-29326	have	_	
161-15	29327-29332	shown	_	
161-16	29333-29340	altered	_	
161-17	29341-29347	limbic	_	
161-18	29348-29358	activation	_	
161-19	29359-29361	in	_	
161-20	29362-29370	response	_	
161-21	29371-29373	to	_	
161-22	29374-29383	naturally	_	
161-23	29384-29393	evocative	_	
161-24	29393-29394	,	_	
161-25	29395-29403	negative	_	
161-26	29404-29413	emotional	_	
161-27	29414-29417	and	_	
161-28	29418-29435	substance-related	_	
161-29	29436-29443	stimuli	_	
161-30	29444-29446	in	_	
161-31	29447-29466	substance-dependent	_	
161-32	29467-29473	groups	_	
161-33	29473-29474	.	_	

#Text=We observed greater task-related activation in the right amygdala during the processing of aversive relative to neutral images under placebo in individuals recovering from alcohol dependence.
162-1	29475-29477	We	_	
162-2	29478-29486	observed	_	
162-3	29487-29494	greater	_	
162-4	29495-29507	task-related	_	
162-5	29508-29518	activation	_	
162-6	29519-29521	in	_	
162-7	29522-29525	the	_	
162-8	29526-29531	right	_	
162-9	29532-29540	amygdala	_	
162-10	29541-29547	during	_	
162-11	29548-29551	the	_	
162-12	29552-29562	processing	_	
162-13	29563-29565	of	_	
162-14	29566-29574	aversive	_	
162-15	29575-29583	relative	_	
162-16	29584-29586	to	_	
162-17	29587-29594	neutral	_	
162-18	29595-29601	images	_	
162-19	29602-29607	under	_	
162-20	29608-29615	placebo	_	
162-21	29616-29618	in	_	
162-22	29619-29630	individuals	_	
162-23	29631-29641	recovering	_	
162-24	29642-29646	from	_	
162-25	29647-29654	alcohol	_	
162-26	29655-29665	dependence	_	
162-27	29665-29666	.	_	

#Text=Heightened reactivity in this region is consistent with previous investigations measuring brain response to negative IAPS images in individuals with alcohol dependence.
163-1	29667-29677	Heightened	_	
163-2	29678-29688	reactivity	_	
163-3	29689-29691	in	_	
163-4	29692-29696	this	_	
163-5	29697-29703	region	_	
163-6	29704-29706	is	_	
163-7	29707-29717	consistent	_	
163-8	29718-29722	with	_	
163-9	29723-29731	previous	_	
163-10	29732-29746	investigations	_	
163-11	29747-29756	measuring	_	
163-12	29757-29762	brain	_	
163-13	29763-29771	response	_	
163-14	29772-29774	to	_	
163-15	29775-29783	negative	_	
163-16	29784-29788	IAPS	_	
163-17	29789-29795	images	_	
163-18	29796-29798	in	_	
163-19	29799-29810	individuals	_	
163-20	29811-29815	with	_	
163-21	29816-29823	alcohol	_	
163-22	29824-29834	dependence	_	
163-23	29834-29835	.	_	

#Text=Similar to our alcohol group, participants from the above studies were characterized by only one drug dependency.
164-1	29836-29843	Similar	_	
164-2	29844-29846	to	_	
164-3	29847-29850	our	_	
164-4	29851-29858	alcohol	_	
164-5	29859-29864	group	_	
164-6	29864-29865	,	_	
164-7	29866-29878	participants	_	
164-8	29879-29883	from	_	
164-9	29884-29887	the	_	
164-10	29888-29893	above	_	
164-11	29894-29901	studies	_	
164-12	29902-29906	were	_	
164-13	29907-29920	characterized	_	
164-14	29921-29923	by	_	
164-15	29924-29928	only	_	
164-16	29929-29932	one	_	
164-17	29933-29937	drug	_	
164-18	29938-29948	dependency	_	
164-19	29948-29949	.	_	

#Text=The lack of discriminatory response between aversive and neutral images was specific to our alcohol/drugs group, possibly reflecting an emotional desensitization following prior exposure to adverse events, an attentional disengagement to aversive images (although we consider this unlikely as our task does not tap into attentional resources) or altered MOR availability/density associated with abstinence from repeated drug exposure (for example, cocaine; opiates; alcohol) and/or individual differences in environment factors.
165-1	29950-29953	The	_	
165-2	29954-29958	lack	_	
165-3	29959-29961	of	_	
165-4	29962-29976	discriminatory	_	
165-5	29977-29985	response	_	
165-6	29986-29993	between	_	
165-7	29994-30002	aversive	_	
165-8	30003-30006	and	_	
165-9	30007-30014	neutral	_	
165-10	30015-30021	images	_	
165-11	30022-30025	was	_	
165-12	30026-30034	specific	_	
165-13	30035-30037	to	_	
165-14	30038-30041	our	_	
165-15	30042-30049	alcohol	_	
165-16	30049-30050	/	_	
165-17	30050-30055	drugs	_	
165-18	30056-30061	group	_	
165-19	30061-30062	,	_	
165-20	30063-30071	possibly	_	
165-21	30072-30082	reflecting	_	
165-22	30083-30085	an	_	
165-23	30086-30095	emotional	_	
165-24	30096-30111	desensitization	_	
165-25	30112-30121	following	_	
165-26	30122-30127	prior	_	
165-27	30128-30136	exposure	_	
165-28	30137-30139	to	_	
165-29	30140-30147	adverse	_	
165-30	30148-30154	events	_	
165-31	30154-30155	,	_	
165-32	30156-30158	an	_	
165-33	30159-30170	attentional	_	
165-34	30171-30184	disengagement	_	
165-35	30185-30187	to	_	
165-36	30188-30196	aversive	_	
165-37	30197-30203	images	_	
165-38	30204-30205	(	_	
165-39	30205-30213	although	_	
165-40	30214-30216	we	_	
165-41	30217-30225	consider	_	
165-42	30226-30230	this	_	
165-43	30231-30239	unlikely	_	
165-44	30240-30242	as	_	
165-45	30243-30246	our	_	
165-46	30247-30251	task	_	
165-47	30252-30256	does	_	
165-48	30257-30260	not	_	
165-49	30261-30264	tap	_	
165-50	30265-30269	into	_	
165-51	30270-30281	attentional	_	
165-52	30282-30291	resources	_	
165-53	30291-30292	)	_	
165-54	30293-30295	or	_	
165-55	30296-30303	altered	_	
165-56	30304-30307	MOR	_	
165-57	30308-30320	availability	_	
165-58	30320-30321	/	_	
165-59	30321-30328	density	_	
165-60	30329-30339	associated	_	
165-61	30340-30344	with	_	
165-62	30345-30355	abstinence	_	
165-63	30356-30360	from	_	
165-64	30361-30369	repeated	_	
165-65	30370-30374	drug	_	
165-66	30375-30383	exposure	_	
165-67	30384-30385	(	_	
165-68	30385-30388	for	_	
165-69	30389-30396	example	_	
165-70	30396-30397	,	_	
165-71	30398-30405	cocaine	_	
165-72	30405-30406	;	_	
165-73	30407-30414	opiates	_	
165-74	30414-30415	;	_	
165-75	30416-30423	alcohol	_	
165-76	30423-30424	)	_	
165-77	30425-30428	and	_	
165-78	30428-30429	/	_	
165-79	30429-30431	or	_	
165-80	30432-30442	individual	_	
165-81	30443-30454	differences	_	
165-82	30455-30457	in	_	
165-83	30458-30469	environment	_	
165-84	30470-30477	factors	_	
165-85	30477-30478	.	_	

#Text=Although speculative for the present study, these possibilities each deserve more detailed investigation in substance-dependent groups, including use of positron emission tomography to elucidate whether associations between MOR binding potential and limbic activation differ during negative emotional processing between alcohol-dependent patients with and without combined drug dependence.
166-1	30479-30487	Although	_	
166-2	30488-30499	speculative	_	
166-3	30500-30503	for	_	
166-4	30504-30507	the	_	
166-5	30508-30515	present	_	
166-6	30516-30521	study	_	
166-7	30521-30522	,	_	
166-8	30523-30528	these	_	
166-9	30529-30542	possibilities	_	
166-10	30543-30547	each	_	
166-11	30548-30555	deserve	_	
166-12	30556-30560	more	_	
166-13	30561-30569	detailed	_	
166-14	30570-30583	investigation	_	
166-15	30584-30586	in	_	
166-16	30587-30606	substance-dependent	_	
166-17	30607-30613	groups	_	
166-18	30613-30614	,	_	
166-19	30615-30624	including	_	
166-20	30625-30628	use	_	
166-21	30629-30631	of	_	
166-22	30632-30640	positron	_	
166-23	30641-30649	emission	_	
166-24	30650-30660	tomography	_	
166-25	30661-30663	to	_	
166-26	30664-30673	elucidate	_	
166-27	30674-30681	whether	_	
166-28	30682-30694	associations	_	
166-29	30695-30702	between	_	
166-30	30703-30706	MOR	_	
166-31	30707-30714	binding	_	
166-32	30715-30724	potential	_	
166-33	30725-30728	and	_	
166-34	30729-30735	limbic	_	
166-35	30736-30746	activation	_	
166-36	30747-30753	differ	_	
166-37	30754-30760	during	_	
166-38	30761-30769	negative	_	
166-39	30770-30779	emotional	_	
166-40	30780-30790	processing	_	
166-41	30791-30798	between	_	
166-42	30799-30816	alcohol-dependent	_	
166-43	30817-30825	patients	_	
166-44	30826-30830	with	_	
166-45	30831-30834	and	_	
166-46	30835-30842	without	_	
166-47	30843-30851	combined	_	
166-48	30852-30856	drug	_	
166-49	30857-30867	dependence	_	
166-50	30867-30868	.	_	

#Text=Our data further showed that naltrexone normalized the pattern of activation in the amygdala for aversive relative to neutral images in our alcohol/drugs group (that is, there was only an effect of treatment at the group level when interacting with the content of the images presented).
167-1	30869-30872	Our	_	
167-2	30873-30877	data	_	
167-3	30878-30885	further	_	
167-4	30886-30892	showed	_	
167-5	30893-30897	that	_	
167-6	30898-30908	naltrexone	_	
167-7	30909-30919	normalized	_	
167-8	30920-30923	the	_	
167-9	30924-30931	pattern	_	
167-10	30932-30934	of	_	
167-11	30935-30945	activation	_	
167-12	30946-30948	in	_	
167-13	30949-30952	the	_	
167-14	30953-30961	amygdala	_	
167-15	30962-30965	for	_	
167-16	30966-30974	aversive	_	
167-17	30975-30983	relative	_	
167-18	30984-30986	to	_	
167-19	30987-30994	neutral	_	
167-20	30995-31001	images	_	
167-21	31002-31004	in	_	
167-22	31005-31008	our	_	
167-23	31009-31016	alcohol	_	
167-24	31016-31017	/	_	
167-25	31017-31022	drugs	_	
167-26	31023-31028	group	_	
167-27	31029-31030	(	_	
167-28	31030-31034	that	_	
167-29	31035-31037	is	_	
167-30	31037-31038	,	_	
167-31	31039-31044	there	_	
167-32	31045-31048	was	_	
167-33	31049-31053	only	_	
167-34	31054-31056	an	_	
167-35	31057-31063	effect	_	
167-36	31064-31066	of	_	
167-37	31067-31076	treatment	_	
167-38	31077-31079	at	_	
167-39	31080-31083	the	_	
167-40	31084-31089	group	_	
167-41	31090-31095	level	_	
167-42	31096-31100	when	_	
167-43	31101-31112	interacting	_	
167-44	31113-31117	with	_	
167-45	31118-31121	the	_	
167-46	31122-31129	content	_	
167-47	31130-31132	of	_	
167-48	31133-31136	the	_	
167-49	31137-31143	images	_	
167-50	31144-31153	presented	_	
167-51	31153-31154	)	_	
167-52	31154-31155	.	_	

#Text=These data demonstrate that naltrexone-induced functional alterations during negative emotional processing are specific to groups characterized by distinct patterns of drug dependencies that can persist in prolonged abstinence.
168-1	31156-31161	These	_	
168-2	31162-31166	data	_	
168-3	31167-31178	demonstrate	_	
168-4	31179-31183	that	_	
168-5	31184-31202	naltrexone-induced	_	
168-6	31203-31213	functional	_	
168-7	31214-31225	alterations	_	
168-8	31226-31232	during	_	
168-9	31233-31241	negative	_	
168-10	31242-31251	emotional	_	
168-11	31252-31262	processing	_	
168-12	31263-31266	are	_	
168-13	31267-31275	specific	_	
168-14	31276-31278	to	_	
168-15	31279-31285	groups	_	
168-16	31286-31299	characterized	_	
168-17	31300-31302	by	_	
168-18	31303-31311	distinct	_	
168-19	31312-31320	patterns	_	
168-20	31321-31323	of	_	
168-21	31324-31328	drug	_	
168-22	31329-31341	dependencies	_	
168-23	31342-31346	that	_	
168-24	31347-31350	can	_	
168-25	31351-31358	persist	_	
168-26	31359-31361	in	_	
168-27	31362-31371	prolonged	_	
168-28	31372-31382	abstinence	_	
168-29	31382-31383	.	_	

#Text=Activation of stress-induced neurocircuitry contributes to the ‘dark side' view of addiction, in which recruitment of brain ‘anti-reward' systems (for example, within motivational circuits of the extended amygdala), an opponent process to hyperactivation of the brain reward system, provides strong motivation for negatively reinforced drug seeking.
169-1	31384-31394	Activation	_	
169-2	31395-31397	of	_	
169-3	31398-31412	stress-induced	_	
169-4	31413-31427	neurocircuitry	_	
169-5	31428-31439	contributes	_	
169-6	31440-31442	to	_	
169-7	31443-31446	the	_	
169-8	31447-31448	‘	_	
169-9	31448-31452	dark	_	
169-10	31453-31457	side	_	
169-11	31457-31458	'	_	
169-12	31459-31463	view	_	
169-13	31464-31466	of	_	
169-14	31467-31476	addiction	_	
169-15	31476-31477	,	_	
169-16	31478-31480	in	_	
169-17	31481-31486	which	_	
169-18	31487-31498	recruitment	_	
169-19	31499-31501	of	_	
169-20	31502-31507	brain	_	
169-21	31508-31509	‘	_	
169-22	31509-31520	anti-reward	_	
169-23	31520-31521	'	_	
169-24	31522-31529	systems	_	
169-25	31530-31531	(	_	
169-26	31531-31534	for	_	
169-27	31535-31542	example	_	
169-28	31542-31543	,	_	
169-29	31544-31550	within	_	
169-30	31551-31563	motivational	_	
169-31	31564-31572	circuits	_	
169-32	31573-31575	of	_	
169-33	31576-31579	the	_	
169-34	31580-31588	extended	_	
169-35	31589-31597	amygdala	_	
169-36	31597-31598	)	_	
169-37	31598-31599	,	_	
169-38	31600-31602	an	_	
169-39	31603-31611	opponent	_	
169-40	31612-31619	process	_	
169-41	31620-31622	to	_	
169-42	31623-31638	hyperactivation	_	
169-43	31639-31641	of	_	
169-44	31642-31645	the	_	
169-45	31646-31651	brain	_	
169-46	31652-31658	reward	_	
169-47	31659-31665	system	_	
169-48	31665-31666	,	_	
169-49	31667-31675	provides	_	
169-50	31676-31682	strong	_	
169-51	31683-31693	motivation	_	
169-52	31694-31697	for	_	
169-53	31698-31708	negatively	_	
169-54	31709-31719	reinforced	_	
169-55	31720-31724	drug	_	
169-56	31725-31732	seeking	_	
169-57	31732-31733	.	_	

#Text=Increased activation in response to aversive images could also lend vulnerability to craving and relapse via stress-induced reinstatement of emotion-processing circuitry.
170-1	31734-31743	Increased	_	
170-2	31744-31754	activation	_	
170-3	31755-31757	in	_	
170-4	31758-31766	response	_	
170-5	31767-31769	to	_	
170-6	31770-31778	aversive	_	
170-7	31779-31785	images	_	
170-8	31786-31791	could	_	
170-9	31792-31796	also	_	
170-10	31797-31801	lend	_	
170-11	31802-31815	vulnerability	_	
170-12	31816-31818	to	_	
170-13	31819-31826	craving	_	
170-14	31827-31830	and	_	
170-15	31831-31838	relapse	_	
170-16	31839-31842	via	_	
170-17	31843-31857	stress-induced	_	
170-18	31858-31871	reinstatement	_	
170-19	31872-31874	of	_	
170-20	31875-31893	emotion-processing	_	
170-21	31894-31903	circuitry	_	
170-22	31903-31904	.	_	

#Text=However, a relative normalization of response by naltrexone in our alcohol/drugs group is likely due to a kappa-antagonist effect being more potent in individuals with increased dynorphin-dependent KOR activation.
171-1	31905-31912	However	_	
171-2	31912-31913	,	_	
171-3	31914-31915	a	_	
171-4	31916-31924	relative	_	
171-5	31925-31938	normalization	_	
171-6	31939-31941	of	_	
171-7	31942-31950	response	_	
171-8	31951-31953	by	_	
171-9	31954-31964	naltrexone	_	
171-10	31965-31967	in	_	
171-11	31968-31971	our	_	
171-12	31972-31979	alcohol	_	
171-13	31979-31980	/	_	
171-14	31980-31985	drugs	_	
171-15	31986-31991	group	_	
171-16	31992-31994	is	_	
171-17	31995-32001	likely	_	
171-18	32002-32005	due	_	
171-19	32006-32008	to	_	
171-20	32009-32010	a	_	
171-21	32011-32027	kappa-antagonist	_	
171-22	32028-32034	effect	_	
171-23	32035-32040	being	_	
171-24	32041-32045	more	_	
171-25	32046-32052	potent	_	
171-26	32053-32055	in	_	
171-27	32056-32067	individuals	_	
171-28	32068-32072	with	_	
171-29	32073-32082	increased	_	
171-30	32083-32102	dynorphin-dependent	_	
171-31	32103-32106	KOR	_	
171-32	32107-32117	activation	_	
171-33	32117-32118	.	_	

#Text=The latter is associated with negative emotional states, higher sensitivity to stress and/or more severe psychopathology as a consequence of combined drug taking.
172-1	32119-32122	The	_	
172-2	32123-32129	latter	_	
172-3	32130-32132	is	_	
172-4	32133-32143	associated	_	
172-5	32144-32148	with	_	
172-6	32149-32157	negative	_	
172-7	32158-32167	emotional	_	
172-8	32168-32174	states	_	
172-9	32174-32175	,	_	
172-10	32176-32182	higher	_	
172-11	32183-32194	sensitivity	_	
172-12	32195-32197	to	_	
172-13	32198-32204	stress	_	
172-14	32205-32208	and	_	
172-15	32208-32209	/	_	
172-16	32209-32211	or	_	
172-17	32212-32216	more	_	
172-18	32217-32223	severe	_	
172-19	32224-32239	psychopathology	_	
172-20	32240-32242	as	_	
172-21	32243-32244	a	_	
172-22	32245-32256	consequence	_	
172-23	32257-32259	of	_	
172-24	32260-32268	combined	_	
172-25	32269-32273	drug	_	
172-26	32274-32280	taking	_	
172-27	32280-32281	.	_	

#Text=Stress-induced activation of the dynorphin/kappa-opioid system has dysphoric-like effects that are thought to mediate negative emotional states.
173-1	32282-32296	Stress-induced	_	
173-2	32297-32307	activation	_	
173-3	32308-32310	of	_	
173-4	32311-32314	the	_	
173-5	32315-32324	dynorphin	_	
173-6	32324-32325	/	_	
173-7	32325-32337	kappa-opioid	_	
173-8	32338-32344	system	_	
173-9	32345-32348	has	_	
173-10	32349-32363	dysphoric-like	_	
173-11	32364-32371	effects	_	
173-12	32372-32376	that	_	
173-13	32377-32380	are	_	
173-14	32381-32388	thought	_	
173-15	32389-32391	to	_	
173-16	32392-32399	mediate	_	
173-17	32400-32408	negative	_	
173-18	32409-32418	emotional	_	
173-19	32419-32425	states	_	
173-20	32425-32426	.	_	

#Text=However, KOR blockade has shown consistent anxiolytic and antidepressant effects in both humans and animals, including attenuation of a stress response.
174-1	32427-32434	However	_	
174-2	32434-32435	,	_	
174-3	32436-32439	KOR	_	
174-4	32440-32448	blockade	_	
174-5	32449-32452	has	_	
174-6	32453-32458	shown	_	
174-7	32459-32469	consistent	_	
174-8	32470-32480	anxiolytic	_	
174-9	32481-32484	and	_	
174-10	32485-32499	antidepressant	_	
174-11	32500-32507	effects	_	
174-12	32508-32510	in	_	
174-13	32511-32515	both	_	
174-14	32516-32522	humans	_	
174-15	32523-32526	and	_	
174-16	32527-32534	animals	_	
174-17	32534-32535	,	_	
174-18	32536-32545	including	_	
174-19	32546-32557	attenuation	_	
174-20	32558-32560	of	_	
174-21	32561-32562	a	_	
174-22	32563-32569	stress	_	
174-23	32570-32578	response	_	
174-24	32578-32579	.	_	

#Text=Evaluation of the potential therapeutic benefits of selective kappa-opioid antagonism in the treatment of addiction and comorbid stress-related mood disorders thus may form an important area of new research.
175-1	32580-32590	Evaluation	_	
175-2	32591-32593	of	_	
175-3	32594-32597	the	_	
175-4	32598-32607	potential	_	
175-5	32608-32619	therapeutic	_	
175-6	32620-32628	benefits	_	
175-7	32629-32631	of	_	
175-8	32632-32641	selective	_	
175-9	32642-32654	kappa-opioid	_	
175-10	32655-32665	antagonism	_	
175-11	32666-32668	in	_	
175-12	32669-32672	the	_	
175-13	32673-32682	treatment	_	
175-14	32683-32685	of	_	
175-15	32686-32695	addiction	_	
175-16	32696-32699	and	_	
175-17	32700-32708	comorbid	_	
175-18	32709-32723	stress-related	_	
175-19	32724-32728	mood	_	
175-20	32729-32738	disorders	_	
175-21	32739-32743	thus	_	
175-22	32744-32747	may	_	
175-23	32748-32752	form	_	
175-24	32753-32755	an	_	
175-25	32756-32765	important	_	
175-26	32766-32770	area	_	
175-27	32771-32773	of	_	
175-28	32774-32777	new	_	
175-29	32778-32786	research	_	
175-30	32786-32787	.	_	

#Text=Increasing activation of the HPA axis with mu-opioid antagonism (including adrenocorticotropic hormone, beta-endorphin and cortisol levels) is also a potential mechanism for reducing craving and withdrawal symptoms in alcohol addiction.
176-1	32788-32798	Increasing	_	
176-2	32799-32809	activation	_	
176-3	32810-32812	of	_	
176-4	32813-32816	the	_	
176-5	32817-32820	HPA	_	
176-6	32821-32825	axis	_	
176-7	32826-32830	with	_	
176-8	32831-32840	mu-opioid	_	
176-9	32841-32851	antagonism	_	
176-10	32852-32853	(	_	
176-11	32853-32862	including	_	
176-12	32863-32882	adrenocorticotropic	_	
176-13	32883-32890	hormone	_	
176-14	32890-32891	,	_	
176-15	32892-32906	beta-endorphin	_	
176-16	32907-32910	and	_	
176-17	32911-32919	cortisol	_	
176-18	32920-32926	levels	_	
176-19	32926-32927	)	_	
176-20	32928-32930	is	_	
176-21	32931-32935	also	_	
176-22	32936-32937	a	_	
176-23	32938-32947	potential	_	
176-24	32948-32957	mechanism	_	
176-25	32958-32961	for	_	
176-26	32962-32970	reducing	_	
176-27	32971-32978	craving	_	
176-28	32979-32982	and	_	
176-29	32983-32993	withdrawal	_	
176-30	32994-33002	symptoms	_	
176-31	33003-33005	in	_	
176-32	33006-33013	alcohol	_	
176-33	33014-33023	addiction	_	
176-34	33023-33024	.	_	

#Text=Treatment implications
#Text=Naltrexone significantly reduces return to heavy drinking (to 83% of the risk of placebo) and decreases drinking days by about 4%.
177-1	33025-33034	Treatment	_	
177-2	33035-33047	implications	_	
177-3	33048-33058	Naltrexone	_	
177-4	33059-33072	significantly	_	
177-5	33073-33080	reduces	_	
177-6	33081-33087	return	_	
177-7	33088-33090	to	_	
177-8	33091-33096	heavy	_	
177-9	33097-33105	drinking	_	
177-10	33106-33107	(	_	
177-11	33107-33109	to	_	
177-12	33110-33113	83%	_	
177-13	33114-33116	of	_	
177-14	33117-33120	the	_	
177-15	33121-33125	risk	_	
177-16	33126-33128	of	_	
177-17	33129-33136	placebo	_	
177-18	33136-33137	)	_	
177-19	33138-33141	and	_	
177-20	33142-33151	decreases	_	
177-21	33152-33160	drinking	_	
177-22	33161-33165	days	_	
177-23	33166-33168	by	_	
177-24	33169-33174	about	_	
177-25	33175-33177	4%	_	
177-26	33177-33178	.	_	

#Text=In individuals with opioid dependence, the efficacy of naltrexone treatment is largely heterogeneous and most effective in subgroups that complete treatment.
178-1	33179-33181	In	_	
178-2	33182-33193	individuals	_	
178-3	33194-33198	with	_	
178-4	33199-33205	opioid	_	
178-5	33206-33216	dependence	_	
178-6	33216-33217	,	_	
178-7	33218-33221	the	_	
178-8	33222-33230	efficacy	_	
178-9	33231-33233	of	_	
178-10	33234-33244	naltrexone	_	
178-11	33245-33254	treatment	_	
178-12	33255-33257	is	_	
178-13	33258-33265	largely	_	
178-14	33266-33279	heterogeneous	_	
178-15	33280-33283	and	_	
178-16	33284-33288	most	_	
178-17	33289-33298	effective	_	
178-18	33299-33301	in	_	
178-19	33302-33311	subgroups	_	
178-20	33312-33316	that	_	
178-21	33317-33325	complete	_	
178-22	33326-33335	treatment	_	
178-23	33335-33336	.	_	

#Text=However, medication compliance and retention rates remain poor (28%), particularly during early stages of recovery.
179-1	33337-33344	However	_	
179-2	33344-33345	,	_	
179-3	33346-33356	medication	_	
179-4	33357-33367	compliance	_	
179-5	33368-33371	and	_	
179-6	33372-33381	retention	_	
179-7	33382-33387	rates	_	
179-8	33388-33394	remain	_	
179-9	33395-33399	poor	_	
179-10	33400-33401	(	_	
179-11	33401-33404	28%	_	
179-12	33404-33405	)	_	
179-13	33405-33406	,	_	
179-14	33407-33419	particularly	_	
179-15	33420-33426	during	_	
179-16	33427-33432	early	_	
179-17	33433-33439	stages	_	
179-18	33440-33442	of	_	
179-19	33443-33451	recovery	_	
179-20	33451-33452	.	_	

#Text=This is likely explained by unwanted side effects such as sedation (for example, daytime sleepiness) and gastrointestinal problems (for example, nausea, stomach pain, loss of appetite).
180-1	33453-33457	This	_	
180-2	33458-33460	is	_	
180-3	33461-33467	likely	_	
180-4	33468-33477	explained	_	
180-5	33478-33480	by	_	
180-6	33481-33489	unwanted	_	
180-7	33490-33494	side	_	
180-8	33495-33502	effects	_	
180-9	33503-33507	such	_	
180-10	33508-33510	as	_	
180-11	33511-33519	sedation	_	
180-12	33520-33521	(	_	
180-13	33521-33524	for	_	
180-14	33525-33532	example	_	
180-15	33532-33533	,	_	
180-16	33534-33541	daytime	_	
180-17	33542-33552	sleepiness	_	
180-18	33552-33553	)	_	
180-19	33554-33557	and	_	
180-20	33558-33574	gastrointestinal	_	
180-21	33575-33583	problems	_	
180-22	33584-33585	(	_	
180-23	33585-33588	for	_	
180-24	33589-33596	example	_	
180-25	33596-33597	,	_	
180-26	33598-33604	nausea	_	
180-27	33604-33605	,	_	
180-28	33606-33613	stomach	_	
180-29	33614-33618	pain	_	
180-30	33618-33619	,	_	
180-31	33620-33624	loss	_	
180-32	33625-33627	of	_	
180-33	33628-33636	appetite	_	
180-34	33636-33637	)	_	
180-35	33637-33638	.	_	

#Text=Extended-release naltrexone has thus been developed and used, with success, to improve adherence over and above other pharmacotherapies used in the treatment of alcohol and opioid dependence (for example, acamprosate, buprenorphine).
181-1	33639-33655	Extended-release	_	
181-2	33656-33666	naltrexone	_	
181-3	33667-33670	has	_	
181-4	33671-33675	thus	_	
181-5	33676-33680	been	_	
181-6	33681-33690	developed	_	
181-7	33691-33694	and	_	
181-8	33695-33699	used	_	
181-9	33699-33700	,	_	
181-10	33701-33705	with	_	
181-11	33706-33713	success	_	
181-12	33713-33714	,	_	
181-13	33715-33717	to	_	
181-14	33718-33725	improve	_	
181-15	33726-33735	adherence	_	
181-16	33736-33740	over	_	
181-17	33741-33744	and	_	
181-18	33745-33750	above	_	
181-19	33751-33756	other	_	
181-20	33757-33774	pharmacotherapies	_	
181-21	33775-33779	used	_	
181-22	33780-33782	in	_	
181-23	33783-33786	the	_	
181-24	33787-33796	treatment	_	
181-25	33797-33799	of	_	
181-26	33800-33807	alcohol	_	
181-27	33808-33811	and	_	
181-28	33812-33818	opioid	_	
181-29	33819-33829	dependence	_	
181-30	33830-33831	(	_	
181-31	33831-33834	for	_	
181-32	33835-33842	example	_	
181-33	33842-33843	,	_	
181-34	33844-33855	acamprosate	_	
181-35	33855-33856	,	_	
181-36	33857-33870	buprenorphine	_	
181-37	33870-33871	)	_	
181-38	33871-33872	.	_	

#Text=Encouragingly, cognitive behavioral therapy with adjunct naltrexone treatment has shown to reduce return to drinking in alcohol-dependent adults, thus suggesting beneficial, synergistic effects of concurrent therapies.
182-1	33873-33886	Encouragingly	_	
182-2	33886-33887	,	_	
182-3	33888-33897	cognitive	_	
182-4	33898-33908	behavioral	_	
182-5	33909-33916	therapy	_	
182-6	33917-33921	with	_	
182-7	33922-33929	adjunct	_	
182-8	33930-33940	naltrexone	_	
182-9	33941-33950	treatment	_	
182-10	33951-33954	has	_	
182-11	33955-33960	shown	_	
182-12	33961-33963	to	_	
182-13	33964-33970	reduce	_	
182-14	33971-33977	return	_	
182-15	33978-33980	to	_	
182-16	33981-33989	drinking	_	
182-17	33990-33992	in	_	
182-18	33993-34010	alcohol-dependent	_	
182-19	34011-34017	adults	_	
182-20	34017-34018	,	_	
182-21	34019-34023	thus	_	
182-22	34024-34034	suggesting	_	
182-23	34035-34045	beneficial	_	
182-24	34045-34046	,	_	
182-25	34047-34058	synergistic	_	
182-26	34059-34066	effects	_	
182-27	34067-34069	of	_	
182-28	34070-34080	concurrent	_	
182-29	34081-34090	therapies	_	
182-30	34090-34091	.	_	

#Text=Cognitive behavioral therapy also has the potential to improve functional abnormalities during emotional processing (in the medial prefrontal and anterior cingulate cortices, for example), as shown in patients with depression.
183-1	34092-34101	Cognitive	_	
183-2	34102-34112	behavioral	_	
183-3	34113-34120	therapy	_	
183-4	34121-34125	also	_	
183-5	34126-34129	has	_	
183-6	34130-34133	the	_	
183-7	34134-34143	potential	_	
183-8	34144-34146	to	_	
183-9	34147-34154	improve	_	
183-10	34155-34165	functional	_	
183-11	34166-34179	abnormalities	_	
183-12	34180-34186	during	_	
183-13	34187-34196	emotional	_	
183-14	34197-34207	processing	_	
183-15	34208-34209	(	_	
183-16	34209-34211	in	_	
183-17	34212-34215	the	_	
183-18	34216-34222	medial	_	
183-19	34223-34233	prefrontal	_	
183-20	34234-34237	and	_	
183-21	34238-34246	anterior	_	
183-22	34247-34256	cingulate	_	
183-23	34257-34265	cortices	_	
183-24	34265-34266	,	_	
183-25	34267-34270	for	_	
183-26	34271-34278	example	_	
183-27	34278-34279	)	_	
183-28	34279-34280	,	_	
183-29	34281-34283	as	_	
183-30	34284-34289	shown	_	
183-31	34290-34292	in	_	
183-32	34293-34301	patients	_	
183-33	34302-34306	with	_	
183-34	34307-34317	depression	_	
183-35	34317-34318	.	_	

#Text=Interventions that combine naltrexone and coping skills have shown to improve treatment outcome in alcohol and cocaine dependence.
184-1	34319-34332	Interventions	_	
184-2	34333-34337	that	_	
184-3	34338-34345	combine	_	
184-4	34346-34356	naltrexone	_	
184-5	34357-34360	and	_	
184-6	34361-34367	coping	_	
184-7	34368-34374	skills	_	
184-8	34375-34379	have	_	
184-9	34380-34385	shown	_	
184-10	34386-34388	to	_	
184-11	34389-34396	improve	_	
184-12	34397-34406	treatment	_	
184-13	34407-34414	outcome	_	
184-14	34415-34417	in	_	
184-15	34418-34425	alcohol	_	
184-16	34426-34429	and	_	
184-17	34430-34437	cocaine	_	
184-18	34438-34448	dependence	_	
184-19	34448-34449	.	_	

#Text=Coping skills therapies with a particular focus on relapse prevention may also help naltrexone-treated patients better manage their emotions after non-substance using strategies are implemented.
185-1	34450-34456	Coping	_	
185-2	34457-34463	skills	_	
185-3	34464-34473	therapies	_	
185-4	34474-34478	with	_	
185-5	34479-34480	a	_	
185-6	34481-34491	particular	_	
185-7	34492-34497	focus	_	
185-8	34498-34500	on	_	
185-9	34501-34508	relapse	_	
185-10	34509-34519	prevention	_	
185-11	34520-34523	may	_	
185-12	34524-34528	also	_	
185-13	34529-34533	help	_	
185-14	34534-34552	naltrexone-treated	_	
185-15	34553-34561	patients	_	
185-16	34562-34568	better	_	
185-17	34569-34575	manage	_	
185-18	34576-34581	their	_	
185-19	34582-34590	emotions	_	
185-20	34591-34596	after	_	
185-21	34597-34610	non-substance	_	
185-22	34611-34616	using	_	
185-23	34617-34627	strategies	_	
185-24	34628-34631	are	_	
185-25	34632-34643	implemented	_	
185-26	34643-34644	.	_	

#Text=As the current treatment length of naltrexone is recommended for 6 months, coping skills for childhood adversity should be addressed and evaluated as part of a longer-term therapeutic process for addiction recovery.
186-1	34645-34647	As	_	
186-2	34648-34651	the	_	
186-3	34652-34659	current	_	
186-4	34660-34669	treatment	_	
186-5	34670-34676	length	_	
186-6	34677-34679	of	_	
186-7	34680-34690	naltrexone	_	
186-8	34691-34693	is	_	
186-9	34694-34705	recommended	_	
186-10	34706-34709	for	_	
186-11	34710-34711	6	_	
186-12	34712-34718	months	_	
186-13	34718-34719	,	_	
186-14	34720-34726	coping	_	
186-15	34727-34733	skills	_	
186-16	34734-34737	for	_	
186-17	34738-34747	childhood	_	
186-18	34748-34757	adversity	_	
186-19	34758-34764	should	_	
186-20	34765-34767	be	_	
186-21	34768-34777	addressed	_	
186-22	34778-34781	and	_	
186-23	34782-34791	evaluated	_	
186-24	34792-34794	as	_	
186-25	34795-34799	part	_	
186-26	34800-34802	of	_	
186-27	34803-34804	a	_	
186-28	34805-34816	longer-term	_	
186-29	34817-34828	therapeutic	_	
186-30	34829-34836	process	_	
186-31	34837-34840	for	_	
186-32	34841-34850	addiction	_	
186-33	34851-34859	recovery	_	
186-34	34859-34860	.	_	

#Text=Limitations
#Text=The main limitation of our analyses is its use of a retrospective self-report measure of childhood adversity.
187-1	34861-34872	Limitations	_	
187-2	34873-34876	The	_	
187-3	34877-34881	main	_	
187-4	34882-34892	limitation	_	
187-5	34893-34895	of	_	
187-6	34896-34899	our	_	
187-7	34900-34908	analyses	_	
187-8	34909-34911	is	_	
187-9	34912-34915	its	_	
187-10	34916-34919	use	_	
187-11	34920-34922	of	_	
187-12	34923-34924	a	_	
187-13	34925-34938	retrospective	_	
187-14	34939-34950	self-report	_	
187-15	34951-34958	measure	_	
187-16	34959-34961	of	_	
187-17	34962-34971	childhood	_	
187-18	34972-34981	adversity	_	
187-19	34981-34982	.	_	

#Text=Measurement of an emotional or traumatic event may be unreliable as recollection is likely to be influenced by several confounding factors including memory biases, memory repression and current mood; however, retrospective recall of physical and sexual abuse is associated with more false negatives than false positives, suggesting a greater tendency for adults to under- rather than to overestimate the occurrence of an abusive experience.
188-1	34983-34994	Measurement	_	
188-2	34995-34997	of	_	
188-3	34998-35000	an	_	
188-4	35001-35010	emotional	_	
188-5	35011-35013	or	_	
188-6	35014-35023	traumatic	_	
188-7	35024-35029	event	_	
188-8	35030-35033	may	_	
188-9	35034-35036	be	_	
188-10	35037-35047	unreliable	_	
188-11	35048-35050	as	_	
188-12	35051-35063	recollection	_	
188-13	35064-35066	is	_	
188-14	35067-35073	likely	_	
188-15	35074-35076	to	_	
188-16	35077-35079	be	_	
188-17	35080-35090	influenced	_	
188-18	35091-35093	by	_	
188-19	35094-35101	several	_	
188-20	35102-35113	confounding	_	
188-21	35114-35121	factors	_	
188-22	35122-35131	including	_	
188-23	35132-35138	memory	_	
188-24	35139-35145	biases	_	
188-25	35145-35146	,	_	
188-26	35147-35153	memory	_	
188-27	35154-35164	repression	_	
188-28	35165-35168	and	_	
188-29	35169-35176	current	_	
188-30	35177-35181	mood	_	
188-31	35181-35182	;	_	
188-32	35183-35190	however	_	
188-33	35190-35191	,	_	
188-34	35192-35205	retrospective	_	
188-35	35206-35212	recall	_	
188-36	35213-35215	of	_	
188-37	35216-35224	physical	_	
188-38	35225-35228	and	_	
188-39	35229-35235	sexual	_	
188-40	35236-35241	abuse	_	
188-41	35242-35244	is	_	
188-42	35245-35255	associated	_	
188-43	35256-35260	with	_	
188-44	35261-35265	more	_	
188-45	35266-35271	false	_	
188-46	35272-35281	negatives	_	
188-47	35282-35286	than	_	
188-48	35287-35292	false	_	
188-49	35293-35302	positives	_	
188-50	35302-35303	,	_	
188-51	35304-35314	suggesting	_	
188-52	35315-35316	a	_	
188-53	35317-35324	greater	_	
188-54	35325-35333	tendency	_	
188-55	35334-35337	for	_	
188-56	35338-35344	adults	_	
188-57	35345-35347	to	_	
188-58	35348-35353	under	_	
188-59	35353-35354	-	_	
188-60	35355-35361	rather	_	
188-61	35362-35366	than	_	
188-62	35367-35369	to	_	
188-63	35370-35382	overestimate	_	
188-64	35383-35386	the	_	
188-65	35387-35397	occurrence	_	
188-66	35398-35400	of	_	
188-67	35401-35403	an	_	
188-68	35404-35411	abusive	_	
188-69	35412-35422	experience	_	
188-70	35422-35423	.	_	

#Text=Secondly, our study only investigated the effects of naltrexone on the processing of aversive images compared with neutral images.
189-1	35424-35432	Secondly	_	
189-2	35432-35433	,	_	
189-3	35434-35437	our	_	
189-4	35438-35443	study	_	
189-5	35444-35448	only	_	
189-6	35449-35461	investigated	_	
189-7	35462-35465	the	_	
189-8	35466-35473	effects	_	
189-9	35474-35476	of	_	
189-10	35477-35487	naltrexone	_	
189-11	35488-35490	on	_	
189-12	35491-35494	the	_	
189-13	35495-35505	processing	_	
189-14	35506-35508	of	_	
189-15	35509-35517	aversive	_	
189-16	35518-35524	images	_	
189-17	35525-35533	compared	_	
189-18	35534-35538	with	_	
189-19	35539-35546	neutral	_	
189-20	35547-35553	images	_	
189-21	35553-35554	.	_	

#Text=Comparison with positive or rewarding non-alcohol and -drug-related images would have allowed us to investigate if the valence of emotional processing had a differential treatment effect, or if motivational salience had the same effect irrespective of emotionality.
190-1	35555-35565	Comparison	_	
190-2	35566-35570	with	_	
190-3	35571-35579	positive	_	
190-4	35580-35582	or	_	
190-5	35583-35592	rewarding	_	
190-6	35593-35604	non-alcohol	_	
190-7	35605-35608	and	_	
190-8	35609-35610	-	_	
190-9	35610-35622	drug-related	_	
190-10	35623-35629	images	_	
190-11	35630-35635	would	_	
190-12	35636-35640	have	_	
190-13	35641-35648	allowed	_	
190-14	35649-35651	us	_	
190-15	35652-35654	to	_	
190-16	35655-35666	investigate	_	
190-17	35667-35669	if	_	
190-18	35670-35673	the	_	
190-19	35674-35681	valence	_	
190-20	35682-35684	of	_	
190-21	35685-35694	emotional	_	
190-22	35695-35705	processing	_	
190-23	35706-35709	had	_	
190-24	35710-35711	a	_	
190-25	35712-35724	differential	_	
190-26	35725-35734	treatment	_	
190-27	35735-35741	effect	_	
190-28	35741-35742	,	_	
190-29	35743-35745	or	_	
190-30	35746-35748	if	_	
190-31	35749-35761	motivational	_	
190-32	35762-35770	salience	_	
190-33	35771-35774	had	_	
190-34	35775-35778	the	_	
190-35	35779-35783	same	_	
190-36	35784-35790	effect	_	
190-37	35791-35803	irrespective	_	
190-38	35804-35806	of	_	
190-39	35807-35819	emotionality	_	
190-40	35819-35820	.	_	

#Text=Lastly, childhood adversity is a robust risk factor for other disorders in which emotional problems pervade.
191-1	35821-35827	Lastly	_	
191-2	35827-35828	,	_	
191-3	35829-35838	childhood	_	
191-4	35839-35848	adversity	_	
191-5	35849-35851	is	_	
191-6	35852-35853	a	_	
191-7	35854-35860	robust	_	
191-8	35861-35865	risk	_	
191-9	35866-35872	factor	_	
191-10	35873-35876	for	_	
191-11	35877-35882	other	_	
191-12	35883-35892	disorders	_	
191-13	35893-35895	in	_	
191-14	35896-35901	which	_	
191-15	35902-35911	emotional	_	
191-16	35912-35920	problems	_	
191-17	35921-35928	pervade	_	
191-18	35928-35929	.	_	

#Text=Major depressive disorder, for example, is associated with abnormal responses to negative emotional stimuli in similar brain regions observed here.
192-1	35930-35935	Major	_	
192-2	35936-35946	depressive	_	
192-3	35947-35955	disorder	_	
192-4	35955-35956	,	_	
192-5	35957-35960	for	_	
192-6	35961-35968	example	_	
192-7	35968-35969	,	_	
192-8	35970-35972	is	_	
192-9	35973-35983	associated	_	
192-10	35984-35988	with	_	
192-11	35989-35997	abnormal	_	
192-12	35998-36007	responses	_	
192-13	36008-36010	to	_	
192-14	36011-36019	negative	_	
192-15	36020-36029	emotional	_	
192-16	36030-36037	stimuli	_	
192-17	36038-36040	in	_	
192-18	36041-36048	similar	_	
192-19	36049-36054	brain	_	
192-20	36055-36062	regions	_	
192-21	36063-36071	observed	_	
192-22	36072-36076	here	_	
192-23	36076-36077	.	_	

#Text=It is possible that variations in anxiety and depression could also drive abnormalities in negative emotional processing in substance use disorders, or that more severe comorbidity has a particularly potent effect for enhancing emotion-processing circuitry.
193-1	36078-36080	It	_	
193-2	36081-36083	is	_	
193-3	36084-36092	possible	_	
193-4	36093-36097	that	_	
193-5	36098-36108	variations	_	
193-6	36109-36111	in	_	
193-7	36112-36119	anxiety	_	
193-8	36120-36123	and	_	
193-9	36124-36134	depression	_	
193-10	36135-36140	could	_	
193-11	36141-36145	also	_	
193-12	36146-36151	drive	_	
193-13	36152-36165	abnormalities	_	
193-14	36166-36168	in	_	
193-15	36169-36177	negative	_	
193-16	36178-36187	emotional	_	
193-17	36188-36198	processing	_	
193-18	36199-36201	in	_	
193-19	36202-36211	substance	_	
193-20	36212-36215	use	_	
193-21	36216-36225	disorders	_	
193-22	36225-36226	,	_	
193-23	36227-36229	or	_	
193-24	36230-36234	that	_	
193-25	36235-36239	more	_	
193-26	36240-36246	severe	_	
193-27	36247-36258	comorbidity	_	
193-28	36259-36262	has	_	
193-29	36263-36264	a	_	
193-30	36265-36277	particularly	_	
193-31	36278-36284	potent	_	
193-32	36285-36291	effect	_	
193-33	36292-36295	for	_	
193-34	36296-36305	enhancing	_	
193-35	36306-36324	emotion-processing	_	
193-36	36325-36334	circuitry	_	
193-37	36334-36335	.	_	

#Text=Although we cannot preclude this possibility from the current data, levels of anxiety and depression were consistent in groups across the experimental medicine sessions (and therefore exerting the same influence on emotional processing at both time points), and sensitivity to stress did not differ between the patient groups at baseline.
194-1	36336-36344	Although	_	
194-2	36345-36347	we	_	
194-3	36348-36354	cannot	_	
194-4	36355-36363	preclude	_	
194-5	36364-36368	this	_	
194-6	36369-36380	possibility	_	
194-7	36381-36385	from	_	
194-8	36386-36389	the	_	
194-9	36390-36397	current	_	
194-10	36398-36402	data	_	
194-11	36402-36403	,	_	
194-12	36404-36410	levels	_	
194-13	36411-36413	of	_	
194-14	36414-36421	anxiety	_	
194-15	36422-36425	and	_	
194-16	36426-36436	depression	_	
194-17	36437-36441	were	_	
194-18	36442-36452	consistent	_	
194-19	36453-36455	in	_	
194-20	36456-36462	groups	_	
194-21	36463-36469	across	_	
194-22	36470-36473	the	_	
194-23	36474-36486	experimental	_	
194-24	36487-36495	medicine	_	
194-25	36496-36504	sessions	_	
194-26	36505-36506	(	_	
194-27	36506-36509	and	_	
194-28	36510-36519	therefore	_	
194-29	36520-36528	exerting	_	
194-30	36529-36532	the	_	
194-31	36533-36537	same	_	
194-32	36538-36547	influence	_	
194-33	36548-36550	on	_	
194-34	36551-36560	emotional	_	
194-35	36561-36571	processing	_	
194-36	36572-36574	at	_	
194-37	36575-36579	both	_	
194-38	36580-36584	time	_	
194-39	36585-36591	points	_	
194-40	36591-36592	)	_	
194-41	36592-36593	,	_	
194-42	36594-36597	and	_	
194-43	36598-36609	sensitivity	_	
194-44	36610-36612	to	_	
194-45	36613-36619	stress	_	
194-46	36620-36623	did	_	
194-47	36624-36627	not	_	
194-48	36628-36634	differ	_	
194-49	36635-36642	between	_	
194-50	36643-36646	the	_	
194-51	36647-36654	patient	_	
194-52	36655-36661	groups	_	
194-53	36662-36664	at	_	
194-54	36665-36673	baseline	_	
194-55	36673-36674	.	_	

#Text=Conclusions
#Text=Problems with emotion regulation may predate substance dependence, or may serve to exacerbate susceptibility to relapse during addiction recovery.
195-1	36675-36686	Conclusions	_	
195-2	36687-36695	Problems	_	
195-3	36696-36700	with	_	
195-4	36701-36708	emotion	_	
195-5	36709-36719	regulation	_	
195-6	36720-36723	may	_	
195-7	36724-36731	predate	_	
195-8	36732-36741	substance	_	
195-9	36742-36752	dependence	_	
195-10	36752-36753	,	_	
195-11	36754-36756	or	_	
195-12	36757-36760	may	_	
195-13	36761-36766	serve	_	
195-14	36767-36769	to	_	
195-15	36770-36780	exacerbate	_	
195-16	36781-36795	susceptibility	_	
195-17	36796-36798	to	_	
195-18	36799-36806	relapse	_	
195-19	36807-36813	during	_	
195-20	36814-36823	addiction	_	
195-21	36824-36832	recovery	_	
195-22	36832-36833	.	_	

#Text=Furthermore, loss of brain reward and recruitment of brain stress systems produces negatively reinforced motivation for compulsive drug seeking and addiction.
196-1	36834-36845	Furthermore	_	
196-2	36845-36846	,	_	
196-3	36847-36851	loss	_	
196-4	36852-36854	of	_	
196-5	36855-36860	brain	_	
196-6	36861-36867	reward	_	
196-7	36868-36871	and	_	
196-8	36872-36883	recruitment	_	
196-9	36884-36886	of	_	
196-10	36887-36892	brain	_	
196-11	36893-36899	stress	_	
196-12	36900-36907	systems	_	
196-13	36908-36916	produces	_	
196-14	36917-36927	negatively	_	
196-15	36928-36938	reinforced	_	
196-16	36939-36949	motivation	_	
196-17	36950-36953	for	_	
196-18	36954-36964	compulsive	_	
196-19	36965-36969	drug	_	
196-20	36970-36977	seeking	_	
196-21	36978-36981	and	_	
196-22	36982-36991	addiction	_	
196-23	36991-36992	.	_	

#Text=The present study demonstrates that the effects of naltrexone on cortical activation and cortical–limbic connectivity are dependent on variations in childhood adversity (that is, the more abuse experienced, the greater the ameliorative effect of naltrexone).
197-1	36993-36996	The	_	
197-2	36997-37004	present	_	
197-3	37005-37010	study	_	
197-4	37011-37023	demonstrates	_	
197-5	37024-37028	that	_	
197-6	37029-37032	the	_	
197-7	37033-37040	effects	_	
197-8	37041-37043	of	_	
197-9	37044-37054	naltrexone	_	
197-10	37055-37057	on	_	
197-11	37058-37066	cortical	_	
197-12	37067-37077	activation	_	
197-13	37078-37081	and	_	
197-14	37082-37097	cortical–limbic	_	
197-15	37098-37110	connectivity	_	
197-16	37111-37114	are	_	
197-17	37115-37124	dependent	_	
197-18	37125-37127	on	_	
197-19	37128-37138	variations	_	
197-20	37139-37141	in	_	
197-21	37142-37151	childhood	_	
197-22	37152-37161	adversity	_	
197-23	37162-37163	(	_	
197-24	37163-37167	that	_	
197-25	37168-37170	is	_	
197-26	37170-37171	,	_	
197-27	37172-37175	the	_	
197-28	37176-37180	more	_	
197-29	37181-37186	abuse	_	
197-30	37187-37198	experienced	_	
197-31	37198-37199	,	_	
197-32	37200-37203	the	_	
197-33	37204-37211	greater	_	
197-34	37212-37215	the	_	
197-35	37216-37228	ameliorative	_	
197-36	37229-37235	effect	_	
197-37	37236-37238	of	_	
197-38	37239-37249	naltrexone	_	
197-39	37249-37250	)	_	
197-40	37250-37251	.	_	

#Text=Pharmacotherapy with naltrexone may also have some ameliorative effects on negative emotional processing in the amygdala in individuals with combined alcohol and drug dependence, but not alcohol dependence alone, possibly because of alterations in endogenous opioid transmission or the KOR antagonist actions of naltrexone.
198-1	37252-37267	Pharmacotherapy	_	
198-2	37268-37272	with	_	
198-3	37273-37283	naltrexone	_	
198-4	37284-37287	may	_	
198-5	37288-37292	also	_	
198-6	37293-37297	have	_	
198-7	37298-37302	some	_	
198-8	37303-37315	ameliorative	_	
198-9	37316-37323	effects	_	
198-10	37324-37326	on	_	
198-11	37327-37335	negative	_	
198-12	37336-37345	emotional	_	
198-13	37346-37356	processing	_	
198-14	37357-37359	in	_	
198-15	37360-37363	the	_	
198-16	37364-37372	amygdala	_	
198-17	37373-37375	in	_	
198-18	37376-37387	individuals	_	
198-19	37388-37392	with	_	
198-20	37393-37401	combined	_	
198-21	37402-37409	alcohol	_	
198-22	37410-37413	and	_	
198-23	37414-37418	drug	_	
198-24	37419-37429	dependence	_	
198-25	37429-37430	,	_	
198-26	37431-37434	but	_	
198-27	37435-37438	not	_	
198-28	37439-37446	alcohol	_	
198-29	37447-37457	dependence	_	
198-30	37458-37463	alone	_	
198-31	37463-37464	,	_	
198-32	37465-37473	possibly	_	
198-33	37474-37481	because	_	
198-34	37482-37484	of	_	
198-35	37485-37496	alterations	_	
198-36	37497-37499	in	_	
198-37	37500-37510	endogenous	_	
198-38	37511-37517	opioid	_	
198-39	37518-37530	transmission	_	
198-40	37531-37533	or	_	
198-41	37534-37537	the	_	
198-42	37538-37541	KOR	_	
198-43	37542-37552	antagonist	_	
198-44	37553-37560	actions	_	
198-45	37561-37563	of	_	
198-46	37564-37574	naltrexone	_	
198-47	37574-37575	.	_	

#Text=Childhood adversity was higher in individuals with combined alcohol and drug dependence compared with individuals dependent on alcohol only and should thus be an important consideration by treatment strategies for addiction.
199-1	37576-37585	Childhood	_	
199-2	37586-37595	adversity	_	
199-3	37596-37599	was	_	
199-4	37600-37606	higher	_	
199-5	37607-37609	in	_	
199-6	37610-37621	individuals	_	
199-7	37622-37626	with	_	
199-8	37627-37635	combined	_	
199-9	37636-37643	alcohol	_	
199-10	37644-37647	and	_	
199-11	37648-37652	drug	_	
199-12	37653-37663	dependence	_	
199-13	37664-37672	compared	_	
199-14	37673-37677	with	_	
199-15	37678-37689	individuals	_	
199-16	37690-37699	dependent	_	
199-17	37700-37702	on	_	
199-18	37703-37710	alcohol	_	
199-19	37711-37715	only	_	
199-20	37716-37719	and	_	
199-21	37720-37726	should	_	
199-22	37727-37731	thus	_	
199-23	37732-37734	be	_	
199-24	37735-37737	an	_	
199-25	37738-37747	important	_	
199-26	37748-37761	consideration	_	
199-27	37762-37764	by	_	
199-28	37765-37774	treatment	_	
199-29	37775-37785	strategies	_	
199-30	37786-37789	for	_	
199-31	37790-37799	addiction	_	
199-32	37799-37800	.	_	

#Text=We conclude that childhood adversity is one environmental factor that influences pharmacological response to naltrexone.
200-1	37801-37803	We	_	
200-2	37804-37812	conclude	_	
200-3	37813-37817	that	_	
200-4	37818-37827	childhood	_	
200-5	37828-37837	adversity	_	
200-6	37838-37840	is	_	
200-7	37841-37844	one	_	
200-8	37845-37858	environmental	_	
200-9	37859-37865	factor	_	
200-10	37866-37870	that	_	
200-11	37871-37881	influences	_	
200-12	37882-37897	pharmacological	_	
200-13	37898-37906	response	_	
200-14	37907-37909	to	_	
200-15	37910-37920	naltrexone	_	
200-16	37920-37921	.	_	

#Text=More tailored treatment approaches are required that take into account such early experiential factors.
201-1	37922-37926	More	_	
201-2	37927-37935	tailored	_	
201-3	37936-37945	treatment	_	
201-4	37946-37956	approaches	_	
201-5	37957-37960	are	_	
201-6	37961-37969	required	_	
201-7	37970-37974	that	_	
201-8	37975-37979	take	_	
201-9	37980-37984	into	_	
201-10	37985-37992	account	_	
201-11	37993-37997	such	_	
201-12	37998-38003	early	_	
201-13	38004-38016	experiential	_	
201-14	38017-38024	factors	_	
201-15	38024-38025	.	_	

#Text=JFWD currently advises or carries out research funded by Autifony, Sunovion, Lundbeck, AstraZeneca and Servier.
202-1	38026-38030	JFWD	_	
202-2	38031-38040	currently	_	
202-3	38041-38048	advises	_	
202-4	38049-38051	or	_	
202-5	38052-38059	carries	_	
202-6	38060-38063	out	_	
202-7	38064-38072	research	_	
202-8	38073-38079	funded	_	
202-9	38080-38082	by	_	
202-10	38083-38091	Autifony	_	
202-11	38091-38092	,	_	
202-12	38093-38101	Sunovion	_	
202-13	38101-38102	,	_	
202-14	38103-38111	Lundbeck	_	
202-15	38111-38112	,	_	
202-16	38113-38124	AstraZeneca	_	
202-17	38125-38128	and	_	
202-18	38129-38136	Servier	_	
202-19	38136-38137	.	_	

#Text=All payment is to the University of Manchester.
203-1	38138-38141	All	_	
203-2	38142-38149	payment	_	
203-3	38150-38152	is	_	
203-4	38153-38155	to	_	
203-5	38156-38159	the	_	
203-6	38160-38170	University	_	
203-7	38171-38173	of	_	
203-8	38174-38184	Manchester	_	
203-9	38184-38185	.	_	

#Text=ARL-H has received honoraria from Lundbeck and research support from GSK for a PhD studentship.
204-1	38186-38191	ARL-H	_	
204-2	38192-38195	has	_	
204-3	38196-38204	received	_	
204-4	38205-38214	honoraria	_	
204-5	38215-38219	from	_	
204-6	38220-38228	Lundbeck	_	
204-7	38229-38232	and	_	
204-8	38233-38241	research	_	
204-9	38242-38249	support	_	
204-10	38250-38254	from	_	
204-11	38255-38258	GSK	_	
204-12	38259-38262	for	_	
204-13	38263-38264	a	_	
204-14	38265-38268	PhD	_	
204-15	38269-38280	studentship	_	
204-16	38280-38281	.	_	

#Text=DJN is an advisor to British National Formulary, MRC, General Medical Council, Department of Health, is President of the European Brain Council, past President of the British Neuroscience Association and European College of Neuropsychopharmacology, chair of the Independent Scientific Committee on Drugs (UK), is a member of the International Centre for Science in Drug Policy, advisor to Swedish government on drug, alcohol and tobacco research, editor of the Journal of Psychopharmacology, sits on advisory Boards at Lundbeck, MSD, Nalpharm, Orexigen, Shire, has received speaking honoraria (in addition to above) from BMS/Otsuka, GSK, Lilly, Janssen, Servier, is a member of the Lundbeck International Neuroscience Foundation, has received grants or clinical trial payments from P1vital, MRC, NHS, Lundbeck, has share options with P1vital, has been expert witness in a number of legal cases relating to psychotropic drugs, and has edited/written 27 books, some purchased by pharmaceutical companies.
205-1	38282-38285	DJN	_	
205-2	38286-38288	is	_	
205-3	38289-38291	an	_	
205-4	38292-38299	advisor	_	
205-5	38300-38302	to	_	
205-6	38303-38310	British	_	
205-7	38311-38319	National	_	
205-8	38320-38329	Formulary	_	
205-9	38329-38330	,	_	
205-10	38331-38334	MRC	_	
205-11	38334-38335	,	_	
205-12	38336-38343	General	_	
205-13	38344-38351	Medical	_	
205-14	38352-38359	Council	_	
205-15	38359-38360	,	_	
205-16	38361-38371	Department	_	
205-17	38372-38374	of	_	
205-18	38375-38381	Health	_	
205-19	38381-38382	,	_	
205-20	38383-38385	is	_	
205-21	38386-38395	President	_	
205-22	38396-38398	of	_	
205-23	38399-38402	the	_	
205-24	38403-38411	European	_	
205-25	38412-38417	Brain	_	
205-26	38418-38425	Council	_	
205-27	38425-38426	,	_	
205-28	38427-38431	past	_	
205-29	38432-38441	President	_	
205-30	38442-38444	of	_	
205-31	38445-38448	the	_	
205-32	38449-38456	British	_	
205-33	38457-38469	Neuroscience	_	
205-34	38470-38481	Association	_	
205-35	38482-38485	and	_	
205-36	38486-38494	European	_	
205-37	38495-38502	College	_	
205-38	38503-38505	of	_	
205-39	38506-38529	Neuropsychopharmacology	_	
205-40	38529-38530	,	_	
205-41	38531-38536	chair	_	
205-42	38537-38539	of	_	
205-43	38540-38543	the	_	
205-44	38544-38555	Independent	_	
205-45	38556-38566	Scientific	_	
205-46	38567-38576	Committee	_	
205-47	38577-38579	on	_	
205-48	38580-38585	Drugs	_	
205-49	38586-38587	(	_	
205-50	38587-38589	UK	_	
205-51	38589-38590	)	_	
205-52	38590-38591	,	_	
205-53	38592-38594	is	_	
205-54	38595-38596	a	_	
205-55	38597-38603	member	_	
205-56	38604-38606	of	_	
205-57	38607-38610	the	_	
205-58	38611-38624	International	_	
205-59	38625-38631	Centre	_	
205-60	38632-38635	for	_	
205-61	38636-38643	Science	_	
205-62	38644-38646	in	_	
205-63	38647-38651	Drug	_	
205-64	38652-38658	Policy	_	
205-65	38658-38659	,	_	
205-66	38660-38667	advisor	_	
205-67	38668-38670	to	_	
205-68	38671-38678	Swedish	_	
205-69	38679-38689	government	_	
205-70	38690-38692	on	_	
205-71	38693-38697	drug	_	
205-72	38697-38698	,	_	
205-73	38699-38706	alcohol	_	
205-74	38707-38710	and	_	
205-75	38711-38718	tobacco	_	
205-76	38719-38727	research	_	
205-77	38727-38728	,	_	
205-78	38729-38735	editor	_	
205-79	38736-38738	of	_	
205-80	38739-38742	the	_	
205-81	38743-38750	Journal	_	
205-82	38751-38753	of	_	
205-83	38754-38772	Psychopharmacology	_	
205-84	38772-38773	,	_	
205-85	38774-38778	sits	_	
205-86	38779-38781	on	_	
205-87	38782-38790	advisory	_	
205-88	38791-38797	Boards	_	
205-89	38798-38800	at	_	
205-90	38801-38809	Lundbeck	_	
205-91	38809-38810	,	_	
205-92	38811-38814	MSD	_	
205-93	38814-38815	,	_	
205-94	38816-38824	Nalpharm	_	
205-95	38824-38825	,	_	
205-96	38826-38834	Orexigen	_	
205-97	38834-38835	,	_	
205-98	38836-38841	Shire	_	
205-99	38841-38842	,	_	
205-100	38843-38846	has	_	
205-101	38847-38855	received	_	
205-102	38856-38864	speaking	_	
205-103	38865-38874	honoraria	_	
205-104	38875-38876	(	_	
205-105	38876-38878	in	_	
205-106	38879-38887	addition	_	
205-107	38888-38890	to	_	
205-108	38891-38896	above	_	
205-109	38896-38897	)	_	
205-110	38898-38902	from	_	
205-111	38903-38906	BMS	_	
205-112	38906-38907	/	_	
205-113	38907-38913	Otsuka	_	
205-114	38913-38914	,	_	
205-115	38915-38918	GSK	_	
205-116	38918-38919	,	_	
205-117	38920-38925	Lilly	_	
205-118	38925-38926	,	_	
205-119	38927-38934	Janssen	_	
205-120	38934-38935	,	_	
205-121	38936-38943	Servier	_	
205-122	38943-38944	,	_	
205-123	38945-38947	is	_	
205-124	38948-38949	a	_	
205-125	38950-38956	member	_	
205-126	38957-38959	of	_	
205-127	38960-38963	the	_	
205-128	38964-38972	Lundbeck	_	
205-129	38973-38986	International	_	
205-130	38987-38999	Neuroscience	_	
205-131	39000-39010	Foundation	_	
205-132	39010-39011	,	_	
205-133	39012-39015	has	_	
205-134	39016-39024	received	_	
205-135	39025-39031	grants	_	
205-136	39032-39034	or	_	
205-137	39035-39043	clinical	_	
205-138	39044-39049	trial	_	
205-139	39050-39058	payments	_	
205-140	39059-39063	from	_	
205-141	39064-39071	P1vital	_	
205-142	39071-39072	,	_	
205-143	39073-39076	MRC	_	
205-144	39076-39077	,	_	
205-145	39078-39081	NHS	_	
205-146	39081-39082	,	_	
205-147	39083-39091	Lundbeck	_	
205-148	39091-39092	,	_	
205-149	39093-39096	has	_	
205-150	39097-39102	share	_	
205-151	39103-39110	options	_	
205-152	39111-39115	with	_	
205-153	39116-39123	P1vital	_	
205-154	39123-39124	,	_	
205-155	39125-39128	has	_	
205-156	39129-39133	been	_	
205-157	39134-39140	expert	_	
205-158	39141-39148	witness	_	
205-159	39149-39151	in	_	
205-160	39152-39153	a	_	
205-161	39154-39160	number	_	
205-162	39161-39163	of	_	
205-163	39164-39169	legal	_	
205-164	39170-39175	cases	_	
205-165	39176-39184	relating	_	
205-166	39185-39187	to	_	
205-167	39188-39200	psychotropic	_	
205-168	39201-39206	drugs	_	
205-169	39206-39207	,	_	
205-170	39208-39211	and	_	
205-171	39212-39215	has	_	
205-172	39216-39222	edited	_	
205-173	39222-39223	/	_	
205-174	39223-39230	written	_	
205-175	39231-39233	27	_	
205-176	39234-39239	books	_	
205-177	39239-39240	,	_	
205-178	39241-39245	some	_	
205-179	39246-39255	purchased	_	
205-180	39256-39258	by	_	
205-181	39259-39273	pharmaceutical	_	
205-182	39274-39283	companies	_	
205-183	39283-39284	.	_	

#Text=BJS consults for Cambridge Cognition, Brainbow (Peak), Servier, Otsuka, and Lundbeck, holds a grant from Janssen/Johnson & Johnson, and has share options in Cambridge Cognition.
206-1	39285-39288	BJS	_	
206-2	39289-39297	consults	_	
206-3	39298-39301	for	_	
206-4	39302-39311	Cambridge	_	
206-5	39312-39321	Cognition	_	
206-6	39321-39322	,	_	
206-7	39323-39331	Brainbow	_	
206-8	39332-39333	(	_	
206-9	39333-39337	Peak	_	
206-10	39337-39338	)	_	
206-11	39338-39339	,	_	
206-12	39340-39347	Servier	_	
206-13	39347-39348	,	_	
206-14	39349-39355	Otsuka	_	
206-15	39355-39356	,	_	
206-16	39357-39360	and	_	
206-17	39361-39369	Lundbeck	_	
206-18	39369-39370	,	_	
206-19	39371-39376	holds	_	
206-20	39377-39378	a	_	
206-21	39379-39384	grant	_	
206-22	39385-39389	from	_	
206-23	39390-39397	Janssen	_	
206-24	39397-39398	/	_	
206-25	39398-39405	Johnson	_	
206-26	39406-39407	&	_	
206-27	39408-39415	Johnson	_	
206-28	39415-39416	,	_	
206-29	39417-39420	and	_	
206-30	39421-39424	has	_	
206-31	39425-39430	share	_	
206-32	39431-39438	options	_	
206-33	39439-39441	in	_	
206-34	39442-39451	Cambridge	_	
206-35	39452-39461	Cognition	_	
206-36	39461-39462	.	_	

#Text=Trevor Robbins has had research grants with Eli Lilly and Lundbeck, has received royalties from Cambridge Cognition (CANTAB), has received editorial honoraria from Springer Verlag, Elsevier, Society for Neuroscience; has performed educational lectures for Merck, Sharpe and Dohme and does consultancy work for Cambridge Cognition, Eli Lilly, Lundbeck, Teva and Shire Pharmaceuticals.
207-1	39463-39469	Trevor	_	
207-2	39470-39477	Robbins	_	
207-3	39478-39481	has	_	
207-4	39482-39485	had	_	
207-5	39486-39494	research	_	
207-6	39495-39501	grants	_	
207-7	39502-39506	with	_	
207-8	39507-39510	Eli	_	
207-9	39511-39516	Lilly	_	
207-10	39517-39520	and	_	
207-11	39521-39529	Lundbeck	_	
207-12	39529-39530	,	_	
207-13	39531-39534	has	_	
207-14	39535-39543	received	_	
207-15	39544-39553	royalties	_	
207-16	39554-39558	from	_	
207-17	39559-39568	Cambridge	_	
207-18	39569-39578	Cognition	_	
207-19	39579-39580	(	_	
207-20	39580-39586	CANTAB	_	
207-21	39586-39587	)	_	
207-22	39587-39588	,	_	
207-23	39589-39592	has	_	
207-24	39593-39601	received	_	
207-25	39602-39611	editorial	_	
207-26	39612-39621	honoraria	_	
207-27	39622-39626	from	_	
207-28	39627-39635	Springer	_	
207-29	39636-39642	Verlag	_	
207-30	39642-39643	,	_	
207-31	39644-39652	Elsevier	_	
207-32	39652-39653	,	_	
207-33	39654-39661	Society	_	
207-34	39662-39665	for	_	
207-35	39666-39678	Neuroscience	_	
207-36	39678-39679	;	_	
207-37	39680-39683	has	_	
207-38	39684-39693	performed	_	
207-39	39694-39705	educational	_	
207-40	39706-39714	lectures	_	
207-41	39715-39718	for	_	
207-42	39719-39724	Merck	_	
207-43	39724-39725	,	_	
207-44	39726-39732	Sharpe	_	
207-45	39733-39736	and	_	
207-46	39737-39742	Dohme	_	
207-47	39743-39746	and	_	
207-48	39747-39751	does	_	
207-49	39752-39763	consultancy	_	
207-50	39764-39768	work	_	
207-51	39769-39772	for	_	
207-52	39773-39782	Cambridge	_	
207-53	39783-39792	Cognition	_	
207-54	39792-39793	,	_	
207-55	39794-39797	Eli	_	
207-56	39798-39803	Lilly	_	
207-57	39803-39804	,	_	
207-58	39805-39813	Lundbeck	_	
207-59	39813-39814	,	_	
207-60	39815-39819	Teva	_	
207-61	39820-39823	and	_	
207-62	39824-39829	Shire	_	
207-63	39830-39845	Pharmaceuticals	_	
207-64	39845-39846	.	_	

#Text=The remaining authors declare no conflict of interest.
208-1	39847-39850	The	_	
208-2	39851-39860	remaining	_	
208-3	39861-39868	authors	_	
208-4	39869-39876	declare	_	
208-5	39877-39879	no	_	
208-6	39880-39888	conflict	_	
208-7	39889-39891	of	_	
208-8	39892-39900	interest	_	
208-9	39900-39901	.	_	

#Text=Neural circuitry of impaired emotion regulation in substance use disorders
#Text=Experience of emotions in substance abusers exposed to images containing neutral, positive, and negative affective stimuli
#Text=In the face of threat: neural and endocrine correlates of impaired facial emotion recognition in cocaine dependence
#Text=Reward craving and withdrawal relief craving: assessment of different motivational pathways to alcohol intake
#Text=Alcohol abuse and dependence symptoms: A multidimensional model of common and specific etiology
#Text=Pharmacogenetic approaches to the treatment of alcohol addiction
#Text=Translating the neuroscience of alcoholism into clinical treatments: From blocking the buzz to curing the blues
#Text=Drug abuse: hedonic homeostatic dysregulation
#Text=Drug addiction, dysregulation of reward, and allostasis
#Text=Divergent responses of the amygdala and ventral striatum predict stress-related problem drinking in young adults: possible differential markers of affective and impulsive pathways of risk for alcohol use disorder
#Text=Childhood maltreatment and amygdala connectivity in methamphetamine dependence
#Text=Basal hippocampal activity and its functional connectivity predicts cocaine relapse
#Text=Stress signalling pathways that impair prefrontal cortex structure and function
#Text=Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
#Text=Emotional processing in anterior cingulate and medial prefrontal cortex
#Text=Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli
#Text=BAP update guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
#Text=mu-Opioid receptors and limbic responses to aversive emotional stimuli
#Text=Naltrexone alters the processing of social and emotional stimuli in healthy adults
#Text=Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval II
#Text=Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure
#Text=Withdrawal from acute morphine dependence is accompanied by increased anxiety-like behaviour in the elevated plus maze
#Text=Repeated experience with naloxone facilitates acute morphine withdrawal: potential role for conditioning processes in acute opioid dependence
#Text=Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment
#Text=Effects of naltrexone on cue-elicited craving for alcohol and cocaine
#Text=Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol
#Text=Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis
#Text=Altered central and μ-opioid receptor binding after psychological trauma
#Text=The response to naltrexone in ethanol-drinking rats depends on early environmental experiences
#Text=A study of the relationship between child abuse and drug addiction in 178 patients: preliminary results
#Text=The role of early life stress as a predictor for alcohol and drug dependence
#Text=Childhood victimization and illicit drug use in middle adulthood
#Text=Childhood adversities and adult psychopathology in the WHO World Mental Healthy Surveys
#Text=Patterns of use of other drugs among those with alcohol dependence: associations with drinking behaviour and psychopathology
#Text=Genetic heterogeneity and the classification of alcoholism
#Text=Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment
#Text=Polydrug use and implications for longitudinal research: ten-year trajectories for heroin, cocaine, and methamphetamine users
#Text=The differences in neural network activity between methamphetamine abusers and healthy subjects performing an emotion-matching task: functional MRI study
#Text=Modulation of brain response to emotional images by alcohol cues in alcohol-dependent patients
#Text=The Imperial College Cambridge Manchester (ICCAM) platform study: an experimental medicine platform for evaluating new drugs for relapse prevention in addiction.
209-1	39902-39908	Neural	_	
209-2	39909-39918	circuitry	_	
209-3	39919-39921	of	_	
209-4	39922-39930	impaired	_	
209-5	39931-39938	emotion	_	
209-6	39939-39949	regulation	_	
209-7	39950-39952	in	_	
209-8	39953-39962	substance	_	
209-9	39963-39966	use	_	
209-10	39967-39976	disorders	_	
209-11	39977-39987	Experience	_	
209-12	39988-39990	of	_	
209-13	39991-39999	emotions	_	
209-14	40000-40002	in	_	
209-15	40003-40012	substance	_	
209-16	40013-40020	abusers	_	
209-17	40021-40028	exposed	_	
209-18	40029-40031	to	_	
209-19	40032-40038	images	_	
209-20	40039-40049	containing	_	
209-21	40050-40057	neutral	_	
209-22	40057-40058	,	_	
209-23	40059-40067	positive	_	
209-24	40067-40068	,	_	
209-25	40069-40072	and	_	
209-26	40073-40081	negative	_	
209-27	40082-40091	affective	_	
209-28	40092-40099	stimuli	_	
209-29	40100-40102	In	_	
209-30	40103-40106	the	_	
209-31	40107-40111	face	_	
209-32	40112-40114	of	_	
209-33	40115-40121	threat	_	
209-34	40121-40122	:	_	
209-35	40123-40129	neural	_	
209-36	40130-40133	and	_	
209-37	40134-40143	endocrine	_	
209-38	40144-40154	correlates	_	
209-39	40155-40157	of	_	
209-40	40158-40166	impaired	_	
209-41	40167-40173	facial	_	
209-42	40174-40181	emotion	_	
209-43	40182-40193	recognition	_	
209-44	40194-40196	in	_	
209-45	40197-40204	cocaine	_	
209-46	40205-40215	dependence	_	
209-47	40216-40222	Reward	_	
209-48	40223-40230	craving	_	
209-49	40231-40234	and	_	
209-50	40235-40245	withdrawal	_	
209-51	40246-40252	relief	_	
209-52	40253-40260	craving	_	
209-53	40260-40261	:	_	
209-54	40262-40272	assessment	_	
209-55	40273-40275	of	_	
209-56	40276-40285	different	_	
209-57	40286-40298	motivational	_	
209-58	40299-40307	pathways	_	
209-59	40308-40310	to	_	
209-60	40311-40318	alcohol	_	
209-61	40319-40325	intake	_	
209-62	40326-40333	Alcohol	_	
209-63	40334-40339	abuse	_	
209-64	40340-40343	and	_	
209-65	40344-40354	dependence	_	
209-66	40355-40363	symptoms	_	
209-67	40363-40364	:	_	
209-68	40365-40366	A	_	
209-69	40367-40383	multidimensional	_	
209-70	40384-40389	model	_	
209-71	40390-40392	of	_	
209-72	40393-40399	common	_	
209-73	40400-40403	and	_	
209-74	40404-40412	specific	_	
209-75	40413-40421	etiology	_	
209-76	40422-40437	Pharmacogenetic	_	
209-77	40438-40448	approaches	_	
209-78	40449-40451	to	_	
209-79	40452-40455	the	_	
209-80	40456-40465	treatment	_	
209-81	40466-40468	of	_	
209-82	40469-40476	alcohol	_	
209-83	40477-40486	addiction	_	
209-84	40487-40498	Translating	_	
209-85	40499-40502	the	_	
209-86	40503-40515	neuroscience	_	
209-87	40516-40518	of	_	
209-88	40519-40529	alcoholism	_	
209-89	40530-40534	into	_	
209-90	40535-40543	clinical	_	
209-91	40544-40554	treatments	_	
209-92	40554-40555	:	_	
209-93	40556-40560	From	_	
209-94	40561-40569	blocking	_	
209-95	40570-40573	the	_	
209-96	40574-40578	buzz	_	
209-97	40579-40581	to	_	
209-98	40582-40588	curing	_	
209-99	40589-40592	the	_	
209-100	40593-40598	blues	_	
209-101	40599-40603	Drug	_	
209-102	40604-40609	abuse	_	
209-103	40609-40610	:	_	
209-104	40611-40618	hedonic	_	
209-105	40619-40630	homeostatic	_	
209-106	40631-40644	dysregulation	_	
209-107	40645-40649	Drug	_	
209-108	40650-40659	addiction	_	
209-109	40659-40660	,	_	
209-110	40661-40674	dysregulation	_	
209-111	40675-40677	of	_	
209-112	40678-40684	reward	_	
209-113	40684-40685	,	_	
209-114	40686-40689	and	_	
209-115	40690-40700	allostasis	_	
209-116	40701-40710	Divergent	_	
209-117	40711-40720	responses	_	
209-118	40721-40723	of	_	
209-119	40724-40727	the	_	
209-120	40728-40736	amygdala	_	
209-121	40737-40740	and	_	
209-122	40741-40748	ventral	_	
209-123	40749-40757	striatum	_	
209-124	40758-40765	predict	_	
209-125	40766-40780	stress-related	_	
209-126	40781-40788	problem	_	
209-127	40789-40797	drinking	_	
209-128	40798-40800	in	_	
209-129	40801-40806	young	_	
209-130	40807-40813	adults	_	
209-131	40813-40814	:	_	
209-132	40815-40823	possible	_	
209-133	40824-40836	differential	_	
209-134	40837-40844	markers	_	
209-135	40845-40847	of	_	
209-136	40848-40857	affective	_	
209-137	40858-40861	and	_	
209-138	40862-40871	impulsive	_	
209-139	40872-40880	pathways	_	
209-140	40881-40883	of	_	
209-141	40884-40888	risk	_	
209-142	40889-40892	for	_	
209-143	40893-40900	alcohol	_	
209-144	40901-40904	use	_	
209-145	40905-40913	disorder	_	
209-146	40914-40923	Childhood	_	
209-147	40924-40936	maltreatment	_	
209-148	40937-40940	and	_	
209-149	40941-40949	amygdala	_	
209-150	40950-40962	connectivity	_	
209-151	40963-40965	in	_	
209-152	40966-40981	methamphetamine	_	
209-153	40982-40992	dependence	_	
209-154	40993-40998	Basal	_	
209-155	40999-41010	hippocampal	_	
209-156	41011-41019	activity	_	
209-157	41020-41023	and	_	
209-158	41024-41027	its	_	
209-159	41028-41038	functional	_	
209-160	41039-41051	connectivity	_	
209-161	41052-41060	predicts	_	
209-162	41061-41068	cocaine	_	
209-163	41069-41076	relapse	_	
209-164	41077-41083	Stress	_	
209-165	41084-41094	signalling	_	
209-166	41095-41103	pathways	_	
209-167	41104-41108	that	_	
209-168	41109-41115	impair	_	
209-169	41116-41126	prefrontal	_	
209-170	41127-41133	cortex	_	
209-171	41134-41143	structure	_	
209-172	41144-41147	and	_	
209-173	41148-41156	function	_	
209-174	41157-41168	Dysfunction	_	
209-175	41169-41171	of	_	
209-176	41172-41175	the	_	
209-177	41176-41186	prefrontal	_	
209-178	41187-41193	cortex	_	
209-179	41194-41196	in	_	
209-180	41197-41206	addiction	_	
209-181	41206-41207	:	_	
209-182	41208-41220	neuroimaging	_	
209-183	41221-41229	findings	_	
209-184	41230-41233	and	_	
209-185	41234-41242	clinical	_	
209-186	41243-41255	implications	_	
209-187	41256-41265	Emotional	_	
209-188	41266-41276	processing	_	
209-189	41277-41279	in	_	
209-190	41280-41288	anterior	_	
209-191	41289-41298	cingulate	_	
209-192	41299-41302	and	_	
209-193	41303-41309	medial	_	
209-194	41310-41320	prefrontal	_	
209-195	41321-41327	cortex	_	
209-196	41328-41339	Cue-induced	_	
209-197	41340-41347	cocaine	_	
209-198	41348-41355	craving	_	
209-199	41355-41356	:	_	
209-200	41357-41372	neuroanatomical	_	
209-201	41373-41384	specificity	_	
209-202	41385-41388	for	_	
209-203	41389-41393	drug	_	
209-204	41394-41399	users	_	
209-205	41400-41403	and	_	
209-206	41404-41408	drug	_	
209-207	41409-41416	stimuli	_	
209-208	41417-41420	BAP	_	
209-209	41421-41427	update	_	
209-210	41428-41438	guidelines	_	
209-211	41438-41439	:	_	
209-212	41440-41454	evidence-based	_	
209-213	41455-41465	guidelines	_	
209-214	41466-41469	for	_	
209-215	41470-41473	the	_	
209-216	41474-41489	pharmacological	_	
209-217	41490-41500	management	_	
209-218	41501-41503	of	_	
209-219	41504-41513	substance	_	
209-220	41514-41519	abuse	_	
209-221	41519-41520	,	_	
209-222	41521-41528	harmful	_	
209-223	41529-41532	use	_	
209-224	41532-41533	,	_	
209-225	41534-41543	addiction	_	
209-226	41544-41547	and	_	
209-227	41548-41559	comorbidity	_	
209-228	41559-41560	:	_	
209-229	41561-41576	recommendations	_	
209-230	41577-41581	from	_	
209-231	41582-41585	BAP	_	
209-232	41586-41595	mu-Opioid	_	
209-233	41596-41605	receptors	_	
209-234	41606-41609	and	_	
209-235	41610-41616	limbic	_	
209-236	41617-41626	responses	_	
209-237	41627-41629	to	_	
209-238	41630-41638	aversive	_	
209-239	41639-41648	emotional	_	
209-240	41649-41656	stimuli	_	
209-241	41657-41667	Naltrexone	_	
209-242	41668-41674	alters	_	
209-243	41675-41678	the	_	
209-244	41679-41689	processing	_	
209-245	41690-41692	of	_	
209-246	41693-41699	social	_	
209-247	41700-41703	and	_	
209-248	41704-41713	emotional	_	
209-249	41714-41721	stimuli	_	
209-250	41722-41724	in	_	
209-251	41725-41732	healthy	_	
209-252	41733-41739	adults	_	
209-253	41740-41745	Acute	_	
209-254	41746-41752	opioid	_	
209-255	41753-41761	physical	_	
209-256	41762-41772	dependence	_	
209-257	41773-41775	in	_	
209-258	41776-41782	humans	_	
209-259	41782-41783	:	_	
209-260	41784-41790	effect	_	
209-261	41791-41793	of	_	
209-262	41794-41801	varying	_	
209-263	41802-41805	the	_	
209-264	41806-41823	morphine-naloxone	_	
209-265	41824-41832	interval	_	
209-266	41833-41835	II	_	
209-267	41836-41841	Acute	_	
209-268	41842-41848	opioid	_	
209-269	41849-41857	physical	_	
209-270	41858-41868	dependence	_	
209-271	41869-41871	in	_	
209-272	41872-41882	postaddict	_	
209-273	41883-41889	humans	_	
209-274	41889-41890	:	_	
209-275	41891-41899	naloxone	_	
209-276	41900-41904	dose	_	
209-277	41905-41912	effects	_	
209-278	41913-41918	after	_	
209-279	41919-41924	brief	_	
209-280	41925-41933	morphine	_	
209-281	41934-41942	exposure	_	
209-282	41943-41953	Withdrawal	_	
209-283	41954-41958	from	_	
209-284	41959-41964	acute	_	
209-285	41965-41973	morphine	_	
209-286	41974-41984	dependence	_	
209-287	41985-41987	is	_	
209-288	41988-41999	accompanied	_	
209-289	42000-42002	by	_	
209-290	42003-42012	increased	_	
209-291	42013-42025	anxiety-like	_	
209-292	42026-42035	behaviour	_	
209-293	42036-42038	in	_	
209-294	42039-42042	the	_	
209-295	42043-42051	elevated	_	
209-296	42052-42056	plus	_	
209-297	42057-42061	maze	_	
209-298	42062-42070	Repeated	_	
209-299	42071-42081	experience	_	
209-300	42082-42086	with	_	
209-301	42087-42095	naloxone	_	
209-302	42096-42107	facilitates	_	
209-303	42108-42113	acute	_	
209-304	42114-42122	morphine	_	
209-305	42123-42133	withdrawal	_	
209-306	42133-42134	:	_	
209-307	42135-42144	potential	_	
209-308	42145-42149	role	_	
209-309	42150-42153	for	_	
209-310	42154-42166	conditioning	_	
209-311	42167-42176	processes	_	
209-312	42177-42179	in	_	
209-313	42180-42185	acute	_	
209-314	42186-42192	opioid	_	
209-315	42193-42203	dependence	_	
209-316	42204-42210	Stress	_	
209-317	42211-42214	and	_	
209-318	42215-42231	drug-cue-induced	_	
209-319	42232-42239	craving	_	
209-320	42240-42242	in	_	
209-321	42243-42259	opioid-dependent	_	
209-322	42260-42271	individuals	_	
209-323	42272-42274	in	_	
209-324	42275-42285	naltrexone	_	
209-325	42286-42295	treatment	_	
209-326	42296-42303	Effects	_	
209-327	42304-42306	of	_	
209-328	42307-42317	naltrexone	_	
209-329	42318-42320	on	_	
209-330	42321-42333	cue-elicited	_	
209-331	42334-42341	craving	_	
209-332	42342-42345	for	_	
209-333	42346-42353	alcohol	_	
209-334	42354-42357	and	_	
209-335	42358-42365	cocaine	_	
209-336	42366-42376	Naltrexone	_	
209-337	42377-42385	aversion	_	
209-338	42386-42389	and	_	
209-339	42390-42399	treatment	_	
209-340	42400-42408	efficacy	_	
209-341	42409-42412	are	_	
209-342	42413-42421	greatest	_	
209-343	42422-42424	in	_	
209-344	42425-42431	humans	_	
209-345	42432-42435	and	_	
209-346	42436-42440	rats	_	
209-347	42441-42445	that	_	
209-348	42446-42454	actively	_	
209-349	42455-42462	consume	_	
209-350	42463-42467	high	_	
209-351	42468-42474	levels	_	
209-352	42475-42477	of	_	
209-353	42478-42485	alcohol	_	
209-354	42486-42496	Naltrexone	_	
209-355	42497-42506	decreases	_	
209-356	42507-42514	craving	_	
209-357	42515-42518	and	_	
209-358	42519-42526	alcohol	_	
209-359	42527-42546	self-administration	_	
209-360	42547-42549	in	_	
209-361	42550-42567	alcohol-dependent	_	
209-362	42568-42576	subjects	_	
209-363	42577-42580	and	_	
209-364	42581-42590	activates	_	
209-365	42591-42594	the	_	
209-366	42595-42631	hypothalamo-pituitary-adrenocortical	_	
209-367	42632-42636	axis	_	
209-368	42637-42644	Altered	_	
209-369	42645-42652	central	_	
209-370	42653-42656	and	_	
209-371	42657-42665	μ-opioid	_	
209-372	42666-42674	receptor	_	
209-373	42675-42682	binding	_	
209-374	42683-42688	after	_	
209-375	42689-42702	psychological	_	
209-376	42703-42709	trauma	_	
209-377	42710-42713	The	_	
209-378	42714-42722	response	_	
209-379	42723-42725	to	_	
209-380	42726-42736	naltrexone	_	
209-381	42737-42739	in	_	
209-382	42740-42756	ethanol-drinking	_	
209-383	42757-42761	rats	_	
209-384	42762-42769	depends	_	
209-385	42770-42772	on	_	
209-386	42773-42778	early	_	
209-387	42779-42792	environmental	_	
209-388	42793-42804	experiences	_	
209-389	42805-42806	A	_	
209-390	42807-42812	study	_	
209-391	42813-42815	of	_	
209-392	42816-42819	the	_	
209-393	42820-42832	relationship	_	
209-394	42833-42840	between	_	
209-395	42841-42846	child	_	
209-396	42847-42852	abuse	_	
209-397	42853-42856	and	_	
209-398	42857-42861	drug	_	
209-399	42862-42871	addiction	_	
209-400	42872-42874	in	_	
209-401	42875-42878	178	_	
209-402	42879-42887	patients	_	
209-403	42887-42888	:	_	
209-404	42889-42900	preliminary	_	
209-405	42901-42908	results	_	
209-406	42909-42912	The	_	
209-407	42913-42917	role	_	
209-408	42918-42920	of	_	
209-409	42921-42926	early	_	
209-410	42927-42931	life	_	
209-411	42932-42938	stress	_	
209-412	42939-42941	as	_	
209-413	42942-42943	a	_	
209-414	42944-42953	predictor	_	
209-415	42954-42957	for	_	
209-416	42958-42965	alcohol	_	
209-417	42966-42969	and	_	
209-418	42970-42974	drug	_	
209-419	42975-42985	dependence	_	
209-420	42986-42995	Childhood	_	
209-421	42996-43009	victimization	_	
209-422	43010-43013	and	_	
209-423	43014-43021	illicit	_	
209-424	43022-43026	drug	_	
209-425	43027-43030	use	_	
209-426	43031-43033	in	_	
209-427	43034-43040	middle	_	
209-428	43041-43050	adulthood	_	
209-429	43051-43060	Childhood	_	
209-430	43061-43072	adversities	_	
209-431	43073-43076	and	_	
209-432	43077-43082	adult	_	
209-433	43083-43098	psychopathology	_	
209-434	43099-43101	in	_	
209-435	43102-43105	the	_	
209-436	43106-43109	WHO	_	
209-437	43110-43115	World	_	
209-438	43116-43122	Mental	_	
209-439	43123-43130	Healthy	_	
209-440	43131-43138	Surveys	_	
209-441	43139-43147	Patterns	_	
209-442	43148-43150	of	_	
209-443	43151-43154	use	_	
209-444	43155-43157	of	_	
209-445	43158-43163	other	_	
209-446	43164-43169	drugs	_	
209-447	43170-43175	among	_	
209-448	43176-43181	those	_	
209-449	43182-43186	with	_	
209-450	43187-43194	alcohol	_	
209-451	43195-43205	dependence	_	
209-452	43205-43206	:	_	
209-453	43207-43219	associations	_	
209-454	43220-43224	with	_	
209-455	43225-43233	drinking	_	
209-456	43234-43243	behaviour	_	
209-457	43244-43247	and	_	
209-458	43248-43263	psychopathology	_	
209-459	43264-43271	Genetic	_	
209-460	43272-43285	heterogeneity	_	
209-461	43286-43289	and	_	
209-462	43290-43293	the	_	
209-463	43294-43308	classification	_	
209-464	43309-43311	of	_	
209-465	43312-43322	alcoholism	_	
209-466	43323-43336	Heterogeneity	_	
209-467	43337-43339	of	_	
209-468	43340-43347	alcohol	_	
209-469	43348-43351	use	_	
209-470	43352-43360	disorder	_	
209-471	43360-43361	:	_	
209-472	43362-43375	understanding	_	
209-473	43376-43386	mechanisms	_	
209-474	43387-43389	to	_	
209-475	43390-43397	advance	_	
209-476	43398-43410	personalized	_	
209-477	43411-43420	treatment	_	
209-478	43421-43429	Polydrug	_	
209-479	43430-43433	use	_	
209-480	43434-43437	and	_	
209-481	43438-43450	implications	_	
209-482	43451-43454	for	_	
209-483	43455-43467	longitudinal	_	
209-484	43468-43476	research	_	
209-485	43476-43477	:	_	
209-486	43478-43486	ten-year	_	
209-487	43487-43499	trajectories	_	
209-488	43500-43503	for	_	
209-489	43504-43510	heroin	_	
209-490	43510-43511	,	_	
209-491	43512-43519	cocaine	_	
209-492	43519-43520	,	_	
209-493	43521-43524	and	_	
209-494	43525-43540	methamphetamine	_	
209-495	43541-43546	users	_	
209-496	43547-43550	The	_	
209-497	43551-43562	differences	_	
209-498	43563-43565	in	_	
209-499	43566-43572	neural	_	
209-500	43573-43580	network	_	
209-501	43581-43589	activity	_	
209-502	43590-43597	between	_	
209-503	43598-43613	methamphetamine	_	
209-504	43614-43621	abusers	_	
209-505	43622-43625	and	_	
209-506	43626-43633	healthy	_	
209-507	43634-43642	subjects	_	
209-508	43643-43653	performing	_	
209-509	43654-43656	an	_	
209-510	43657-43673	emotion-matching	_	
209-511	43674-43678	task	_	
209-512	43678-43679	:	_	
209-513	43680-43690	functional	_	
209-514	43691-43694	MRI	_	
209-515	43695-43700	study	_	
209-516	43701-43711	Modulation	_	
209-517	43712-43714	of	_	
209-518	43715-43720	brain	_	
209-519	43721-43729	response	_	
209-520	43730-43732	to	_	
209-521	43733-43742	emotional	_	
209-522	43743-43749	images	_	
209-523	43750-43752	by	_	
209-524	43753-43760	alcohol	_	
209-525	43761-43765	cues	_	
209-526	43766-43768	in	_	
209-527	43769-43786	alcohol-dependent	_	
209-528	43787-43795	patients	_	
209-529	43796-43799	The	_	
209-530	43800-43808	Imperial	_	
209-531	43809-43816	College	_	
209-532	43817-43826	Cambridge	_	
209-533	43827-43837	Manchester	_	
209-534	43838-43839	(	_	
209-535	43839-43844	ICCAM	_	
209-536	43844-43845	)	_	
209-537	43846-43854	platform	_	
209-538	43855-43860	study	_	
209-539	43860-43861	:	_	
209-540	43862-43864	an	_	
209-541	43865-43877	experimental	_	
209-542	43878-43886	medicine	_	
209-543	43887-43895	platform	_	
209-544	43896-43899	for	_	
209-545	43900-43910	evaluating	_	
209-546	43911-43914	new	_	
209-547	43915-43920	drugs	_	
209-548	43921-43924	for	_	
209-549	43925-43932	relapse	_	
209-550	43933-43943	prevention	_	
209-551	43944-43946	in	_	
209-552	43947-43956	addiction	_	
209-553	43956-43957	.	_	

#Text=Part A: study description
#Text=The ICCAM platform study: an experimental platform study for evaluating new drugs for relapse prevention in addiction.
210-1	43958-43962	Part	_	
210-2	43963-43964	A	_	
210-3	43964-43965	:	_	
210-4	43966-43971	study	_	
210-5	43972-43983	description	_	
210-6	43984-43987	The	_	
210-7	43988-43993	ICCAM	_	
210-8	43994-44002	platform	_	
210-9	44003-44008	study	_	
210-10	44008-44009	:	_	
210-11	44010-44012	an	_	
210-12	44013-44025	experimental	_	
210-13	44026-44034	platform	_	
210-14	44035-44040	study	_	
210-15	44041-44044	for	_	
210-16	44045-44055	evaluating	_	
210-17	44056-44059	new	_	
210-18	44060-44065	drugs	_	
210-19	44066-44069	for	_	
210-20	44070-44077	relapse	_	
210-21	44078-44088	prevention	_	
210-22	44089-44091	in	_	
210-23	44092-44101	addiction	_	
210-24	44101-44102	.	_	

#Text=Part B: fMRI description
#Text=Impulsivity in abstinent alcohol and polydrug dependence: a multidimensional approach
#Text=
#Text=Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task
#Text=Structural brain differences in alcohol-dependent individuals with and without comorbid substance dependence
#Text=Alcohol and drug use and the developing brain
#Text=The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings
#Text=
#Text=A global measure of perceived stress
#Text=
#Text=Who do you think is in control in addiction?
211-1	44103-44107	Part	_	
211-2	44108-44109	B	_	
211-3	44109-44110	:	_	
211-4	44111-44115	fMRI	_	
211-5	44116-44127	description	_	
211-6	44128-44139	Impulsivity	_	
211-7	44140-44142	in	_	
211-8	44143-44152	abstinent	_	
211-9	44153-44160	alcohol	_	
211-10	44161-44164	and	_	
211-11	44165-44173	polydrug	_	
211-12	44174-44184	dependence	_	
211-13	44184-44185	:	_	
211-14	44186-44187	a	_	
211-15	44188-44204	multidimensional	_	
211-16	44205-44213	approach	_	
211-17	44215-44220	Acute	_	
211-18	44221-44231	naltrexone	_	
211-19	44232-44236	does	_	
211-20	44237-44240	not	_	
211-21	44241-44250	remediate	_	
211-22	44251-44266	fronto-striatal	_	
211-23	44267-44279	disturbances	_	
211-24	44280-44282	in	_	
211-25	44283-44292	alcoholic	_	
211-26	44293-44296	and	_	
211-27	44297-44306	alcoholic	_	
211-28	44307-44330	polysubstance-dependent	_	
211-29	44331-44342	populations	_	
211-30	44343-44349	during	_	
211-31	44350-44351	a	_	
211-32	44352-44360	monetary	_	
211-33	44361-44370	incentive	_	
211-34	44371-44376	delay	_	
211-35	44377-44381	task	_	
211-36	44382-44392	Structural	_	
211-37	44393-44398	brain	_	
211-38	44399-44410	differences	_	
211-39	44411-44413	in	_	
211-40	44414-44431	alcohol-dependent	_	
211-41	44432-44443	individuals	_	
211-42	44444-44448	with	_	
211-43	44449-44452	and	_	
211-44	44453-44460	without	_	
211-45	44461-44469	comorbid	_	
211-46	44470-44479	substance	_	
211-47	44480-44490	dependence	_	
211-48	44491-44498	Alcohol	_	
211-49	44499-44502	and	_	
211-50	44503-44507	drug	_	
211-51	44508-44511	use	_	
211-52	44512-44515	and	_	
211-53	44516-44519	the	_	
211-54	44520-44530	developing	_	
211-55	44531-44536	brain	_	
211-56	44537-44540	The	_	
211-57	44541-44548	Alcohol	_	
211-58	44549-44552	Use	_	
211-59	44553-44562	Disorders	_	
211-60	44563-44577	Identification	_	
211-61	44578-44582	Test	_	
211-62	44583-44584	(	_	
211-63	44584-44589	AUDIT	_	
211-64	44589-44590	)	_	
211-65	44590-44591	:	_	
211-66	44592-44602	validation	_	
211-67	44603-44605	of	_	
211-68	44606-44607	a	_	
211-69	44608-44617	screening	_	
211-70	44618-44628	instrument	_	
211-71	44629-44632	for	_	
211-72	44633-44636	use	_	
211-73	44637-44639	in	_	
211-74	44640-44647	medical	_	
211-75	44648-44656	settings	_	
211-76	44658-44659	A	_	
211-77	44660-44666	global	_	
211-78	44667-44674	measure	_	
211-79	44675-44677	of	_	
211-80	44678-44687	perceived	_	
211-81	44688-44694	stress	_	
211-82	44696-44699	Who	_	
211-83	44700-44702	do	_	
211-84	44703-44706	you	_	
211-85	44707-44712	think	_	
211-86	44713-44715	is	_	
211-87	44716-44718	in	_	
211-88	44719-44726	control	_	
211-89	44727-44729	in	_	
211-90	44730-44739	addiction	_	
211-91	44739-44740	?	_	

#Text=A pilot study on drug-related locus of control beliefs
#Text=Interaction between family history of alcoholism and locus of control in the opioid regulation of impulsive responding under the influence of alcohol
#Text=Generalized expectancies for internal versus external control of reinforcement
#Text=
#Text=
#Text=Testing for anatomically specified regional effects
#Text=Region of interest anlysis for fMRI
#Text=Indepndence in ROI analyses: where is the voodoo
#Text=A unified statistical approach for determining significant signals in images of cerbral activation
#Text=Smaller amygdala and medial prefrontal cortex predict escalating stimulant use
#Text=Childhood trauma and neural responses to personalized stress, favorite-food and neutral-relaxing cues in adolescents
#Text=Localization of Mu and delta opioid receptors to anterior cingulate afferents and projection neurons and input/output model of Mu regulation
#Text=Modeling regional an and psychophysiologic interactions in fMRI: the importance of hemodynamic deconvolution
#Text=Plasticity of reward neurocicruitry and the ‘dark side' of drug addiction
#Text=Exploring the relationship between childhood maltreatment and addiction: a review of the neurocognitive evidence
#Text=Child maltreatment and neural systems underlying emotion regulation
#Text=Effects of childhood maltreatment on the neural correlates of stress- and drug cue-induced cocaine craving
#Text=Emotional, physical and sexual abuse are associated with a heightened limbic response to cocaine cues
#Text=Neuroimaging studies of mood disorders
#Text=Systems reconsolidation reveals a selective role for the anterior cingulate cortex in generalized contextual fear memory expression
#Text=Structural and functional connectivity in posttraumatic stress disorder: associations with FKBP5
#Text=Ethanol-induced effects on opioid peptides in adult male Wistar rats are dependent on early environmental factors
#Text=The impact of postnatal environment on opioid peptides in young and adult male Wistar rats
#Text=Activation of prefrontal cortex and anterior thalamus in alcoholic subjects on exposure to alcohol-specific cues
#Text=Activation of memory circuits during cue-elicited cocaine craving
#Text=Limbic activation during cue-induced cocaine craving
#Text=Dysfunction of reward processing correlates with alcohol craving in detoxified alcoholics
#Text=Functional magnetic resonance imaging of cocaine craving
#Text=Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving
#Text=Increased mu opioid receptor binding detected by PET in cocaine-dependent men associated with cocaine craving
#Text=Brain opioid receptor binding in early abstinence from opioid dependence: positron emission tomography
#Text=Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects
#Text=Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeld carfentanil
#Text=The dark side of emotion: the addiction perspective
#Text=Alcohol-induced plasticity in the dynorphin/kappa-opioid receptor system
#Text=The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors
#Text=The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse
#Text=Role of kappa-opioid receptors in stress and anxiety-related behaviour
#Text=Dynorphin, dysphoria, and dependence: the stress of addiction
#Text=Opioid antagonists for alcohol dependence
#Text=Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review
#Text=Oral naltrexone maintenance treatment for opioid dependence
#Text=Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies
#Text=Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis
#Text=Neural correlates of emotional processing in depression: changes with cognitive behavioral therapy and predictors of treatment response
#Text=Cognitive behavioral therapy for depression changes medial prefrontal and ventral anterior cingulate cortex activity associated with self-referential processing
#Text=Naltrexone and coping skills therapy for alcohol dependence.
212-1	44741-44742	A	_	
212-2	44743-44748	pilot	_	
212-3	44749-44754	study	_	
212-4	44755-44757	on	_	
212-5	44758-44770	drug-related	_	
212-6	44771-44776	locus	_	
212-7	44777-44779	of	_	
212-8	44780-44787	control	_	
212-9	44788-44795	beliefs	_	
212-10	44796-44807	Interaction	_	
212-11	44808-44815	between	_	
212-12	44816-44822	family	_	
212-13	44823-44830	history	_	
212-14	44831-44833	of	_	
212-15	44834-44844	alcoholism	_	
212-16	44845-44848	and	_	
212-17	44849-44854	locus	_	
212-18	44855-44857	of	_	
212-19	44858-44865	control	_	
212-20	44866-44868	in	_	
212-21	44869-44872	the	_	
212-22	44873-44879	opioid	_	
212-23	44880-44890	regulation	_	
212-24	44891-44893	of	_	
212-25	44894-44903	impulsive	_	
212-26	44904-44914	responding	_	
212-27	44915-44920	under	_	
212-28	44921-44924	the	_	
212-29	44925-44934	influence	_	
212-30	44935-44937	of	_	
212-31	44938-44945	alcohol	_	
212-32	44946-44957	Generalized	_	
212-33	44958-44970	expectancies	_	
212-34	44971-44974	for	_	
212-35	44975-44983	internal	_	
212-36	44984-44990	versus	_	
212-37	44991-44999	external	_	
212-38	45000-45007	control	_	
212-39	45008-45010	of	_	
212-40	45011-45024	reinforcement	_	
212-41	45027-45034	Testing	_	
212-42	45035-45038	for	_	
212-43	45039-45051	anatomically	_	
212-44	45052-45061	specified	_	
212-45	45062-45070	regional	_	
212-46	45071-45078	effects	_	
212-47	45079-45085	Region	_	
212-48	45086-45088	of	_	
212-49	45089-45097	interest	_	
212-50	45098-45105	anlysis	_	
212-51	45106-45109	for	_	
212-52	45110-45114	fMRI	_	
212-53	45115-45126	Indepndence	_	
212-54	45127-45129	in	_	
212-55	45130-45133	ROI	_	
212-56	45134-45142	analyses	_	
212-57	45142-45143	:	_	
212-58	45144-45149	where	_	
212-59	45150-45152	is	_	
212-60	45153-45156	the	_	
212-61	45157-45163	voodoo	_	
212-62	45164-45165	A	_	
212-63	45166-45173	unified	_	
212-64	45174-45185	statistical	_	
212-65	45186-45194	approach	_	
212-66	45195-45198	for	_	
212-67	45199-45210	determining	_	
212-68	45211-45222	significant	_	
212-69	45223-45230	signals	_	
212-70	45231-45233	in	_	
212-71	45234-45240	images	_	
212-72	45241-45243	of	_	
212-73	45244-45251	cerbral	_	
212-74	45252-45262	activation	_	
212-75	45263-45270	Smaller	_	
212-76	45271-45279	amygdala	_	
212-77	45280-45283	and	_	
212-78	45284-45290	medial	_	
212-79	45291-45301	prefrontal	_	
212-80	45302-45308	cortex	_	
212-81	45309-45316	predict	_	
212-82	45317-45327	escalating	_	
212-83	45328-45337	stimulant	_	
212-84	45338-45341	use	_	
212-85	45342-45351	Childhood	_	
212-86	45352-45358	trauma	_	
212-87	45359-45362	and	_	
212-88	45363-45369	neural	_	
212-89	45370-45379	responses	_	
212-90	45380-45382	to	_	
212-91	45383-45395	personalized	_	
212-92	45396-45402	stress	_	
212-93	45402-45403	,	_	
212-94	45404-45417	favorite-food	_	
212-95	45418-45421	and	_	
212-96	45422-45438	neutral-relaxing	_	
212-97	45439-45443	cues	_	
212-98	45444-45446	in	_	
212-99	45447-45458	adolescents	_	
212-100	45459-45471	Localization	_	
212-101	45472-45474	of	_	
212-102	45475-45477	Mu	_	
212-103	45478-45481	and	_	
212-104	45482-45487	delta	_	
212-105	45488-45494	opioid	_	
212-106	45495-45504	receptors	_	
212-107	45505-45507	to	_	
212-108	45508-45516	anterior	_	
212-109	45517-45526	cingulate	_	
212-110	45527-45536	afferents	_	
212-111	45537-45540	and	_	
212-112	45541-45551	projection	_	
212-113	45552-45559	neurons	_	
212-114	45560-45563	and	_	
212-115	45564-45569	input	_	
212-116	45569-45570	/	_	
212-117	45570-45576	output	_	
212-118	45577-45582	model	_	
212-119	45583-45585	of	_	
212-120	45586-45588	Mu	_	
212-121	45589-45599	regulation	_	
212-122	45600-45608	Modeling	_	
212-123	45609-45617	regional	_	
212-124	45618-45620	an	_	
212-125	45621-45624	and	_	
212-126	45625-45642	psychophysiologic	_	
212-127	45643-45655	interactions	_	
212-128	45656-45658	in	_	
212-129	45659-45663	fMRI	_	
212-130	45663-45664	:	_	
212-131	45665-45668	the	_	
212-132	45669-45679	importance	_	
212-133	45680-45682	of	_	
212-134	45683-45694	hemodynamic	_	
212-135	45695-45708	deconvolution	_	
212-136	45709-45719	Plasticity	_	
212-137	45720-45722	of	_	
212-138	45723-45729	reward	_	
212-139	45730-45744	neurocicruitry	_	
212-140	45745-45748	and	_	
212-141	45749-45752	the	_	
212-142	45753-45754	‘	_	
212-143	45754-45758	dark	_	
212-144	45759-45763	side	_	
212-145	45763-45764	'	_	
212-146	45765-45767	of	_	
212-147	45768-45772	drug	_	
212-148	45773-45782	addiction	_	
212-149	45783-45792	Exploring	_	
212-150	45793-45796	the	_	
212-151	45797-45809	relationship	_	
212-152	45810-45817	between	_	
212-153	45818-45827	childhood	_	
212-154	45828-45840	maltreatment	_	
212-155	45841-45844	and	_	
212-156	45845-45854	addiction	_	
212-157	45854-45855	:	_	
212-158	45856-45857	a	_	
212-159	45858-45864	review	_	
212-160	45865-45867	of	_	
212-161	45868-45871	the	_	
212-162	45872-45886	neurocognitive	_	
212-163	45887-45895	evidence	_	
212-164	45896-45901	Child	_	
212-165	45902-45914	maltreatment	_	
212-166	45915-45918	and	_	
212-167	45919-45925	neural	_	
212-168	45926-45933	systems	_	
212-169	45934-45944	underlying	_	
212-170	45945-45952	emotion	_	
212-171	45953-45963	regulation	_	
212-172	45964-45971	Effects	_	
212-173	45972-45974	of	_	
212-174	45975-45984	childhood	_	
212-175	45985-45997	maltreatment	_	
212-176	45998-46000	on	_	
212-177	46001-46004	the	_	
212-178	46005-46011	neural	_	
212-179	46012-46022	correlates	_	
212-180	46023-46025	of	_	
212-181	46026-46032	stress	_	
212-182	46032-46033	-	_	
212-183	46034-46037	and	_	
212-184	46038-46042	drug	_	
212-185	46043-46054	cue-induced	_	
212-186	46055-46062	cocaine	_	
212-187	46063-46070	craving	_	
212-188	46071-46080	Emotional	_	
212-189	46080-46081	,	_	
212-190	46082-46090	physical	_	
212-191	46091-46094	and	_	
212-192	46095-46101	sexual	_	
212-193	46102-46107	abuse	_	
212-194	46108-46111	are	_	
212-195	46112-46122	associated	_	
212-196	46123-46127	with	_	
212-197	46128-46129	a	_	
212-198	46130-46140	heightened	_	
212-199	46141-46147	limbic	_	
212-200	46148-46156	response	_	
212-201	46157-46159	to	_	
212-202	46160-46167	cocaine	_	
212-203	46168-46172	cues	_	
212-204	46173-46185	Neuroimaging	_	
212-205	46186-46193	studies	_	
212-206	46194-46196	of	_	
212-207	46197-46201	mood	_	
212-208	46202-46211	disorders	_	
212-209	46212-46219	Systems	_	
212-210	46220-46235	reconsolidation	_	
212-211	46236-46243	reveals	_	
212-212	46244-46245	a	_	
212-213	46246-46255	selective	_	
212-214	46256-46260	role	_	
212-215	46261-46264	for	_	
212-216	46265-46268	the	_	
212-217	46269-46277	anterior	_	
212-218	46278-46287	cingulate	_	
212-219	46288-46294	cortex	_	
212-220	46295-46297	in	_	
212-221	46298-46309	generalized	_	
212-222	46310-46320	contextual	_	
212-223	46321-46325	fear	_	
212-224	46326-46332	memory	_	
212-225	46333-46343	expression	_	
212-226	46344-46354	Structural	_	
212-227	46355-46358	and	_	
212-228	46359-46369	functional	_	
212-229	46370-46382	connectivity	_	
212-230	46383-46385	in	_	
212-231	46386-46399	posttraumatic	_	
212-232	46400-46406	stress	_	
212-233	46407-46415	disorder	_	
212-234	46415-46416	:	_	
212-235	46417-46429	associations	_	
212-236	46430-46434	with	_	
212-237	46435-46440	FKBP5	_	
212-238	46441-46456	Ethanol-induced	_	
212-239	46457-46464	effects	_	
212-240	46465-46467	on	_	
212-241	46468-46474	opioid	_	
212-242	46475-46483	peptides	_	
212-243	46484-46486	in	_	
212-244	46487-46492	adult	_	
212-245	46493-46497	male	_	
212-246	46498-46504	Wistar	_	
212-247	46505-46509	rats	_	
212-248	46510-46513	are	_	
212-249	46514-46523	dependent	_	
212-250	46524-46526	on	_	
212-251	46527-46532	early	_	
212-252	46533-46546	environmental	_	
212-253	46547-46554	factors	_	
212-254	46555-46558	The	_	
212-255	46559-46565	impact	_	
212-256	46566-46568	of	_	
212-257	46569-46578	postnatal	_	
212-258	46579-46590	environment	_	
212-259	46591-46593	on	_	
212-260	46594-46600	opioid	_	
212-261	46601-46609	peptides	_	
212-262	46610-46612	in	_	
212-263	46613-46618	young	_	
212-264	46619-46622	and	_	
212-265	46623-46628	adult	_	
212-266	46629-46633	male	_	
212-267	46634-46640	Wistar	_	
212-268	46641-46645	rats	_	
212-269	46646-46656	Activation	_	
212-270	46657-46659	of	_	
212-271	46660-46670	prefrontal	_	
212-272	46671-46677	cortex	_	
212-273	46678-46681	and	_	
212-274	46682-46690	anterior	_	
212-275	46691-46699	thalamus	_	
212-276	46700-46702	in	_	
212-277	46703-46712	alcoholic	_	
212-278	46713-46721	subjects	_	
212-279	46722-46724	on	_	
212-280	46725-46733	exposure	_	
212-281	46734-46736	to	_	
212-282	46737-46753	alcohol-specific	_	
212-283	46754-46758	cues	_	
212-284	46759-46769	Activation	_	
212-285	46770-46772	of	_	
212-286	46773-46779	memory	_	
212-287	46780-46788	circuits	_	
212-288	46789-46795	during	_	
212-289	46796-46808	cue-elicited	_	
212-290	46809-46816	cocaine	_	
212-291	46817-46824	craving	_	
212-292	46825-46831	Limbic	_	
212-293	46832-46842	activation	_	
212-294	46843-46849	during	_	
212-295	46850-46861	cue-induced	_	
212-296	46862-46869	cocaine	_	
212-297	46870-46877	craving	_	
212-298	46878-46889	Dysfunction	_	
212-299	46890-46892	of	_	
212-300	46893-46899	reward	_	
212-301	46900-46910	processing	_	
212-302	46911-46921	correlates	_	
212-303	46922-46926	with	_	
212-304	46927-46934	alcohol	_	
212-305	46935-46942	craving	_	
212-306	46943-46945	in	_	
212-307	46946-46956	detoxified	_	
212-308	46957-46967	alcoholics	_	
212-309	46968-46978	Functional	_	
212-310	46979-46987	magnetic	_	
212-311	46988-46997	resonance	_	
212-312	46998-47005	imaging	_	
212-313	47006-47008	of	_	
212-314	47009-47016	cocaine	_	
212-315	47017-47024	craving	_	
212-316	47025-47032	Imaging	_	
212-317	47033-47038	brain	_	
212-318	47039-47048	mu-opioid	_	
212-319	47049-47058	receptors	_	
212-320	47059-47061	in	_	
212-321	47062-47071	abstinent	_	
212-322	47072-47079	cocaine	_	
212-323	47080-47085	users	_	
212-324	47085-47086	:	_	
212-325	47087-47091	time	_	
212-326	47092-47098	course	_	
212-327	47099-47102	and	_	
212-328	47103-47111	relation	_	
212-329	47112-47114	to	_	
212-330	47115-47122	cocaine	_	
212-331	47123-47130	craving	_	
212-332	47131-47140	Increased	_	
212-333	47141-47143	mu	_	
212-334	47144-47150	opioid	_	
212-335	47151-47159	receptor	_	
212-336	47160-47167	binding	_	
212-337	47168-47176	detected	_	
212-338	47177-47179	by	_	
212-339	47180-47183	PET	_	
212-340	47184-47186	in	_	
212-341	47187-47204	cocaine-dependent	_	
212-342	47205-47208	men	_	
212-343	47209-47219	associated	_	
212-344	47220-47224	with	_	
212-345	47225-47232	cocaine	_	
212-346	47233-47240	craving	_	
212-347	47241-47246	Brain	_	
212-348	47247-47253	opioid	_	
212-349	47254-47262	receptor	_	
212-350	47263-47270	binding	_	
212-351	47271-47273	in	_	
212-352	47274-47279	early	_	
212-353	47280-47290	abstinence	_	
212-354	47291-47295	from	_	
212-355	47296-47302	opioid	_	
212-356	47303-47313	dependence	_	
212-357	47313-47314	:	_	
212-358	47315-47323	positron	_	
212-359	47324-47332	emission	_	
212-360	47333-47343	tomography	_	
212-361	47344-47352	Positron	_	
212-362	47353-47361	emission	_	
212-363	47362-47372	tomography	_	
212-364	47373-47380	imaging	_	
212-365	47381-47383	of	_	
212-366	47384-47386	mu	_	
212-367	47386-47387	-	_	
212-368	47388-47391	and	_	
212-369	47392-47404	delta-opioid	_	
212-370	47405-47413	receptor	_	
212-371	47414-47421	binding	_	
212-372	47422-47424	in	_	
212-373	47425-47442	alcohol-dependent	_	
212-374	47443-47446	and	_	
212-375	47447-47454	healthy	_	
212-376	47455-47462	control	_	
212-377	47463-47471	subjects	_	
212-378	47472-47483	Correlation	_	
212-379	47484-47486	of	_	
212-380	47487-47493	stable	_	
212-381	47494-47504	elevations	_	
212-382	47505-47507	in	_	
212-383	47508-47516	striatal	_	
212-384	47517-47526	mu-opioid	_	
212-385	47527-47535	receptor	_	
212-386	47536-47548	availability	_	
212-387	47549-47551	in	_	
212-388	47552-47562	detoxified	_	
212-389	47563-47572	alcoholic	_	
212-390	47573-47581	patients	_	
212-391	47582-47586	with	_	
212-392	47587-47594	alcohol	_	
212-393	47595-47602	craving	_	
212-394	47602-47603	:	_	
212-395	47604-47605	a	_	
212-396	47606-47614	positron	_	
212-397	47615-47623	emission	_	
212-398	47624-47634	tomography	_	
212-399	47635-47640	study	_	
212-400	47641-47646	using	_	
212-401	47647-47653	carbon	_	
212-402	47654-47656	11	_	
212-403	47656-47657	-	_	
212-404	47657-47663	labeld	_	
212-405	47664-47675	carfentanil	_	
212-406	47676-47679	The	_	
212-407	47680-47684	dark	_	
212-408	47685-47689	side	_	
212-409	47690-47692	of	_	
212-410	47693-47700	emotion	_	
212-411	47700-47701	:	_	
212-412	47702-47705	the	_	
212-413	47706-47715	addiction	_	
212-414	47716-47727	perspective	_	
212-415	47728-47743	Alcohol-induced	_	
212-416	47744-47754	plasticity	_	
212-417	47755-47757	in	_	
212-418	47758-47761	the	_	
212-419	47762-47771	dynorphin	_	
212-420	47771-47772	/	_	
212-421	47772-47784	kappa-opioid	_	
212-422	47785-47793	receptor	_	
212-423	47794-47800	system	_	
212-424	47801-47804	The	_	
212-425	47805-47814	dynorphin	_	
212-426	47814-47815	/	_	
212-427	47815-47820	kappa	_	
212-428	47821-47827	opioid	_	
212-429	47828-47834	system	_	
212-430	47835-47837	as	_	
212-431	47838-47839	a	_	
212-432	47840-47849	modulator	_	
212-433	47850-47852	of	_	
212-434	47853-47867	stress-induced	_	
212-435	47868-47871	and	_	
212-436	47872-47885	pro-addictive	_	
212-437	47886-47895	behaviors	_	
212-438	47896-47899	The	_	
212-439	47900-47904	role	_	
212-440	47905-47907	of	_	
212-441	47908-47911	the	_	
212-442	47912-47927	dynorphin-kappa	_	
212-443	47928-47934	opioid	_	
212-444	47935-47941	system	_	
212-445	47942-47944	in	_	
212-446	47945-47948	the	_	
212-447	47949-47960	reinforcing	_	
212-448	47961-47968	effects	_	
212-449	47969-47971	of	_	
212-450	47972-47977	drugs	_	
212-451	47978-47980	of	_	
212-452	47981-47986	abuse	_	
212-453	47987-47991	Role	_	
212-454	47992-47994	of	_	
212-455	47995-48007	kappa-opioid	_	
212-456	48008-48017	receptors	_	
212-457	48018-48020	in	_	
212-458	48021-48027	stress	_	
212-459	48028-48031	and	_	
212-460	48032-48047	anxiety-related	_	
212-461	48048-48057	behaviour	_	
212-462	48058-48067	Dynorphin	_	
212-463	48067-48068	,	_	
212-464	48069-48078	dysphoria	_	
212-465	48078-48079	,	_	
212-466	48080-48083	and	_	
212-467	48084-48094	dependence	_	
212-468	48094-48095	:	_	
212-469	48096-48099	the	_	
212-470	48100-48106	stress	_	
212-471	48107-48109	of	_	
212-472	48110-48119	addiction	_	
212-473	48120-48126	Opioid	_	
212-474	48127-48138	antagonists	_	
212-475	48139-48142	for	_	
212-476	48143-48150	alcohol	_	
212-477	48151-48161	dependence	_	
212-478	48162-48170	Efficacy	_	
212-479	48171-48173	of	_	
212-480	48174-48185	maintenance	_	
212-481	48186-48195	treatment	_	
212-482	48196-48200	with	_	
212-483	48201-48211	naltrexone	_	
212-484	48212-48215	for	_	
212-485	48216-48222	opioid	_	
212-486	48223-48233	dependence	_	
212-487	48233-48234	:	_	
212-488	48235-48236	a	_	
212-489	48237-48252	meta-analytical	_	
212-490	48253-48259	review	_	
212-491	48260-48264	Oral	_	
212-492	48265-48275	naltrexone	_	
212-493	48276-48287	maintenance	_	
212-494	48288-48297	treatment	_	
212-495	48298-48301	for	_	
212-496	48302-48308	opioid	_	
212-497	48309-48319	dependence	_	
212-498	48320-48336	Extended-release	_	
212-499	48337-48347	naltrexone	_	
212-500	48348-48351	for	_	
212-501	48352-48359	alcohol	_	
212-502	48360-48363	and	_	
212-503	48364-48370	opioid	_	
212-504	48371-48381	dependence	_	
212-505	48381-48382	:	_	
212-506	48383-48384	a	_	
212-507	48385-48398	meta-analysis	_	
212-508	48399-48401	of	_	
212-509	48402-48412	healthcare	_	
212-510	48413-48424	utilization	_	
212-511	48425-48432	studies	_	
212-512	48433-48448	Pharmacotherapy	_	
212-513	48449-48452	for	_	
212-514	48453-48459	adults	_	
212-515	48460-48464	with	_	
212-516	48465-48472	alcohol	_	
212-517	48473-48476	use	_	
212-518	48477-48486	disorders	_	
212-519	48487-48489	in	_	
212-520	48490-48500	outpatient	_	
212-521	48501-48509	settings	_	
212-522	48509-48510	:	_	
212-523	48511-48512	a	_	
212-524	48513-48523	systematic	_	
212-525	48524-48530	review	_	
212-526	48531-48534	and	_	
212-527	48535-48548	meta-analysis	_	
212-528	48549-48555	Neural	_	
212-529	48556-48566	correlates	_	
212-530	48567-48569	of	_	
212-531	48570-48579	emotional	_	
212-532	48580-48590	processing	_	
212-533	48591-48593	in	_	
212-534	48594-48604	depression	_	
212-535	48604-48605	:	_	
212-536	48606-48613	changes	_	
212-537	48614-48618	with	_	
212-538	48619-48628	cognitive	_	
212-539	48629-48639	behavioral	_	
212-540	48640-48647	therapy	_	
212-541	48648-48651	and	_	
212-542	48652-48662	predictors	_	
212-543	48663-48665	of	_	
212-544	48666-48675	treatment	_	
212-545	48676-48684	response	_	
212-546	48685-48694	Cognitive	_	
212-547	48695-48705	behavioral	_	
212-548	48706-48713	therapy	_	
212-549	48714-48717	for	_	
212-550	48718-48728	depression	_	
212-551	48729-48736	changes	_	
212-552	48737-48743	medial	_	
212-553	48744-48754	prefrontal	_	
212-554	48755-48758	and	_	
212-555	48759-48766	ventral	_	
212-556	48767-48775	anterior	_	
212-557	48776-48785	cingulate	_	
212-558	48786-48792	cortex	_	
212-559	48793-48801	activity	_	
212-560	48802-48812	associated	_	
212-561	48813-48817	with	_	
212-562	48818-48834	self-referential	_	
212-563	48835-48845	processing	_	
212-564	48846-48856	Naltrexone	_	
212-565	48857-48860	and	_	
212-566	48861-48867	coping	_	
212-567	48868-48874	skills	_	
212-568	48875-48882	therapy	_	
212-569	48883-48886	for	_	
212-570	48887-48894	alcohol	_	
212-571	48895-48905	dependence	_	
212-572	48905-48906	.	_	

#Text=A controlled study
#Text=Six-month follow-up of naltrexone and psychotherapy for alcohol dependence
#Text=Naltrexone and relapse prevention treatment for cocaine-dependent patients
#Text=Validity of adult retrospective reports of adverse childhood experiences: review of the evidence
#Text=Naltrexone modulated (a) task-related activation in the right medial prefrontal cortex (mPFC; MNI coordinates: x,y,z: 20,60,0; z-score=3.71, P=0.004) and (b) functional connectivity between the right anterior cingulate cortex (ACC; seed coordinates: x,y,z: −14,62,1) and the right hippocampus (MNI coordinates: x,y,z: 22,−16, −10; z-score=3.11; P=0.002) as a function of childhood adversity (Childhood Trauma Questionnaire (CTQ) abuse score) in all groups.
213-1	48907-48908	A	_	
213-2	48909-48919	controlled	_	
213-3	48920-48925	study	_	
213-4	48926-48935	Six-month	_	
213-5	48936-48945	follow-up	_	
213-6	48946-48948	of	_	
213-7	48949-48959	naltrexone	_	
213-8	48960-48963	and	_	
213-9	48964-48977	psychotherapy	_	
213-10	48978-48981	for	_	
213-11	48982-48989	alcohol	_	
213-12	48990-49000	dependence	_	
213-13	49001-49011	Naltrexone	_	
213-14	49012-49015	and	_	
213-15	49016-49023	relapse	_	
213-16	49024-49034	prevention	_	
213-17	49035-49044	treatment	_	
213-18	49045-49048	for	_	
213-19	49049-49066	cocaine-dependent	_	
213-20	49067-49075	patients	_	
213-21	49076-49084	Validity	_	
213-22	49085-49087	of	_	
213-23	49088-49093	adult	_	
213-24	49094-49107	retrospective	_	
213-25	49108-49115	reports	_	
213-26	49116-49118	of	_	
213-27	49119-49126	adverse	_	
213-28	49127-49136	childhood	_	
213-29	49137-49148	experiences	_	
213-30	49148-49149	:	_	
213-31	49150-49156	review	_	
213-32	49157-49159	of	_	
213-33	49160-49163	the	_	
213-34	49164-49172	evidence	_	
213-35	49173-49183	Naltrexone	_	
213-36	49184-49193	modulated	_	
213-37	49194-49195	(	_	
213-38	49195-49196	a	_	
213-39	49196-49197	)	_	
213-40	49198-49210	task-related	_	
213-41	49211-49221	activation	_	
213-42	49222-49224	in	_	
213-43	49225-49228	the	_	
213-44	49229-49234	right	_	
213-45	49235-49241	medial	_	
213-46	49242-49252	prefrontal	_	
213-47	49253-49259	cortex	_	
213-48	49260-49261	(	_	
213-49	49261-49265	mPFC	_	
213-50	49265-49266	;	_	
213-51	49267-49270	MNI	_	
213-52	49271-49282	coordinates	_	
213-53	49282-49283	:	_	
213-54	49284-49285	x	_	
213-55	49285-49286	,	_	
213-56	49286-49287	y	_	
213-57	49287-49288	,	_	
213-58	49288-49289	z	_	
213-59	49289-49290	:	_	
213-60	49291-49298	20,60,0	_	
213-61	49298-49299	;	_	
213-62	49300-49307	z-score	_	
213-63	49307-49308	=	_	
213-64	49308-49312	3.71	_	
213-65	49312-49313	,	_	
213-66	49314-49315	P	_	
213-67	49315-49316	=	_	
213-68	49316-49321	0.004	_	
213-69	49321-49322	)	_	
213-70	49323-49326	and	_	
213-71	49327-49328	(	_	
213-72	49328-49329	b	_	
213-73	49329-49330	)	_	
213-74	49331-49341	functional	_	
213-75	49342-49354	connectivity	_	
213-76	49355-49362	between	_	
213-77	49363-49366	the	_	
213-78	49367-49372	right	_	
213-79	49373-49381	anterior	_	
213-80	49382-49391	cingulate	_	
213-81	49392-49398	cortex	_	
213-82	49399-49400	(	_	
213-83	49400-49403	ACC	_	
213-84	49403-49404	;	_	
213-85	49405-49409	seed	_	
213-86	49410-49421	coordinates	_	
213-87	49421-49422	:	_	
213-88	49423-49424	x	_	
213-89	49424-49425	,	_	
213-90	49425-49426	y	_	
213-91	49426-49427	,	_	
213-92	49427-49428	z	_	
213-93	49428-49429	:	_	
213-94	49430-49431	−	_	
213-95	49431-49438	14,62,1	_	
213-96	49438-49439	)	_	
213-97	49440-49443	and	_	
213-98	49444-49447	the	_	
213-99	49448-49453	right	_	
213-100	49454-49465	hippocampus	_	
213-101	49466-49467	(	_	
213-102	49467-49470	MNI	_	
213-103	49471-49482	coordinates	_	
213-104	49482-49483	:	_	
213-105	49484-49485	x	_	
213-106	49485-49486	,	_	
213-107	49486-49487	y	_	
213-108	49487-49488	,	_	
213-109	49488-49489	z	_	
213-110	49489-49490	:	_	
213-111	49491-49493	22	_	
213-112	49493-49494	,	_	
213-113	49494-49495	−	_	
213-114	49495-49497	16	_	
213-115	49497-49498	,	_	
213-116	49499-49500	−	_	
213-117	49500-49502	10	_	
213-118	49502-49503	;	_	
213-119	49504-49511	z-score	_	
213-120	49511-49512	=	_	
213-121	49512-49516	3.11	_	
213-122	49516-49517	;	_	
213-123	49518-49519	P	_	
213-124	49519-49520	=	_	
213-125	49520-49525	0.002	_	
213-126	49525-49526	)	_	
213-127	49527-49529	as	_	
213-128	49530-49531	a	_	
213-129	49532-49540	function	_	
213-130	49541-49543	of	_	
213-131	49544-49553	childhood	_	
213-132	49554-49563	adversity	_	
213-133	49564-49565	(	_	
213-134	49565-49574	Childhood	_	
213-135	49575-49581	Trauma	_	
213-136	49582-49595	Questionnaire	_	
213-137	49596-49597	(	_	
213-138	49597-49600	CTQ	_	
213-139	49600-49601	)	_	
213-140	49602-49607	abuse	_	
213-141	49608-49613	score	_	
213-142	49613-49614	)	_	
213-143	49615-49617	in	_	
213-144	49618-49621	all	_	
213-145	49622-49628	groups	_	
213-146	49628-49629	.	_	

#Text=(a) Significant group-by-treatment-by-condition interaction in the right amygdala (MNI coordinates: x,y,z: 26,2,−24; z-score=2.66; P=0.032).
214-1	49630-49631	(	_	
214-2	49631-49632	a	_	
214-3	49632-49633	)	_	
214-4	49634-49645	Significant	_	
214-5	49646-49677	group-by-treatment-by-condition	_	
214-6	49678-49689	interaction	_	
214-7	49690-49692	in	_	
214-8	49693-49696	the	_	
214-9	49697-49702	right	_	
214-10	49703-49711	amygdala	_	
214-11	49712-49713	(	_	
214-12	49713-49716	MNI	_	
214-13	49717-49728	coordinates	_	
214-14	49728-49729	:	_	
214-15	49730-49731	x	_	
214-16	49731-49732	,	_	
214-17	49732-49733	y	_	
214-18	49733-49734	,	_	
214-19	49734-49735	z	_	
214-20	49735-49736	:	_	
214-21	49737-49741	26,2	_	
214-22	49741-49742	,	_	
214-23	49742-49743	−	_	
214-24	49743-49745	24	_	
214-25	49745-49746	;	_	
214-26	49747-49754	z-score	_	
214-27	49754-49755	=	_	
214-28	49755-49759	2.66	_	
214-29	49759-49760	;	_	
214-30	49761-49762	P	_	
214-31	49762-49763	=	_	
214-32	49763-49768	0.032	_	
214-33	49768-49769	)	_	
214-34	49769-49770	.	_	

#Text=(b) On placebo, the control and alcohol groups showed increased activation to aversive relative to neutral images, whereas the alcohol/drugs groups showed increased activation to all visual images, irrespective of emotional valence.
215-1	49771-49772	(	_	
215-2	49772-49773	b	_	
215-3	49773-49774	)	_	
215-4	49775-49777	On	_	
215-5	49778-49785	placebo	_	
215-6	49785-49786	,	_	
215-7	49787-49790	the	_	
215-8	49791-49798	control	_	
215-9	49799-49802	and	_	
215-10	49803-49810	alcohol	_	
215-11	49811-49817	groups	_	
215-12	49818-49824	showed	_	
215-13	49825-49834	increased	_	
215-14	49835-49845	activation	_	
215-15	49846-49848	to	_	
215-16	49849-49857	aversive	_	
215-17	49858-49866	relative	_	
215-18	49867-49869	to	_	
215-19	49870-49877	neutral	_	
215-20	49878-49884	images	_	
215-21	49884-49885	,	_	
215-22	49886-49893	whereas	_	
215-23	49894-49897	the	_	
215-24	49898-49905	alcohol	_	
215-25	49905-49906	/	_	
215-26	49906-49911	drugs	_	
215-27	49912-49918	groups	_	
215-28	49919-49925	showed	_	
215-29	49926-49935	increased	_	
215-30	49936-49946	activation	_	
215-31	49947-49949	to	_	
215-32	49950-49953	all	_	
215-33	49954-49960	visual	_	
215-34	49961-49967	images	_	
215-35	49967-49968	,	_	
215-36	49969-49981	irrespective	_	
215-37	49982-49984	of	_	
215-38	49985-49994	emotional	_	
215-39	49995-50002	valence	_	
215-40	50002-50003	.	_	

#Text=(c) Naltrexone normalized activation in the alcohol/drugs group, such that activation was higher to aversive relative to neutral images, but did not change the pattern of activation in the control or alcohol groups.
216-1	50004-50005	(	_	
216-2	50005-50006	c	_	
216-3	50006-50007	)	_	
216-4	50008-50018	Naltrexone	_	
216-5	50019-50029	normalized	_	
216-6	50030-50040	activation	_	
216-7	50041-50043	in	_	
216-8	50044-50047	the	_	
216-9	50048-50055	alcohol	_	
216-10	50055-50056	/	_	
216-11	50056-50061	drugs	_	
216-12	50062-50067	group	_	
216-13	50067-50068	,	_	
216-14	50069-50073	such	_	
216-15	50074-50078	that	_	
216-16	50079-50089	activation	_	
216-17	50090-50093	was	_	
216-18	50094-50100	higher	_	
216-19	50101-50103	to	_	
216-20	50104-50112	aversive	_	
216-21	50113-50121	relative	_	
216-22	50122-50124	to	_	
216-23	50125-50132	neutral	_	
216-24	50133-50139	images	_	
216-25	50139-50140	,	_	
216-26	50141-50144	but	_	
216-27	50145-50148	did	_	
216-28	50149-50152	not	_	
216-29	50153-50159	change	_	
216-30	50160-50163	the	_	
216-31	50164-50171	pattern	_	
216-32	50172-50174	of	_	
216-33	50175-50185	activation	_	
216-34	50186-50188	in	_	
216-35	50189-50192	the	_	
216-36	50193-50200	control	_	
216-37	50201-50203	or	_	
216-38	50204-50211	alcohol	_	
216-39	50212-50218	groups	_	
216-40	50218-50219	.	_	

#Text=MNI, Montreal Neurological Institute.
217-1	50220-50223	MNI	_	
217-2	50223-50224	,	_	
217-3	50225-50233	Montreal	_	
217-4	50234-50246	Neurological	_	
217-5	50247-50256	Institute	_	
217-6	50256-50257	.	_	

#Text=Evocative Images task mean group latencies (ms) and standard deviations in response to neutral and aversive images on placebo and naltrexone
#Text=Condition\tTreatment\tControl group, n=21\tAlcohol group, n=18\tAlcohol/drugs group, n=21\t \tNeutral images\tPlacebo\t691.14 (±294.94)\t862.17 (±291.95)\t740.62 (±313.31)\t \tNeutral images\tNaltrexone\t671.14 (±237)\t893.50 (±354.28)\t724.29 (±219.06)\t \tAversive images\tPlacebo\t684.48 (±261.16)\t945.94 (±368.01)\t855.71 (±457.75)\t \tAversive images\tNaltrexone\t689.76 (±238.30)\t970.39 (±478.30)\t806.71 (±382.78)\t \t
#Text=Means are untransformed scores.
218-1	50258-50267	Evocative	_	
218-2	50268-50274	Images	_	
218-3	50275-50279	task	_	
218-4	50280-50284	mean	_	
218-5	50285-50290	group	_	
218-6	50291-50300	latencies	_	
218-7	50301-50302	(	_	
218-8	50302-50304	ms	_	
218-9	50304-50305	)	_	
218-10	50306-50309	and	_	
218-11	50310-50318	standard	_	
218-12	50319-50329	deviations	_	
218-13	50330-50332	in	_	
218-14	50333-50341	response	_	
218-15	50342-50344	to	_	
218-16	50345-50352	neutral	_	
218-17	50353-50356	and	_	
218-18	50357-50365	aversive	_	
218-19	50366-50372	images	_	
218-20	50373-50375	on	_	
218-21	50376-50383	placebo	_	
218-22	50384-50387	and	_	
218-23	50388-50398	naltrexone	_	
218-24	50399-50408	Condition	_	
218-25	50409-50418	Treatment	_	
218-26	50419-50426	Control	_	
218-27	50427-50432	group	_	
218-28	50432-50433	,	_	
218-29	50434-50435	n	_	
218-30	50435-50436	=	_	
218-31	50436-50438	21	_	
218-32	50439-50446	Alcohol	_	
218-33	50447-50452	group	_	
218-34	50452-50453	,	_	
218-35	50454-50455	n	_	
218-36	50455-50456	=	_	
218-37	50456-50458	18	_	
218-38	50459-50466	Alcohol	_	
218-39	50466-50467	/	_	
218-40	50467-50472	drugs	_	
218-41	50473-50478	group	_	
218-42	50478-50479	,	_	
218-43	50480-50481	n	_	
218-44	50481-50482	=	_	
218-45	50482-50484	21	_	
218-46	50487-50494	Neutral	_	
218-47	50495-50501	images	_	
218-48	50502-50509	Placebo	_	
218-49	50510-50516	691.14	_	
218-50	50517-50518	(	_	
218-51	50518-50519	±	_	
218-52	50519-50525	294.94	_	
218-53	50525-50526	)	_	
218-54	50527-50533	862.17	_	
218-55	50534-50535	(	_	
218-56	50535-50536	±	_	
218-57	50536-50542	291.95	_	
218-58	50542-50543	)	_	
218-59	50544-50550	740.62	_	
218-60	50551-50552	(	_	
218-61	50552-50553	±	_	
218-62	50553-50559	313.31	_	
218-63	50559-50560	)	_	
218-64	50563-50570	Neutral	_	
218-65	50571-50577	images	_	
218-66	50578-50588	Naltrexone	_	
218-67	50589-50595	671.14	_	
218-68	50596-50597	(	_	
218-69	50597-50598	±	_	
218-70	50598-50601	237	_	
218-71	50601-50602	)	_	
218-72	50603-50609	893.50	_	
218-73	50610-50611	(	_	
218-74	50611-50612	±	_	
218-75	50612-50618	354.28	_	
218-76	50618-50619	)	_	
218-77	50620-50626	724.29	_	
218-78	50627-50628	(	_	
218-79	50628-50629	±	_	
218-80	50629-50635	219.06	_	
218-81	50635-50636	)	_	
218-82	50639-50647	Aversive	_	
218-83	50648-50654	images	_	
218-84	50655-50662	Placebo	_	
218-85	50663-50669	684.48	_	
218-86	50670-50671	(	_	
218-87	50671-50672	±	_	
218-88	50672-50678	261.16	_	
218-89	50678-50679	)	_	
218-90	50680-50686	945.94	_	
218-91	50687-50688	(	_	
218-92	50688-50689	±	_	
218-93	50689-50695	368.01	_	
218-94	50695-50696	)	_	
218-95	50697-50703	855.71	_	
218-96	50704-50705	(	_	
218-97	50705-50706	±	_	
218-98	50706-50712	457.75	_	
218-99	50712-50713	)	_	
218-100	50716-50724	Aversive	_	
218-101	50725-50731	images	_	
218-102	50732-50742	Naltrexone	_	
218-103	50743-50749	689.76	_	
218-104	50750-50751	(	_	
218-105	50751-50752	±	_	
218-106	50752-50758	238.30	_	
218-107	50758-50759	)	_	
218-108	50760-50766	970.39	_	
218-109	50767-50768	(	_	
218-110	50768-50769	±	_	
218-111	50769-50775	478.30	_	
218-112	50775-50776	)	_	
218-113	50777-50783	806.71	_	
218-114	50784-50785	(	_	
218-115	50785-50786	±	_	
218-116	50786-50792	382.78	_	
218-117	50792-50793	)	_	
218-118	50797-50802	Means	_	
218-119	50803-50806	are	_	
218-120	50807-50820	untransformed	_	
218-121	50821-50827	scores	_	
218-122	50827-50828	.	_	

#Text=Group demographic information and baseline assessment prior to the experimental medicine sessions
#Text= \tControl group, n=21\tAlcohol group, n=18\tAlcohol/drugs group, n=21\tStatistic, P-value\t \tSite (London: Cambridge: Manchester)\t8 L: 12 C: 1 M\t9 L: 6 C: 3M\t12 L: 7 C: 2 M\tX2=4.04, P=0.40\t \tGender (male: female)\t17 M: 4 F\t14 M: 4 F\t16 M: 5 F\tX2=0.15, P=0.93\t \tAge (years)\t41.52 (±10.05)\t44.22 (±8.72)\t40.57 (±7.43)\tF2,57=0.88, P=0.42\t \tVerbal IQ (WTAR)\t106.57 (±10.88)\t105.78 (±8.31)\t99.57 (±11.45)\tF2,57=2.80, P=0.07\t \tHandedness (Edinburgh Inventory)\t40.62 (±67.71)\t58.39 (±66.72)\t61.33 (±58.06)\tF2,57=0.63, P=0.54\t \tSmoking (smoker: non-smoker)\t9 S: 12 N-S\t13 S: 5 N-S\t16 S: 5 N-S\tX2=5.90, P=0.052\t \tStress sensitivity (PSS-14, total score)\t15.10 (±6.36)\t18 (±7.23)\t21.95 (±6.27)\tF2,57=5.71, P=0.005\t \tChildhood adversity (CTQ total abuse score)\t21.90 (±10.07)\t22.61 (±12.06)\t34.24 (±16.50)\tF2,57=6.63, P=0.003\t \tLocus of control (Rotter's I–E)\t10.25 (±43.18)\t10.76 (±43.39)\t10.40 (±43.28)\tF2,57=0.05, P=0.95\t \tDrug-related locus of control (DR-LOC recovery)\t1.24 (±1.61)\t1.50 (±1.58)\t1.48 (±.98)\tF2,57=0.21, P=0.81\t \t
#Text=Abbreviations: CTQ, Childhood Trauma Questionnaire; DR-LOC, drug-related locus of control; PSS-14, Perceived Stress Scale; Rotter's I–E, Rotter's internal–external control scale; WTAR, Wechsler Test of Adult Reading.
219-1	50829-50834	Group	_	
219-2	50835-50846	demographic	_	
219-3	50847-50858	information	_	
219-4	50859-50862	and	_	
219-5	50863-50871	baseline	_	
219-6	50872-50882	assessment	_	
219-7	50883-50888	prior	_	
219-8	50889-50891	to	_	
219-9	50892-50895	the	_	
219-10	50896-50908	experimental	_	
219-11	50909-50917	medicine	_	
219-12	50918-50926	sessions	_	
219-13	50927-50928	 	_	
219-14	50929-50936	Control	_	
219-15	50937-50942	group	_	
219-16	50942-50943	,	_	
219-17	50944-50945	n	_	
219-18	50945-50946	=	_	
219-19	50946-50948	21	_	
219-20	50949-50956	Alcohol	_	
219-21	50957-50962	group	_	
219-22	50962-50963	,	_	
219-23	50964-50965	n	_	
219-24	50965-50966	=	_	
219-25	50966-50968	18	_	
219-26	50969-50976	Alcohol	_	
219-27	50976-50977	/	_	
219-28	50977-50982	drugs	_	
219-29	50983-50988	group	_	
219-30	50988-50989	,	_	
219-31	50990-50991	n	_	
219-32	50991-50992	=	_	
219-33	50992-50994	21	_	
219-34	50995-51004	Statistic	_	
219-35	51004-51005	,	_	
219-36	51006-51013	P-value	_	
219-37	51016-51020	Site	_	
219-38	51021-51022	(	_	
219-39	51022-51028	London	_	
219-40	51028-51029	:	_	
219-41	51030-51039	Cambridge	_	
219-42	51039-51040	:	_	
219-43	51041-51051	Manchester	_	
219-44	51051-51052	)	_	
219-45	51053-51054	8	_	
219-46	51055-51056	L	_	
219-47	51056-51057	:	_	
219-48	51058-51060	12	_	
219-49	51061-51062	C	_	
219-50	51062-51063	:	_	
219-51	51064-51065	1	_	
219-52	51066-51067	M	_	
219-53	51068-51069	9	_	
219-54	51070-51071	L	_	
219-55	51071-51072	:	_	
219-56	51073-51074	6	_	
219-57	51075-51076	C	_	
219-58	51076-51077	:	_	
219-59	51078-51080	3M	_	
219-60	51081-51083	12	_	
219-61	51084-51085	L	_	
219-62	51085-51086	:	_	
219-63	51087-51088	7	_	
219-64	51089-51090	C	_	
219-65	51090-51091	:	_	
219-66	51092-51093	2	_	
219-67	51094-51095	M	_	
219-68	51096-51098	X2	_	
219-69	51098-51099	=	_	
219-70	51099-51103	4.04	_	
219-71	51103-51104	,	_	
219-72	51105-51106	P	_	
219-73	51106-51107	=	_	
219-74	51107-51111	0.40	_	
219-75	51114-51120	Gender	_	
219-76	51121-51122	(	_	
219-77	51122-51126	male	_	
219-78	51126-51127	:	_	
219-79	51128-51134	female	_	
219-80	51134-51135	)	_	
219-81	51136-51138	17	_	
219-82	51139-51140	M	_	
219-83	51140-51141	:	_	
219-84	51142-51143	4	_	
219-85	51144-51145	F	_	
219-86	51146-51148	14	_	
219-87	51149-51150	M	_	
219-88	51150-51151	:	_	
219-89	51152-51153	4	_	
219-90	51154-51155	F	_	
219-91	51156-51158	16	_	
219-92	51159-51160	M	_	
219-93	51160-51161	:	_	
219-94	51162-51163	5	_	
219-95	51164-51165	F	_	
219-96	51166-51168	X2	_	
219-97	51168-51169	=	_	
219-98	51169-51173	0.15	_	
219-99	51173-51174	,	_	
219-100	51175-51176	P	_	
219-101	51176-51177	=	_	
219-102	51177-51181	0.93	_	
219-103	51184-51187	Age	_	
219-104	51188-51189	(	_	
219-105	51189-51194	years	_	
219-106	51194-51195	)	_	
219-107	51196-51201	41.52	_	
219-108	51202-51203	(	_	
219-109	51203-51204	±	_	
219-110	51204-51209	10.05	_	
219-111	51209-51210	)	_	
219-112	51211-51216	44.22	_	
219-113	51217-51218	(	_	
219-114	51218-51219	±	_	
219-115	51219-51223	8.72	_	
219-116	51223-51224	)	_	
219-117	51225-51230	40.57	_	
219-118	51231-51232	(	_	
219-119	51232-51233	±	_	
219-120	51233-51237	7.43	_	
219-121	51237-51238	)	_	
219-122	51239-51244	F2,57	_	
219-123	51244-51245	=	_	
219-124	51245-51249	0.88	_	
219-125	51249-51250	,	_	
219-126	51251-51252	P	_	
219-127	51252-51253	=	_	
219-128	51253-51257	0.42	_	
219-129	51260-51266	Verbal	_	
219-130	51267-51269	IQ	_	
219-131	51270-51271	(	_	
219-132	51271-51275	WTAR	_	
219-133	51275-51276	)	_	
219-134	51277-51283	106.57	_	
219-135	51284-51285	(	_	
219-136	51285-51286	±	_	
219-137	51286-51291	10.88	_	
219-138	51291-51292	)	_	
219-139	51293-51299	105.78	_	
219-140	51300-51301	(	_	
219-141	51301-51302	±	_	
219-142	51302-51306	8.31	_	
219-143	51306-51307	)	_	
219-144	51308-51313	99.57	_	
219-145	51314-51315	(	_	
219-146	51315-51316	±	_	
219-147	51316-51321	11.45	_	
219-148	51321-51322	)	_	
219-149	51323-51328	F2,57	_	
219-150	51328-51329	=	_	
219-151	51329-51333	2.80	_	
219-152	51333-51334	,	_	
219-153	51335-51336	P	_	
219-154	51336-51337	=	_	
219-155	51337-51341	0.07	_	
219-156	51344-51354	Handedness	_	
219-157	51355-51356	(	_	
219-158	51356-51365	Edinburgh	_	
219-159	51366-51375	Inventory	_	
219-160	51375-51376	)	_	
219-161	51377-51382	40.62	_	
219-162	51383-51384	(	_	
219-163	51384-51385	±	_	
219-164	51385-51390	67.71	_	
219-165	51390-51391	)	_	
219-166	51392-51397	58.39	_	
219-167	51398-51399	(	_	
219-168	51399-51400	±	_	
219-169	51400-51405	66.72	_	
219-170	51405-51406	)	_	
219-171	51407-51412	61.33	_	
219-172	51413-51414	(	_	
219-173	51414-51415	±	_	
219-174	51415-51420	58.06	_	
219-175	51420-51421	)	_	
219-176	51422-51427	F2,57	_	
219-177	51427-51428	=	_	
219-178	51428-51432	0.63	_	
219-179	51432-51433	,	_	
219-180	51434-51435	P	_	
219-181	51435-51436	=	_	
219-182	51436-51440	0.54	_	
219-183	51443-51450	Smoking	_	
219-184	51451-51452	(	_	
219-185	51452-51458	smoker	_	
219-186	51458-51459	:	_	
219-187	51460-51470	non-smoker	_	
219-188	51470-51471	)	_	
219-189	51472-51473	9	_	
219-190	51474-51475	S	_	
219-191	51475-51476	:	_	
219-192	51477-51479	12	_	
219-193	51480-51483	N-S	_	
219-194	51484-51486	13	_	
219-195	51487-51488	S	_	
219-196	51488-51489	:	_	
219-197	51490-51491	5	_	
219-198	51492-51495	N-S	_	
219-199	51496-51498	16	_	
219-200	51499-51500	S	_	
219-201	51500-51501	:	_	
219-202	51502-51503	5	_	
219-203	51504-51507	N-S	_	
219-204	51508-51510	X2	_	
219-205	51510-51511	=	_	
219-206	51511-51515	5.90	_	
219-207	51515-51516	,	_	
219-208	51517-51518	P	_	
219-209	51518-51519	=	_	
219-210	51519-51524	0.052	_	
219-211	51527-51533	Stress	_	
219-212	51534-51545	sensitivity	_	
219-213	51546-51547	(	_	
219-214	51547-51550	PSS	_	
219-215	51550-51551	-	_	
219-216	51551-51553	14	_	
219-217	51553-51554	,	_	
219-218	51555-51560	total	_	
219-219	51561-51566	score	_	
219-220	51566-51567	)	_	
219-221	51568-51573	15.10	_	
219-222	51574-51575	(	_	
219-223	51575-51576	±	_	
219-224	51576-51580	6.36	_	
219-225	51580-51581	)	_	
219-226	51582-51584	18	_	
219-227	51585-51586	(	_	
219-228	51586-51587	±	_	
219-229	51587-51591	7.23	_	
219-230	51591-51592	)	_	
219-231	51593-51598	21.95	_	
219-232	51599-51600	(	_	
219-233	51600-51601	±	_	
219-234	51601-51605	6.27	_	
219-235	51605-51606	)	_	
219-236	51607-51612	F2,57	_	
219-237	51612-51613	=	_	
219-238	51613-51617	5.71	_	
219-239	51617-51618	,	_	
219-240	51619-51620	P	_	
219-241	51620-51621	=	_	
219-242	51621-51626	0.005	_	
219-243	51629-51638	Childhood	_	
219-244	51639-51648	adversity	_	
219-245	51649-51650	(	_	
219-246	51650-51653	CTQ	_	
219-247	51654-51659	total	_	
219-248	51660-51665	abuse	_	
219-249	51666-51671	score	_	
219-250	51671-51672	)	_	
219-251	51673-51678	21.90	_	
219-252	51679-51680	(	_	
219-253	51680-51681	±	_	
219-254	51681-51686	10.07	_	
219-255	51686-51687	)	_	
219-256	51688-51693	22.61	_	
219-257	51694-51695	(	_	
219-258	51695-51696	±	_	
219-259	51696-51701	12.06	_	
219-260	51701-51702	)	_	
219-261	51703-51708	34.24	_	
219-262	51709-51710	(	_	
219-263	51710-51711	±	_	
219-264	51711-51716	16.50	_	
219-265	51716-51717	)	_	
219-266	51718-51723	F2,57	_	
219-267	51723-51724	=	_	
219-268	51724-51728	6.63	_	
219-269	51728-51729	,	_	
219-270	51730-51731	P	_	
219-271	51731-51732	=	_	
219-272	51732-51737	0.003	_	
219-273	51740-51745	Locus	_	
219-274	51746-51748	of	_	
219-275	51749-51756	control	_	
219-276	51757-51758	(	_	
219-277	51758-51766	Rotter's	_	
219-278	51767-51770	I–E	_	
219-279	51770-51771	)	_	
219-280	51772-51777	10.25	_	
219-281	51778-51779	(	_	
219-282	51779-51780	±	_	
219-283	51780-51785	43.18	_	
219-284	51785-51786	)	_	
219-285	51787-51792	10.76	_	
219-286	51793-51794	(	_	
219-287	51794-51795	±	_	
219-288	51795-51800	43.39	_	
219-289	51800-51801	)	_	
219-290	51802-51807	10.40	_	
219-291	51808-51809	(	_	
219-292	51809-51810	±	_	
219-293	51810-51815	43.28	_	
219-294	51815-51816	)	_	
219-295	51817-51822	F2,57	_	
219-296	51822-51823	=	_	
219-297	51823-51827	0.05	_	
219-298	51827-51828	,	_	
219-299	51829-51830	P	_	
219-300	51830-51831	=	_	
219-301	51831-51835	0.95	_	
219-302	51838-51850	Drug-related	_	
219-303	51851-51856	locus	_	
219-304	51857-51859	of	_	
219-305	51860-51867	control	_	
219-306	51868-51869	(	_	
219-307	51869-51875	DR-LOC	_	
219-308	51876-51884	recovery	_	
219-309	51884-51885	)	_	
219-310	51886-51890	1.24	_	
219-311	51891-51892	(	_	
219-312	51892-51893	±	_	
219-313	51893-51897	1.61	_	
219-314	51897-51898	)	_	
219-315	51899-51903	1.50	_	
219-316	51904-51905	(	_	
219-317	51905-51906	±	_	
219-318	51906-51910	1.58	_	
219-319	51910-51911	)	_	
219-320	51912-51916	1.48	_	
219-321	51917-51918	(	_	
219-322	51918-51919	±	_	
219-323	51919-51922	.98	_	
219-324	51922-51923	)	_	
219-325	51924-51929	F2,57	_	
219-326	51929-51930	=	_	
219-327	51930-51934	0.21	_	
219-328	51934-51935	,	_	
219-329	51936-51937	P	_	
219-330	51937-51938	=	_	
219-331	51938-51942	0.81	_	
219-332	51946-51959	Abbreviations	_	
219-333	51959-51960	:	_	
219-334	51961-51964	CTQ	_	
219-335	51964-51965	,	_	
219-336	51966-51975	Childhood	_	
219-337	51976-51982	Trauma	_	
219-338	51983-51996	Questionnaire	_	
219-339	51996-51997	;	_	
219-340	51998-52004	DR-LOC	_	
219-341	52004-52005	,	_	
219-342	52006-52018	drug-related	_	
219-343	52019-52024	locus	_	
219-344	52025-52027	of	_	
219-345	52028-52035	control	_	
219-346	52035-52036	;	_	
219-347	52037-52040	PSS	_	
219-348	52040-52041	-	_	
219-349	52041-52043	14	_	
219-350	52043-52044	,	_	
219-351	52045-52054	Perceived	_	
219-352	52055-52061	Stress	_	
219-353	52062-52067	Scale	_	
219-354	52067-52068	;	_	
219-355	52069-52077	Rotter's	_	
219-356	52078-52081	I–E	_	
219-357	52081-52082	,	_	
219-358	52083-52091	Rotter's	_	
219-359	52092-52109	internal–external	_	
219-360	52110-52117	control	_	
219-361	52118-52123	scale	_	
219-362	52123-52124	;	_	
219-363	52125-52129	WTAR	_	
219-364	52129-52130	,	_	
219-365	52131-52139	Wechsler	_	
219-366	52140-52144	Test	_	
219-367	52145-52147	of	_	
219-368	52148-52153	Adult	_	
219-369	52154-52161	Reading	_	
219-370	52161-52162	.	_	

#Text=Significant whole-brain-corrected regions for the main effect of group, main effect of condition and group-by-treatment-by-condition interaction
#Text= \tHemisphere\tP-value\tz-score\tCoordinates (x:y:z)\t \tMain effect of group\t \t Fusiform gyrus\tLeft\t0.012\t4.83\t−26, −66, −16\t \t Inferior occipital gyrus\tLeft\t0.025\t4.66\t−26, −82, −6\t \t Precuneus\tRight\t0.029\t4.63\t30, −60, 28\t \t \t \t \t \t \t \tMain effect of condition\t \t Inferior temporal gyrus\tRight\t0.001\t5.27\t46, −44, −18\t \t Superior temporal gyrus\tLeft\t0.023\t4.66\t−58, −12, 4\t \t Middle occipital gyrus\tLeft\t0.028\t4.61\t−44, −80, −2\t \t \t \t \t \t \t \tGroup-by-treatment-by-condition interaction\t \t Amygdala\tRight\t0.032\t2.66\t26, 2, −24
220-1	52163-52174	Significant	_	
220-2	52175-52196	whole-brain-corrected	_	
220-3	52197-52204	regions	_	
220-4	52205-52208	for	_	
220-5	52209-52212	the	_	
220-6	52213-52217	main	_	
220-7	52218-52224	effect	_	
220-8	52225-52227	of	_	
220-9	52228-52233	group	_	
220-10	52233-52234	,	_	
220-11	52235-52239	main	_	
220-12	52240-52246	effect	_	
220-13	52247-52249	of	_	
220-14	52250-52259	condition	_	
220-15	52260-52263	and	_	
220-16	52264-52295	group-by-treatment-by-condition	_	
220-17	52296-52307	interaction	_	
220-18	52308-52309	 	_	
220-19	52310-52320	Hemisphere	_	
220-20	52321-52328	P-value	_	
220-21	52329-52336	z-score	_	
220-22	52337-52348	Coordinates	_	
220-23	52349-52350	(	_	
220-24	52350-52351	x	_	
220-25	52351-52352	:	_	
220-26	52352-52353	y	_	
220-27	52353-52354	:	_	
220-28	52354-52355	z	_	
220-29	52355-52356	)	_	
220-30	52359-52363	Main	_	
220-31	52364-52370	effect	_	
220-32	52371-52373	of	_	
220-33	52374-52379	group	_	
220-34	52383-52391	Fusiform	_	
220-35	52392-52397	gyrus	_	
220-36	52398-52402	Left	_	
220-37	52403-52408	0.012	_	
220-38	52409-52413	4.83	_	
220-39	52414-52415	−	_	
220-40	52415-52417	26	_	
220-41	52417-52418	,	_	
220-42	52419-52420	−	_	
220-43	52420-52422	66	_	
220-44	52422-52423	,	_	
220-45	52424-52425	−	_	
220-46	52425-52427	16	_	
220-47	52431-52439	Inferior	_	
220-48	52440-52449	occipital	_	
220-49	52450-52455	gyrus	_	
220-50	52456-52460	Left	_	
220-51	52461-52466	0.025	_	
220-52	52467-52471	4.66	_	
220-53	52472-52473	−	_	
220-54	52473-52475	26	_	
220-55	52475-52476	,	_	
220-56	52477-52478	−	_	
220-57	52478-52480	82	_	
220-58	52480-52481	,	_	
220-59	52482-52483	−	_	
220-60	52483-52484	6	_	
220-61	52488-52497	Precuneus	_	
220-62	52498-52503	Right	_	
220-63	52504-52509	0.029	_	
220-64	52510-52514	4.63	_	
220-65	52515-52517	30	_	
220-66	52517-52518	,	_	
220-67	52519-52520	−	_	
220-68	52520-52522	60	_	
220-69	52522-52523	,	_	
220-70	52524-52526	28	_	
220-71	52529-52538	 	 	 	 	 	_	
220-72	52541-52545	Main	_	
220-73	52546-52552	effect	_	
220-74	52553-52555	of	_	
220-75	52556-52565	condition	_	
220-76	52569-52577	Inferior	_	
220-77	52578-52586	temporal	_	
220-78	52587-52592	gyrus	_	
220-79	52593-52598	Right	_	
220-80	52599-52604	0.001	_	
220-81	52605-52609	5.27	_	
220-82	52610-52612	46	_	
220-83	52612-52613	,	_	
220-84	52614-52615	−	_	
220-85	52615-52617	44	_	
220-86	52617-52618	,	_	
220-87	52619-52620	−	_	
220-88	52620-52622	18	_	
220-89	52626-52634	Superior	_	
220-90	52635-52643	temporal	_	
220-91	52644-52649	gyrus	_	
220-92	52650-52654	Left	_	
220-93	52655-52660	0.023	_	
220-94	52661-52665	4.66	_	
220-95	52666-52667	−	_	
220-96	52667-52669	58	_	
220-97	52669-52670	,	_	
220-98	52671-52672	−	_	
220-99	52672-52674	12	_	
220-100	52674-52675	,	_	
220-101	52676-52677	4	_	
220-102	52681-52687	Middle	_	
220-103	52688-52697	occipital	_	
220-104	52698-52703	gyrus	_	
220-105	52704-52708	Left	_	
220-106	52709-52714	0.028	_	
220-107	52715-52719	4.61	_	
220-108	52720-52721	−	_	
220-109	52721-52723	44	_	
220-110	52723-52724	,	_	
220-111	52725-52726	−	_	
220-112	52726-52728	80	_	
220-113	52728-52729	,	_	
220-114	52730-52731	−	_	
220-115	52731-52732	2	_	
220-116	52735-52744	 	 	 	 	 	_	
220-117	52747-52778	Group-by-treatment-by-condition	_	
220-118	52779-52790	interaction	_	
220-119	52794-52802	Amygdala	_	
220-120	52803-52808	Right	_	
220-121	52809-52814	0.032	_	
220-122	52815-52819	2.66	_	
220-123	52820-52822	26	_	
220-124	52822-52823	,	_	
220-125	52824-52825	2	_	
220-126	52825-52826	,	_	
220-127	52827-52828	−	_	
220-128	52828-52830	24	_	
